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The use of natural antimicrobials as antibiotics has divested considerable clinical benefit, with the 
consequence being that pathogenic species are well-prepared to counteract their effects in new, 
clinical settings.  
When considering antimicrobial resistance, the ecological origins of an antibiotic class can direct 
the conditions under which resistance is promoted, or constrained. By inducing protective 
transcriptional regulation, bacteria quickly reconcile with otherwise bactericidal compounds in 
their local environment. The polymyxin antibiotics, Polymyxin B and Colistin, are highly 
efficacious against pathogenic Gram-negative bacteria, but are nevertheless overcome by such 
resistance mechanisms. This has been ascribed to the similarities between polymyxins and 
endogenous cationic antimicrobial peptides, which must be deflected by commensal bacteria and 
pathogens alike to survive within a variety of hosts.  
To repel cationic antimicrobials, bacteria activate transcriptional pathways that reduce the 
intrinsic anionic charges of the cell envelope. Polymyxin resistant Klebsiella pneumoniae, and 
Escherichia coli possess both the arnBCADTEF-ugd and eptA operons, expression of which 
modifies lipid A with the cationic L-Ara4N and pEtN moieties respectively. Electrostatic 
repulsion of polymyxins by either moiety alone is sufficient for Pseudomonas aeruginosa and 
Acinetobacter baumannii to attain therapeutically dangerous levels of polymyxin resistance, 
raising questions as to why certain Enterobacteriaceae maintain both.  
The aim of this study was to investigate non-pathogenic E. coli strain BW25113 and the isogenic 
single deletion strains BW25113∆arnT, and BW25113∆eptA. Each mutant strain lacks the final 
transferase necessary for modification with either L-Ara4N (ArnT), or pEtN (EptA). By 
constraining E. coli to a singular modification type, the relative influence each moiety exerts on 
both polymyxin resistance, and pathogenically relevant phenotypes can be uncovered.  
Due to their role in eroding polymyxin efficacy, and enhancing pathogenesis, both ArnT and EptA 
are potential candidates for antivirulence drug design. Therefore, bioinformatics analyses of both 
enzymes were conducted between E. coli BW25113 and select Gram-negative pathogens. 
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Homologous enzymes demonstrated preservation of key sites implicated in catalysis, indicating 
that inhibitors designed to disrupt activity in E. coli may have a broad-spectrum action. Parallel 
phenotypic assessment of E. coli ArnT and EptA mutant strains under polymyxin exposure, 
acidification, and within the J774.A1 macrophage survival model suggests that E. coli can readily 
compensate for individual deficiencies in lipid A modification. This raises implications for the 
sole pursuit of either enzyme to conquer burgeoning polymyxin resistance, as the 
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1.1 Antimicrobial Resistance  
1.1.1 State of Global Antimicrobial Resistance (AMR) 
The modern clinical environment is immersed in antimicrobials; advances in medical treatment 
are inseparable from the drugs used to support inherently riskier procedures. A decade of 
antimicrobial consumption from 2000 – 2010 has seen global use rise 35% to 70 440 786 553 
standard units per year1. Gradual erosion of efficacy has accompanied increased use, forcing 
clinicians to reach for antibiotics formerly consigned to history due to their unfavourable toxicity2. 
To preserve these “critically important” antimicrobials, the World Health Organisation has 
recommended complete restriction of certain drugs to life-threatening human infections, 
especially those agents that are the sole therapeutic options for highly-resistant Gram-negative 
bacteria (GNB), such as the polymyxins. Drug-resistant reservoirs are maintained within the 
human and animal gut microbiome, and the external environment with genetic arbiters of 
resistance flowing continuously between these populations. Careful antimicrobial stewardship 
and surveillance can stem the rise of AMR, yet the crisis will inevitably worsen without 
investigation into novel drug targets, as strains surpass multidrug resistance (MDR) to become 
extensively, and even pan-drug resistant (XDR and PDR).  
1.1.2 The Problem of Resistant Gram-negative Bacteria  
Gram-negative bacteria have come to represent a formidable swathe of AMR infections world-
wide. The rapidity at which GNB can evade antimicrobials has not been met with similarly 
aggressive practices to halt the rise of resistance, the bulk of which have been formerly 
preoccupied with MDR Gram-positive species such as Staphylococcus aureus3.  
European surveillance measures have identified a suite of critically important GNB that exert a 
considerable burden on healthcare systems due to their high-level resistance. Predominant species 
include the opportunists Acinetobacter and Pseudomonas, and the Enterobacteriaceae family. The 
magnitude of nosocomial Enterobacteriaceae infections exceeds that inflicted by the opportunists, 
with E. coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter spp. highly prevalent at 
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vulnerable anatomical sites. Pathogens able to withstand empirical antimicrobial treatment have 
severe consequences for health; attributable mortality of 18.8% is attained in patient cohorts 
infected with Carbapenem-resistant Enterobacteriaceae (CRE), while MDR P. aeruginosa and A. 
baumannii inflict a mortality rate between 20 – 61.9%3. The global burden of MDR GNB can be 
partially understood via the total European MDR mortality rate which stands at 25 000 per year, 
two-thirds of which is assumed to be Gram-negative in origin4. Immense societal costs are also 
imposed by Gram-negative MDR. Bacteraemia caused by E. coli, Klebsiella spp., and P. 
aeruginosa cost European Union member states more than 800 million Euros per annum, and 
MDR Pseudomonas species alone siphon 2.7 billion USD away from the United States healthcare 
system each year5.  
1.1.3 Antimicrobial Resistance in Escherichia coli: Silent Threat of the Microbiome 
Clinical encounters with antibiotic resistant E. coli typically concern extra-intestinal pathogenic 
strains (ExPEC), etiological agent of ascending urinary tract infections, hospital acquired 
pneumonia and life-threatening abdominal infections6. Simultaneously ExPEC with pathogenic 
serotypes are effectively dormant when situated away from sterile extra-intestinal sites; as they 
constitute the dominant normal faecal inhabitants in 20% of healthy subjects6,7. The latent 
pathogenic potential of each E. coli cell, coupled with its near universal carriage amongst ~90% 
of the population creates a sizable stock from which antibiotic resistance can arise8. These 
characteristics have been utilized in AMR surveillance where E. coli are co-opted as sentinels to 
detect resistance genes intrusion in humans and livestock9.  
• General Antimicrobial Resistance 
Insight into the current resistance status of E. coli at the frontline of clinical encounters is provided 
by patient isolates. In 2011, Australian surveillance programs observed MDR in 12.6% of the 
1827 E. coli samples collected10. No isolate harboured a known carbapenemases. Subsequent 
reports have since detailed the presence of 14 CRE drawn from bacteraemic patients, including 
E. coli possessing New Delhi beta-lactamase blaNDM-411. Across the entire E. coli cohort (3493 
isolates) overall MDR rates were in excess of 10%11.  
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The temporal trend of increasing resistance was also apparent upon retrospective analysis of E. 
coli isolates in the United States, taken from 1950 – 20029. Across the period 1950-1959, 73.9% 
of all E. coli recovered from both human and animal samples were pan-susceptible; this fell to 
just 18.5% in isolates collected from 2000-20029. Most E. coli assessed by the investigation were 
in fact resistant to ≥ 1 antimicrobial, and resistance to upwards of two antimicrobial classes is not 
unusual in livestock microflora, healthy individuals, and current clinical settings9,12. General 
resistance to antimicrobials in E. coli is mediated by specific and extended-spectrum β-lactamases 
(ESBLs), porin-channel alteration, antimicrobial efflux systems, and mutation of targets 
structures to evade antibiotic binding. 
• Efficacy of Polymyxin treatment against focus pathogen, E. coli.  
The Polymyxin class of antibiotics remain highly effective against E. coli. Resistance is extremely 
uncommon with global isolates from 2006 – 2009 recording susceptibility rates of between 99.8 
– 99.9% for colistin (CST), and 99.8 – 100% for Polymyxin B (PxB)13. Few clinical isolates of 
polymyxin-resistant (PMR) E. coli have been reported as most infections are successfully treated 
by a variety of antibiotic classes, masking any unexpressed resistance before strains can be 
challenged by PxB or CST treatment. Laboratory surveillance at the community level is not 
routine, as such the actual prevalence of E. coli, and Enterobacteriaceae polymyxin resistance is 
unknown14.  
Any form of PMR in E. coli clinical isolates warrants attention due to its rarity. Two such isolates 
have been previously identified in the US; cellulitis without prior polymyxin exposure, and a case 
of mixed GNB pneumonia subjected to recurrent rounds of PxB treatment15. Beyond these 
sporadic cases, acquired PMR in E. coli is largely confined to laboratory strains16. 
1.2 Polymyxin Antibiotics  
1.2.1 Structure 
Polymyxins are a fermentative product of the soil bacterium Paenibacillus polymyxa, and 
constitute a formidable defence mechanism of this bacterium against Gram-negative antagonists 
and fungal phytopathogens in the rhizosphere17. There are eight members of the Polymyxin 
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family, each presenting subtle difference in amino acid composition17. Clinical interest has thus 
far centred on Polymyxin B (PxB) and Polymyxin E, known as Colistin (CST).  
Structural heterogeneity exists within batches of polymyxin, however five key features are 
retained: the heptapeptide ring, hydrophobic residues at heptapeptide positions-6 and -7, a linear 
exocyclic tripeptide, the N-terminal fatty acyl chain consisting of methyl octanoate, and a 
minimum of five nonproteogenic 2,4-L-α, γ-diaminobutyric acid (Dab) residues (Figure 1.1)18-20. 
PxB presents a D-Phenylalanine at position-6, CST substitutes this with a D-Leucine, and both 
compounds preserve an L-leucine at position-719 (Figure 1.1). Diversity abounds within these 
structural groups; PxB consists of seven individual lipopeptides, and CST encompasses six, 
however only two major components (PxB1/PxB2 and CST1/CST2) constitute >80% of each 
commercial preparation19.  
 
 
The functional segments of Polymyxin compounds are indicated above; N-terminal fatty acyl chain 
(purple), linear tripeptide (green), and the heptapeptide ring (blue). Within the heptapeptide, position R6 
may be occupied by hydrophobic residues D-PHE (PxB) or D-LEU (CST)21. At the membrane, these 
residues act cooperatively with the N-terminal chain to broach the hydrophobic lipid bilayer22.  
 
Polymyxins have a high affinity for the lipid A constituent of lipopolysaccharide (LPS), and bind 
with micromolar dissociation constants as low as 90 µM toward the P. aeruginosa lipid A anchor, 
attributable to the unique structural features of both molecules20,23. At physiological pH, free γ-
Figure 1.1 Consensus Structure of the Polymyxin Antibiotic Class. 
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amines harboured on the Dab residues protonate rendering the entire peptide strongly cationic and 
well suited for electrostatic interaction with polyanionic bacterial structures24.  
When targeting Gram-negative bacteria hydrophobic residues, PHE-6 and LEU-7 dock with the 
proximal fatty acid tails of lipid A23,25. In conjunction with the hydrophobic residues, the N-
terminal fatty acyl tail integrates into the fatty acid region of the lipid A substrate23. These 
hydrophobic contacts constitute a substantial proportion of total target affinity, as modification of 
the PHE/LEU-7 site by hydrophobic L-octylglycine can overcome electrostatic repulsion, a 









A) Modelled interactions between PxB and Lipopolysaccharide, PxB depicted in yellow, with LPS lipid 
and sugars coloured blue and green respectively26.  
B) Deposition of PxB on E. coli model membranes, in this system the cationic antimicrobial is attracted to 
outer membranes within ~2 microseconds27.   
 
1.2.2 Function  
Binding to lipid A molecules in vitro launches a sequence of interactions between polymyxins 
and the Gram-negative membrane that culminate in the death of the bacterial cell (Figure 1.2.) 
The consensus pathway starts at the outer membrane with the displacement of intercalated Ca2+ 
and Mg2+ ions by protonated γ-amines (Figure 1.1). This destabilizes the tight packing of LPS and 
permits entry of the N-terminus fatty acyl tails into the outer leaflet, accelerating the disintegration 
A.     B. 
Figure 1.2 Interactions Between Polymyxin B and Lipopolysaccharide 
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of the membrane. Hydrophobic contacts are formed across the periplasmic space into the 
cytoplasmic membrane resulting in the characteristic “self-promoted uptake” of the polymyxin 
class28. Although intracellular targets such as members of the type II NADH-quinone 
oxidoreductase pathway are implicated in cell death, disruption of both membrane leaflets may 
be enough to exert the bactericidal effects29. Cell structure is so deranged after treatment with 
25µg of PxB that fibrous threads of cytoplasmic content are observed extruding through cracks 
in the membranous sheath, or forming multiple blebs that coat the cellular surface of  E. coli30. 
1.2.3 Clinical use of Polymyxins  
Treatment with polymyxins is an option where infections arise due to susceptible Gram-negative 
bacteria that exhibit multidrug-resistance to other agents. Both PxB and CST may be delivered 
by the intravenous, intrathecal, topical routes, or via nebulizer to permit deep penetration to foci 
of infection within the respiratory tract31,32. Global consumption of polymyxins rose 13% between 
2000 – 2010, attributed to the gradual lessening carbapenem efficacy1,33.  
Polymyxin treatment for a Gram-negative infection comes with side-effects befitting its status as 
a last-resort option. The therapeutic window is constrained by both nephrotoxicity and 
neurotoxicity34. In contemporary studies, CST treatments return a renal toxicity rates of between 
10 – 37% with acute kidney injury developing in 15.4% of patients receiving >72 hours of 
intravenous colistin2,35,36. Incidence of neurotoxicity, as defined by focal seizure, sits lower, at 
~5%35. Similar boundaries are reported for PxB with regard to renal failure37.  
The high cure rate demonstrated by both compounds against MDR GNB renders these adverse 
effects tolerable; 88% overall with PxB, and response rates of 60 – 100% in bloodstream 
infections (BSI) treated with CST35.  
1.2.4 Inducing Polymyxin Resistance 
The destructive, bactericidal nature of polymyxin treatment potentiates resistance. Due to its 
ecological origin, a spectrum of PMR strategies have been generated by the GNB that are readily 
deployed by pathogens reencountering PxB or CST in clinical contexts 
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1.2.4.1 Intrinsic Resistance to the Polymyxin Class 
Intrinsic PMR is demonstrated by several GNB classes including members of the 
Enterobacteriaceae, and non-fermentative bacteria38. The genera Providencia and Proteus, and 
the species Serratia marcescens, Morganella morganii, Chromobacterium violaceum and 
Yersinia pseudotuberculosis are all intrinsically polymyxin resistant GNB (IPRG)38,39. Pathogenic 
Neisseriaceae, Neisseria meningitidis and Neisseria gonorrhoeae withstand PxB ≥512 µg/mL, 
well in excess of clinically useful concentrations40. Members of the Burkholderia cepacia 
complex including B. cenocepacia represent the non-fermentative class of PMR bacteria38.  
The shared PMR phenotype is derived from modification or substitution of the LPS target41. 
Polyanionicity of LPS is the primary determinant for polymyxin affinity with the outer membrane, 
and much of this charge is derived from bis-phosphorylated glucosamine backbone of lipid A25. 
Phosphate headgroups are therefore subjected to extensive modification or complete removal. 
Formation of phosphorester linkages to various cationic moieties neutralize almost all anionic 
charges in S. marcescens, and C. violaceum to the detriment of PxB avidity42,43. Extreme lipid A 
divergence and resultant extreme PMR is pursued by Capnocytophaga canimorsus, resident of 
the canine oral cavity44. To withstand PxB at concentrations >1024 µg/mL,  
C. canimorsus removes an entire phosphate headgroup, and neutralizes the other by 
esterification44. 
1.2.4.2 Acquired Resistance to PxB and CST 
More commonly, resistance is acquired when bacterial populations, already in possession of 
polymyxin-activated protective pathways, are subjected to sub-inhibitory polymyxin treatment. 
Exposure to CST, PxB, or other chemical proxies that mimic their effect activates latent genetic 
loci that mediate adaptive resistance45. Selective pressure subsequently favours the generation of 
permanent mutations interspersed throughout protective pathways, resulting in constitutive 
activation of previously dormant alterations in cell physiology and LPS.  
Inducible polymyxin resistance within most Enterobacteriaceae is controlled by the two-
component regulatory systems (TCRS); PhoPQ, and PmrAB. Both systems encode a sensor 
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kinase (PhoQ, PmrB) and its cognate response-regulator (PhoP, PmrA). Point mutations in either 
participant can bestow high-level PMR upon susceptible organisms, as they exert transcriptional 
control over an immense cohort of PMR-linked operons46. Isolates of E. coli, K. pneumoniae, P. 
aeruginosa, and A. baumannii bearing TCRS point mutations are frequently recovered from PMR 
infection47. The de-repression of such TCRS can also engender PMR in K. pneumoniae, whereby 
PhoPQ suppressor protein mgrB is characteristically inactivated post-CST treatment48. Complete 
abandonment of the anionic LPS leaflet, and pre-emptive lipid A decoration are additional 
strategies deployed by a wide variety of GNB49. All acquired resistor phenotypes may be transient, 
or easily outcompeted in the host due to the pressure that the constitutive modification places 
upon bacterial metabolic networks50.  
1.2.4.3 Transmissible PMR 
The discovery of transmissible PMR, mediated by plasmid-mobilized polymyxin resistance 
enzymes mcr-1 and later mcr-2 ushered in the possibility that previously susceptible Gram-
negative bacteria could now in fact surmount the last-line of antibiotics almost instantaneously51.  
In 2015 recovery of a Chinese porcine E. coli strain exhibiting PMR of 4 mg/L for PxB, and 8 
mg/L for CST led to the identification of plasmid pHNSHP45; capable of increasing wild-type E. 
coli PMR 16-fold upon successful conjugation52. The 1626-bp resistance determinant harboured 
by pHNSHP45 was subsequently named mcr-152, with a secondary 1617-bp agent mcr-2 
discovered in Belgium, 201653. Both enzymes confer relatively low level polymyxin resistance (4 
– 8 mg/L, versus >512 mg/L in clinical isolates P. aeruginosa)54, and have since been 
retrospectively identified in E. coli isolates collected from bovine and swine digestive infections 
since 2004, and at the earliest from single isolates in 198055,56. More recent interrogation of the 
SENTRY Antimicrobial Surveillance 2014 – 2015 clinical isolate cohort revealed that 4.9% of 
CST-resistant E. coli carried mcr-1, with isolates recovered from multiple countries and diverse 
anatomical sites57. This corresponds to only 19 bacteria from a total pool of 390 CST-resistant 
bacteria, within >13 000 clinically relevant isolates57. Concern surrounding mcr-1 and other 
members of the expanding MCR-like cohort is therefore not drawn from fears of an innumerable 
avalanche of Gram-negative “super-bugs”, able to rebuff potent polymyxin treatment, but from 
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the unseen passage of mobilized PMR throughout the community, gradually eroding 
susceptibility and permitting the development of MDR outside of the health-care setting14,55.  
1.3 Escherichia coli Lipid A  
1.3.1 Lipopolysaccharide, Crown Jewels of the Gram-negative Bacteria  
1.3.2 Outer Membrane 
The most salient feature that distinguishes the GNB from their Gram-positive counterparts is the 
complete envelopment of cells within an additional outer membrane. Outer membranes (OM) are 
the primary interface through which GNB negotiate their surroundings, and have likely been 
preserved across the class as a means of withstanding antibiotic secretion in polymicrobial 
communities58. To exert any bactericidal or bacteriostatic effects in the cytoplasm all antibiotics 
must traverse both leaflets of the OM58. Hydrophobic molecules are readily blocked by hydrated 
saccharide chains in the LPS coat, whereas the hydrophobic character of the inner 
glycerophospholipid leaflet repels hydrophilic antimicrobials59,60.  
1.3.3 Lipopolysaccharide 
LPS is subdivided into three distinct molecules, each assembled in parallel by their own distinct 
set of biosynthetic enzymes prior to LPS formation (Fig. 4). The outermost segment is the O-
antigen (O-Ag), consisting of oligosaccharide units between 1 – 10 sugars in length, repeated 
upwards of 300-times61. The presence of O-antigen is extraneous to cell viability, yet the Smooth-
LPS phenotype (categorized by the possession of complete O-Ag) dominates pathogenic 
Enterobacteriaceae isolates, suggestive of the purported role of O-antigens in successful host 
evasion or colonization61,62. 
While O-Ag is completely exposed to the external environment, the core oligosaccharide of LPS 
that provides an attachment point for the polysaccharide is partially protected within the outer 
leaflet. The core is split into the membrane-proximal inner core, and the O-Ag linked outer core63. 
The characteristic core constituent is Kdo, (3-deoxy-D-manno-oct-2-ulosonic acid) which is 
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typically present in minor quantities (2 – 3 residues) in addition to 6 – 10 sugars of various other 














Main image: The bis-phosphorylated diglucosamine backbone and six fatty acid tails of lipid A are shown 
in black, three Kdo residues depicted in aqua characteristic are linked to the backbone by a 6’-hydroxyl 
group ketosidic bond. Phosphate headgroups (4’-PO4, 1-PO4).  
Inset: Lipid A phosphate modifications available to E. coli. Typically, the 4’-PO4 is decorated by 4-amino-
4-deoxy-L-arabinose (L-Ara4N), while phosphoethanolamine (pEtN) is preferentially added to 1-PO4.  
 
 
In the Enterobacteriaceae, Kdo is always attached via (26) linkage to the reducing end of the 
LPS membrane anchor, lipid A64. The lipid A molecule is a β-1’,6-linked glucosamine 
disaccharide, phosphorylated at the 4’- and 1-hydroxyl positions and acylated at C-2, C-2’ and C-
3, C-3’ (Figure 1.3)62.    
Figure 1.3 Escherichia coli Lipopolysaccharide. 
4’-L-Ara4N 
1-pEtN 






1.3.4 Biosynthesis of Lipid A 
Nascent lipid A molecules undergo a series of modifications conducted by a set of highly 
conserved enzymes65. The lipid A biosynthesis pathway of E. coli is initiated in the cytoplasm66, 
with the acylation and subsequent deacetylation of UDP-GlcNAc. This step marks substrate 
commitment to the lipid A pathway66. Modification with R-3-Hydroxymyristate forms UDP-2,3-
bis(β-hydroxymyristoyl)-D-glucosamine (UDP-2,3-diacyl-GlcN)65. Further processing occurs at 
the membrane where the pyrophosphate linkage anchoring the UDP moiety is cleaved; forming 
the intermediary lipid X. A second molecule of the lipid X predecessor is recruited to form the 
disaccharide β (1’-6) linkage of lipid A. Immature lipid A must undergo further processing before 
expression within the outer membrane leaflet. Late modification begins with phosphorylation at 
the 4’-position of the disaccharide, and subsequent transfer of two Kdo sugars to form Kdo2 IVA 
Lipid A. The final bis-phosphorylated lipid A contains acyloxyacyl linked lauroyl and myristoyl 
chains for a total of 6 chains per molecule67. Completed lipid A molecules exert a characteristic 
net negative charge due to the presence of phosphate groups, certain amino acids residues, and 
Kdo carboxyl groups68.   
1.3.5 Detection of Lipid A by TLR-4/MD-2 Complex 
Abundant, indispensable, and generally conserved across Gram-negative species; lipid A 
possesses features that render it a highly immunogenic pathogen-associated molecular pattern 
(PAMP)69. Consistent antagonism over evolutionary timescales has resulted in mammalian hosts 
expressing an array of lipid A and LPS specific pattern recognition receptors (PRRs) capable of 
launching an immune response following exposure to a picomolar dose63.   
Systemic exposure to LPS can be catastrophic for the host. The generalized inflammatory 
response mounted by non-specific effectors of innate immunity is referred to as septic shock, 
where derangement in coagulation coupled with high levels of circulating cytokines culminates 
in organ hypoperfusion, hypotension, and an attributable mortality rate of ~50%70. The toxigenic 
effect of LPS accounts for its rebranding as ‘endotoxin’, of which lipid A is the ‘endotoxic 
principle’ due to its capacity to induce all aspects of the systemic LPS-response in vivo71,72.  
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During an infection, LPS sloughed into the cellular environment is shuttled to its dedicated PRR 
by a series of coordinated interactions between LPS-binding protein (LBP) and the 
monocyte/macrophage marker CD14, which may also extract molecules from bacterial 
membranes68,73. Pattern recognition of lipid A is performed by the cell-surface heterodimer Toll-
like receptor 4 (TLR-4) in complex with myeloid differentiation factor-2 (MD-2)74. Dimerization 
of the TLR-4/MD-2 complex launches the signal transduction pathways necessary for response 
to soluble endotoxin.  
Conformational changes in the TLR-4/MD-2 heterodimer recruit downstream signalling 
pathways coordinated by the MyD88 and TRIF adaptor proteins mediating the induction of pro-
inflammatory cytokines and Type I interferons69. This response is protective if localized. However 
systemic release of TNF-α, IL-6, IL-1 and interferons by constituents of the reticuloendothelial 
system exceeds the protective threshold resulting in LPS-induced septic shock75.  
Bacteria with highly immunogenic lipid A can be rapidly identified and eliminated from the 
system76. The classical lipid A incorporated within the outer leaflet of Escherichia coli provokes 
a considerable immune response, reflective of structural characteristics that optimize contact 
points between the endotoxin and MD-2. Any divergence in the lipid A structural pattern evokes 
similarly divergent LPS bioactivity, to the extent that coinfection with under-acylated E. coli 
obstructs the detection of wild-type ExPEC in bladder epithelial models by 60%76,74,77. The 
opportunity to escape immune effectors presents bacteria with a strong impetus for lipid A 
modification.  
1.3.6 Lipid A and the Host Antimicrobial Peptides  
The uninterrupted armaments race between pathogenic bacteria and their hosts has generated 
diverse sets of bactericidal peptides that cooperate with other effectors of the innate immune 
system. Antimicrobial peptides (AMPs) are interspersed throughout the natural world and over 
2800 AMPs are currently recognized in the Antimicrobial Peptide Database (APD, 
http://aps.unmc.edu/AP/)78. Eukaryotic AMPs comprise the bulk of this collection; of which there 
are 119 human AMPs, or human host defence peptides.  
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Strict conservation of AMPs across almost all domains of life is suggestive of the critical role 
they play in host defence. Irrespective of individual structural differences, AMPs typically present 
two characteristics; amphipathicity, and an overall net charge79. Cationic AMPs (CAMPs) are the 
norm with the entire AMP cohort possessing an average charge of +3.2, conferring broad 
specificity for bacterial membranes80. Compared to predominately neutral eukaryotic cell 
membranes, a far greater fraction of the bacterial outer envelope is anionic consisting of up to 
~20% negatively charged phospholipids79,81. Electrostatic interaction is therefore assumed to be 
the instigating event that precedes bactericidal activity in Gram-negatives, drawing CAMPs 
toward the phosphorylated sugars interspersed across LPS, and the anionic phospholipids of the 
inner leaflet81,82.  
Competitive displacement of intercalated Ca2+ and Mg2+ bridging ions within LPS molecules 
permits incorporation of CAMPs into the cellular membrane, however the precipitating cause of 
cell death is less apparent83. Pore formation is the primary mechanism put forward by both the 
barrel-stave, and toroidal pore models; relying on perpendicular or parallel puncturing of the cell 
envelope respectively79. Simple CAMP accumulation is considered the critical factor in carpet 
and “detergent-like” models, which suggest that membranes are dismantled piecemeal or 
collapsed into micelles at threshold concentrations79,84. The activity of CAMPs does not 
necessarily subside following membrane disruption. Other polyanionic targets such as nucleic 
acid and mediators of protein synthesis abound within the cytoplasm, providing suitable 
intracellular targets for the CAMPs85.  
Multiple classes of CAMPs are present throughout the various anatomical environments heavily 
frequented by bacteria. Pathogens attempting to establish infection at mucosal surfaces must 
contend with both continuous and responsive CAMP secretion. The human α-defensins (HD1-6), 
β-defensins (hBD1-6), salivary histatins (His1-5), and cathelicidin LL-37, each occupy different 
mucosal niches86. Within the gastrointestinal tract (GIT) constitutive production of HD5 and 
hBD1 by Paneth cells and colonocytes establishes a protective barrier against enteric pathogens 
and commensals87. Ciliated epithelial cells load respiratory secretions with β-defensins hBD1 and 
hBD2 both constitutively and secondary to bacterial provocation88. The primary effectors of 
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cellular innate immunity, polymorphonuclear leukocytes (PMN) unleash granulated α-defensins 
into local microenvironments at concentrations of 10 mg/mL; providing inducible CAMP defence 
in the bloodstream and tissues89.  
When challenged by sufficiently high concentrations of HD5 (>40 µM), the cell envelopes of E. 
coli, P. aeruginosa, and K. pneumoniae develop disfiguring blebs and elongations which can then 
rupture (Figure 1.4)90,91. Representative of the broad effects exerted by CAMPs, PMN granule 
constituents HD1, HD2, and HD3 instead act by forcing the periplasmic accumulation of cellular 
materials and membrane leakage. Avoiding the bactericidal mechanism of host CAMPs forces 
bacteria to alter several intrinsic characteristics of the outer envelope; but with the potential 






Enteric α-defensin HD5 exerts bactericidal effects on E. coli BW25113. Bacterial cells were treated with 
40µM oxidized HD5. Bleb formation via extrusion of cytoplasmic contents is highlighted within the in 
external inset91.  
 
1.4 Modified Lipid A: Multiple paths to Virulence  
Virulent GNB present lipid A alterations that accompany severe disease states. Adjustment of 
phosphorylation and acylation patterns away from the consensus lipid A scaffold can potentiate 
pathogenesis in different host compartments, and etiological agents92. Primarily, these effects 
originate from shifted interactions between lipid A and host effectors.  
• Terminal phosphate groups  
During TLR-4/MD-2 dimerization, conformational change permits electrostatic attraction 
between protruding lipid A phosphate groups and charged heterodimer residues (Figure 1.3). 
Figure 1.4 E. coli BW25113 Treated With Oxidized CAMP HD5. 
15 
 
Receptor affinity is redoubled as the 1-phosphate contacts cationic lysine and arginine residues, 
while hydrogen-bonding serine-118 on MD-293. Increased affinity begets heightened 
immunostimulatory effects, alerting the host at the onset of infection. Prototypical lipid A bearing 
the bis-phosphorylated diglucosamine can launch TLR-4/MD-2 responses at minute 
concentrations (~10ng/mL), due to the provision of moieties that favour strong dimerization94. 
Phosphorylation state is therefore the primary target of alterations designed to silence lipid A. 
Within E. coli, synthetic 4’-monophosphorylated lipid A (MPL), generated by the action of 
Francisella novicida membrane phosphatases on the bis-phosphoryl variant exerts a lesser 
immunostimulatory effect than MPL retaining the 1-phosphate95,96.  
This discrepancy in phosphoryl participation is also reflected outside the laboratory. Human 
commensal gut bacterium Bacteroides thetaiotaomicron and oral pathogen Porphymonas 
gingivalis both synthesize penta-acylated MPL, excluding the 4’- and 1-phosphate respectively95. 
Exposure to B. thetaiotaomicron triggers more potent downstream TLR-4/MD-2 effects than its 
pathogenic counterpart, which utilises non-provocative LPS to aid unimpeded destruction of bone 
and gingival tissue97,98. Causative agent of tularaemia Francisella tularensis encodes the lipid A 
4’-phosphatase LpxF, the absence of which effectively incapacitates virulence in otherwise lethal 
intradermal challenge99. This indicates that placement of phosphoryl groups can affect virulence, 
but the effects vary within the broader context of species-specific lipid A molecules.  
• Acylation state 
The glucosamine backbone of E. coli lipid A is directly hexa-acylated by four primary (R)-3-
hydroxytetradeanoic acid (3-OH-14: O) chains at the C-2, C-3, C-2’, and C-3’ sites. Primary 
acylation is performed by LpxA, which is absolutely selective for C14 chain length65. The final 
complement of six acyl chains is fulfilled by secondary acylation, with lauroyl and myristoyl 
added to the C-2’ and C-3’ chains100.  
Each aspect of lipid A acylation can be adapted to benefit pathogenesis. While full hexa-acylation 
improves the barrier function of the outer membrane, invasive bacteria risk clearance by immune 
effectors. The characteristic hydrophobic bloc provided by hexa-acylation facilitates TLR-4/MD-
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2 dimerization, interacting with substrate binding pockets in MD-294. Forgoing acyl groups to 
express variant under-acylated lipid A enhances virulence and survival across diverse 
microenvironments, and is demonstrated in the Yersiniae spp., Bordetella bronchisepta, and 
Burkholderia cenocepacia. Temperature increase shifts Y. pestis lipid A to an under-acylated, 
low-endotoxicity state, linking immune evasion with entrance to the endothermic mammalian 
host101, 102. Over-acylation can also assist survival65. Palmitoylation creates hepta-acylated lipid A 
variants, evident in S. Typhimurium, E. coli, P. aeruginosa, and Bordetella spp. after TCRS 
stimulation by CAMP damage or Mg2+-limitation103. Integral outer membrane protein pagP is the 
source of lipid A palmitate derivatives, and operates under PhoPQ regulatory control in both 
Salmonella and E. coli104. Hepta-acylation confers greater hydrophobicity, and tighter packing; 
reinforcing outer leaflets weakened by loss of Mg2+ cation-bridges, or CAMP accumulation104.  
1.5 L-Ara4N and EptA: determinants of virulence in the Enterobacteriaceae, and other 
Gram-negative bacteria.  
Certain effectors of innate immunity act in a non-specific manner, and can be circumvented by 
altering equally non-specific outer membrane characteristics. The “fatal attraction” between 
anionic LPS and CAMPs is partially neutralized by adding cationic polar residues to the distal 
phosphate groups of lipid A. At physiological pH, lipid A phosphates (4’-PO4, 1-PO4) exert a net 
charge of -1.5. Esterification with 4-amino-4-deoxy-L-arabinose (L-Ara4N) or 
phosphoethanolamine (pEtN) can redress this charge to 0 and -1.0 respectively105 (Figure 1.3). 
Precursors of the pEtN decoration can be extracted from phosphatidylethanolamine residing in 
the inner membrane, however L-Ara4N substitution requires the presence of specialized 
enzymatic machinery106,107. 
• Enterobacteriaceae  
Enteric bacteria must run the gauntlet of GIT defence mechanisms: steep pH gradients, 
constitutive CAMP secretion, mucosal shedding, and the duodenal bile salts. Polar modifications 
assist survival in these otherwise inhospitable conditions and have significant implications for 
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virulence. Decoration with L-Ara4N and pEtN can be induced by both bile salts and acidity, 
signals that directly endanger the cell and provide cues that host internalization has occurred.  
Escherichia coli, strains of Enterohaemorrhagic E. coli (EHEC) serotype O157:H7 are partially 
distinguished from their commensal counterparts by differential expression of their shared genetic 
repertoire, including loci governing LPS. Lipid A harvested from EHEC under laboratory 
conditions displays constitutive 1-O-pEtN modification at the 1-position, a variant absent in E. 
coli K-12 not subjected to prior mutation108. Permanently modified membranes provide a more 
robust barrier between O157:H7 and the external environment following shedding108. Bile 
exposure upregulates all members involved in L-Ara4N synthesis enabling E. coli to synthesise 
heavily decorated outer membranes that can repulse lethal concentrations of PxB109. However 
linking CAMP evasion to bile detection has a cost; as overexpression of L-Ara4N and pEtN 
results in hypersensitivity to anionic bile detergents, rendering constitutive pmrA mutants unfit110.   
Helicobacter pylori encodes a suite of lipid A alteration enzymes to create a single tetra-acylated 
disaccharide lipid species without any phosphate groups, and complete substitution with pEtN111. 
Entirely supplanting phosphate with pEtN has a greater effect on negative charge than 
phosphodiester formation112. As such, post-modification H. pylori PxB MIC values exceed 
250µg/mL112. Displacing the 1-phosphate with pEtN and abolishing the 4’-phosphate also 
attenuates TLR-4/MD-2 responses, by 2- and 6-fold respectively113.  
Intracellular species Salmonella and Shigella provide a counterpoint to the modification 
patterns of E. coli, to contend with pressures imposed by the intracellular milieu. 
Phylogenetically, the Shigella spp. are embedded within Escherichia, although unlike E. coli they 
can establish successful infections from a starting inoculum of 10-100 bacteria114. At 
physiological pH Shigella flexneri esterifies its 4’-phosphate with L-Ara4N, and as pH 
approaches gastric acidity, pEtN supplants all L-Ara4N moieties114. Extreme acidity further 
potentiates the protective effect of pEtN, as pH conditions of ≤2.5 bolster the net positive charge 
conferred by internal amine groups114.  
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Wild-type S. Typhimurium evoke a similar state of pre-preparedness for gastrointestinal 
conditions in their OM, but give primacy to the L-Ara4N moiety. The relevance of L-Ara4N to 
S. Typhimurium virulence has since been defined; mutants with defective aminoarabinose 
modification pathways are unable to cause disease when introduced to mice via the oral route, but 
retain their lethality following intraperitoneal inoculation115, 116. Phagocytosed Salmonella spp. 
are inundated with CAMPs, and acidified to pH 4.5. Polar modification attenuates the efficacy of 
these intracellular stressors, to the extent that virulence is actually promoted post-ingestion104,117.  
• Pathogens of the Respiratory tract  
Opportunistic pathogens of the respiratory tract, Burkholderia cenocepacia and Pseudomonas 
aeruginosa use cationic sugar decorations to survive the lung environment and effect desirable 
changes in the host defence systems. The OM lipid A composition of P. aeruginosa shifts from 
unmodified penta-acylated species, to a heterogenous collection of hexa-acylated, double or 
single L-Ara4N-esterified molecules under Mg2+-limitation or CAMP exposure (Figure 1.5)118. 
For the Pseudomonas spp., the Mg2+-chelating properties of extracellular DNA cemented within 
biofilms provides in vivo relevancy to the divalent cation limitation signal. Infected airways of 
patients with Cystic Fibrosis (CF) accumulate DNA-rich sputum at concentrations up to 
20mg/mL, and the prospect of P. aeruginosa passing through these localized pockets of Mg2+-
limitation is highly likely119. 
Along the respiratory tract bacteria are exposed to human β-defensins, and as infection progresses 
pathogens may be challenged by the exogenous CAMPs PxB and CST120. Strains of P. aeruginosa 
that demonstrate moderate PxB resistance (8 µg/mL), and resist human hBD-2, hBD-1, and LL37 
in vitro, are united in decorating lipid A with L-Ara4N at both sites120. Higher levels of CST 
resistance (>512 µg/mL) are also demonstrated in CF-sputum isolates that acclimatize to 
nebulized or intravenous CST treatment via constitutively modifying the 1- and 4’-phosphate54,118.  
Constitutive modification by L-Ara4N is strictly preserved in opportunistic pathogen 
Burkholderia cenocepacia, and the entire Burkholderia cepacia complex (BCC). BCC LPS 
export machinery is blind to unaltered molecules, evidenced by severe OM malformation and 
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death in all L-Ara4N pathway mutants121. Thus, BCC lipid A is heavily modified under non-
inducing conditions, esterifying both external phosphate residues and the inner core 
oligosaccharide to exert a net positive or isoelectric OM charge122. Without 4’-, 1-, and inner core 
L-Ara4N moieties, PxB resistance is reduced 16 000-fold in suppressor mutants that permit 
unmodified LPS export122.  
Membrane alteration has implications for TLR-4/MD-2 induction. Destructive lung tissue 
pathogenesis characterizes B. cenocepacia infection, accelerated via potent TLR-4/MD-2 
signalling releasing a deluge of downstream effectors123. Electrostatic anchorage points develop 
between L-Ara4N and TLR-4 residues ASP-294, and ASP-264, while hydrogen bonds are 
simultaneously formed with serine residues in secondary TLR-4 molecules (TLR-4*)123. These 
two TLR-4/MD-2 interfaces increase BCC LPS endotoxicity five-fold, when compared to P. 









Note the esterification of both 4’- and 1-phosphates with L-Ara4N. Hepta-acylation (indicated by blue and 
red acyl chains) is another feature CF-derived P. aeruginosa54. Acyl-oxy-acylation at the 3’, 2’, 2-positions 
with palmitate (C16:0), and laurate (C12:0) is absent from sensitive strains. Removal of the 3OH-C10:0, at 
the 3-position also occurs subsequent to PagL activity. Note the absence of pEtN residues, as P. aeruginosa 





Figure 1.5 Extensively Decorated Lipid A of PMR P. aeruginosa. 
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1.6 The Biosynthesis of L-Ara4N and pEtN. 
1.6.1 Controlling L-Ara4N and pEtN modification  
The need for enteric bacteria to respond effectively following exposure to new sets of toxic 
compounds has promoted the development of two-component regulatory systems that can exert 
pleiotropic effects across the bacterial genome; selecting a balanced “best fit” phenotype for the 
cell microenvironment. Enterobacteriaceae frequently encounter stressors mandating an urgent 
response including high acidity, and bactericidal compounds.  Twin two-component regulatory 
systems (TCRS) acting concordantly with cross-regulatory effectors dominate the L-Ara4N, and 
pEtN response; PmrAB and PhoPQ. 
1.6.1.1 PmrAB 
The pmrCAB operon transcribes components of the TCRS PmrA-PmrB, and the 
phosphoethanolamine transferase EptA (pmrC) (Figure 1.6). This operon was originally described 
in S. Typhimurium for its capacity to induce Polymyxin B resistance (hence “Pmr”), but can exert 






Figure adapted from NCBI, Gene ID: 948629. Gene of interest eptA spans 4333947 – 4335590-bp (1644-
bp). 
In Escherichia coli, the Salmonella spp. PmrA-PmrB system is entirely supplanted by 
homologous proteins BasS-BasR, partly accounting for the slight phenotype divergence observed 
between the two enteric pathogens. The pathway begins with basS, one of the 30 E. coli sensor 
kinases capable of auto-phosphorylation126. BasS integrates into the cytoplasmic membrane and 
extends a stretch of 31-amino acids into the periplasmic space, while retaining a cytoplasmic 
kinase domain in the cytosol127. The periplasmic domain is necessary for detecting extracellular 
Figure 1.6 Organization of the basRS-eptA operon, E. coli Counterpart of pmrCAB. 
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ferric-iron (Fe3+); collected by electrostatic attraction to the anionic outer membrane in high iron 
environments127. Both BasS and PmrB harbour the Fe3+-binding motif ExxE, consisting of 
repeating arrangements of glutamate residues and a conserved serine residue exposed to the 
periplasmic space127,128. This motif enables BasS to directly bind Fe3+, inducing a conformational 
change that triggers auto-phosphorylation at a cytosolic histidine residue110. DNA-binding protein 
BasR accepts the phosphoryl group via conserved N-terminal aspartate residue, ASP-51128,129. In 
this form BasR-P can now launch the transcriptional response to ferric-iron. Expressing the full 
complement of ferric-iron response genes requires selective binding of BasR-P to 38 promoters 
throughout the genome, including those proceeding the L-Ara4N synthesizing arnBCADTEF-
pmrE operon, and the positively autoregulated basRS-eptA operon126,110,128.  
Iron is a useful proxy for host gastrointestinal environments, attaining concentrations of 
up to 733 µM in the stomach, and between 10-100 µM in the duodenum127. Detection of Fe3+ 
above a threshold of 0.1 mM by BasS is sufficient to generate a response126,129. Growth in the 
presence of 0.4 mM FeSO4 upregulates expression of arnA and arnD between 8.2- to 9.6-fold, 
while generation of eptA transcripts in 200 µM FeSO4 is induced 100-fold110,126,129. Furthermore, 
soil samples have been demonstrated to contain levels of 350 µmol cm-3 free ferric iron130. 
Upon ingestion, bacteria encounter pH < 3, for up to two hours prior to gastric 
emptying131. E. coli demonstrate resistance to pH 2.5 across 80% of isolates taken from the normal 
flora10. Acidity is directly sensed via the periplasmic domain of BasS, in a separate motif to the 
region governing responses to ferric-iron 104. Protonation of conserved histidine and glutamic acid 
residues at pH ~5.8 sets off the BasS-BasR cascade104,125. Exposure to mildly acidic conditions 
can have a massive impact on polymyxin resistance; driving cell survival up 100 000-fold104. 
Increased eptA expression may account for the PMR-phenotype of acid-treated E. coli, as lipid A 
species modified with greater amounts of phosphoethanolamine modification are present104.  
Other Gram-negative pathogens may also utilise a BasS-BasR homolog that reflects the 
demands placed on them by their physiological niche. In Pseudomonas aeruginosa, an intact 
pmrAB operon is mandatory for polymyxin resistance, yet Pseudomonal PmrB is divergent to 
BasS by exhibiting sensitivity to acidity while being blind to ferric-iron120. Other non-enteric 
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bacteria including Acinetobacter baumannii launch massive programs pmrCAB over-expression 
to escape colistin treatment132.  
1.6.1.2 PhoPQ 
In the regulatory architecture governing lipid A decoration, PhoPQ is situated directly above 
PmrAB. Sensor kinase PhoQ is responsive to Mg2+-limitation, acidity, and the integration of 
CAMPs within its immediate environment133. Subsequent auto-phosphorylation in response to 
such stimuli phosphorylates response regulator PhoP, permitting the transcription of downstream 
effectors in possession of a PhoP promoter134. To expand the breadth of stimuli able to provide 
protective OM modification, PhoPQ preserves the phosphorylated state of PmrA by expressing 
PmrD, a PhoP-regulated PmrB-antagonist135. Essential for PhoPQ/PmrAB crosstalk, phosphatase 
inhibitor PmrD is present in S. Typhimurium, E. coli W3110, and K. pneumoniae135,136. In S. 
Typhimurium, this feedback loop is fine-tuned by PmrA suppression of PmrD under exposure to 
stimuli necessitating a PmrAB exclusive transcriptional programme, such as Fe3+137.  
1.7 The arnBCADTEF-ugd operon 
Modification of lipid A by L-Ara4N requires coordinated expression of the enzymatic products 
encoded by the arnBCADTEF and pmrE or ugd operon (Figure 1.7). Without the full complement 






Adapted from NCBI Gene ID: 947297. The gene encoding enzyme ArnT is located from 2370908 – 
2372560-bp (1653-bp).  
 
Biosynthesis begins with production of the primary substrate, uridine 5’-β-threo-pentapyranosyl-
4”-ulose diphosphate138 (UDP-L-Ara4O); a sugar nucleotide that is only generated due to the 
Figure 1.7 Genomic Organization of the arnBCADTEF-ugd Operon in E. coli. 
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actions of both ugd and ArnA. The ugd locus encodes UDP-glucose 6-dehydrogenase, a 
cytoplasmic enzyme that oxidizes UDP-glucose to UDP-glucuronic acid acted upon by the first 
member of the arn enzyme cohort ArnA (Figure 1.8)139. The first action of ArnA in the L-Ara4N 
pathway is NAD+-dependent oxidative decarboxylation of UDP-glucuronic acid to UDP-L-
Ara4O, performed by its C-terminal domain with the release of NADH. The new ketopentose 
substrate is now suitable for transamination by ArnB which uses glutamic acid to alter the 4”-
ketone of UDP-L-Ara4O, forming UDP-β-L-Ara4N138,139. 
The second action of ArnA is now required, using the N-terminal domain and N-10-
formyltetrahydrofolate to catalyse N-formylation of UDP-β-L-Ara4N. ArnC selectively transfers 
only the newly generated L-Ara4-formyl-N residue to undecaprenyl phosphate (Und-P) a 
“universal lipid carrier” that permits the trafficking of intermediates toward the periplasm125, 140. 
Before translocation to the periplasmic face of the inner membrane, ArnD rapidly deformylates 
L-Ara4-formyl-N; this action renders the substrate irrecoverably committed to the lipid A 
modification pathway139. Finally, the ArnE-ArnF flippase heterodimer encounters undecaprenyl 
phosphate L-Ara4N in the inner membrane, and flips the substrate to the outer leaflet139. This 
completes the cytoplasmic activities of the arn operon.   
ArnT extracts L-Ara4N from its Und-P carrier and transfers it to the 4’-phosphate group of 
nascent lipid A molecules. Less commonly, addition of L-Ara4N to the 1-phosphate also occurs 
allowing ArnT potentially to neutralize both anionic points protruding from the disaccharide. The 
absence of any enzyme in this pathway is sufficient to abolish intrinsic resistance in certain 




















Biosynthetic pathways controlling addition of the L-Ara4N moiety to Lipid A. All requisite enzymes are 
expressed by arnBCADTEF, apart from Ugd139. The pathway is well conserved across the 
Enterobacteriaceae and Gram-negative bacteria with some exceptions regarding the exact enzymes used: 
i.e. Burkholderia spp. express ArnA1/ArnA2 instead of the conventional bi-functional ArnA122. 
 
1.8 ArnT: Structure and Function  
Structural investigations into the physical properties of ArnT, and the functional importance 
thereof, have been conducted in Cupriavidus metallidurans141, and B. cenocepacia142. In addition, 
investigations of ArnT functional loops within S. Typhimurium have also occurred116. At the most 
basic level, amino acid sequence identity can provide a point of reference for establishing whether 
features highlighted by functional studies are pertinent sites in E. coli ArnT.  
1.8.1 Function 
ArnT recognises the Und-P-linked donor substrate undecaprenyl-α-L-Ara4N, extracts the L-
Ara4N sugar moiety, and esterifies the anomeric 4’-phosphate group106,143. Both phosphates of 
the glucosamine disaccharide backbone are potential esterification sites for ArnT but lipid A 




species with two aminoarabinose moieties are only a minor component in S. Typhimurium, and 
are absent from E. coli under normal conditions144. Functionally, the formation of a glycosidic 
link between the glucosamine disaccharide acceptor and the Ara4N sugar using an Und-P-linked 
donor classifies ArnT as a member of the Glycosyltransferase C (GT-C) superfamily145. 
Furthermore, ArnT is likely to be an inverting GT-C as the Und-P-α-L-Ara4N substrate is 
converted to a β-linked sugar on the phosphate groups142.   
1.8.2 Structure of ArnT in Cupriavidus metallidurans, Salmonella enterica, and 
Burkholderia cenocepacia.  
ArnT is an integral membrane protein with both a soluble domain exposed to the periplasm and a 
large embedded transmembrane domain (Figure 1.9)146. Structural studies into the topology of C. 
metallidurans ArnT (ArnTCM) suggest that thirteen transmembrane helices (TMH) are threaded 
through the inner membrane in a hydrophobic belt, an arrangement which has been similarly 








Schematic representation of Cupriavidus metallidurans ArnT consisting of thirteen transmembrane helices 
(green), three juxtamembrane helices (gold), periplasmic loop 4 (*), and the soluble periplasmic domain 
consisting of α-helices (pink) and β-sheets (blue)141.  
 
Alongside the transmembrane domain are juxta-membrane helices (JMH) that form part of a 
series of up to four periplasmic loops (PL)142,146. While the N-terminal of ArnT trails into the 
cytoplasm, the C-terminus extends into the periplasm as a globular region (Figure 1.9)142. 




Comparison with other members of the GT-C class, such as Campylobacter lari PglB N-
oligosaccharyltrasnferase suggest that this globular C-terminal domain is used to corral the lipid 
acceptor18,24,25. Periplasmic loop extensions PL2, and PL3 may also assist the coordination of 
substrate lipid A142,147. At the membrane, ArnTCM is folded to create three cavities with cavity-1 
(C1) proposed as the docking site for lipid A due to its easily accessible hydrophobic portions146. 
Cavity-2 (C2) and cavity-3 (C3) accept Und-P with some degree of flexibility, hydrophilic C2 
accommodating the phosphate head group, while hydrophobic C3 encompasses the lipid tail 









A) Model generated by PDB coordinates of ArnTCM. Black lines indicate the inner membrane boundaries, 
with TMH demonstrated spanning the bilayer. B) Appromixate locations of Cavities-1, -2, and -3, are 
highlighted by blue, green, and purple shading respectively141.  
 
Successful binding of UndP-α-L-Ara4N may induce a conformational shift to a more stable 
arrangement able to accept lipid A.  Purportedly catalytic residues are tightly conserved, necessary 
for the retrieval of L-Ara4N modified Lipid A species, and harboured on regions exposed to the 
periplasm. ArnTBC cannot function as a potentiator of polymyxin B resistance without TYR-43, 
LYS-69, and ARG-254; all situated in PL118, 147. This result was reflected for ArnT of S. enterica, 
A.           B. 
Figure 1.10 Visualization of ArnTCM (PDB 5F15) by pyMOL. 
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with critical residues corresponding to TYR-36, LYS-62, and GLU-478. However, these residues 
were found to play a role in a much larger signature motif spearheaded by ASP-39 and GLU-40: 
the 39DEXRYAX(5)MX(3)GXWX(9)YFEKPX72 feature147. Mutant ArnTBC with alanine 
substitution in D-39 could not rescue the polymyxin resistant phenotype displayed by the isogenic 
wild-type, ArnTSE exhibited even more stringency at this site as substitutions at both ASP-32 and 
GLU-33 rendered the mutant non-functional147. Other known residues necessary for function in 
S. enterica ArnT and ArnTCM, entrap Zn2+ within C2. The zinc cation may assist function by 
pinning back PL4 to allow Und-P-α-L-Ara4N access to the catalytic site141,148. 
1.9 EptA: Structure and Function  
The structural features and catalytic function of phosphoethanolamine (pEtN) transferases have 
been investigated in depth within Neisseria meningitidis (LptA), Campylobacter jejuni (EptC), 
the Moraxella spp., and Salmonella enterica (EptA/PmrC). Due to its great clinical importance, 
the plasmid-borne MCR-1 pEtN transferase has also been subject to structural investigation 
focused on its putative catalytic site149-151.  
1.9.1 Function  
EptA mediates the esterification of lipid A phosphate groups with the cationic moiety, pEtN. 
Transferases can modify both anionic points on the lipid A disaccharide, with uniform pEtN-
coating of phosphate head-groups often demonstrated by species lacking a defined arnBCADTEF 
homologue44,152,153. PMR in pathogenic GNB Acinetobacter baumannii and Helicobacter pylori, 
is inextricably linked with the presence of a fully functional pEtN transferase as the sole cation 
decoration available to each species113,132. Enterobacteriaceae must coordinate pEtN-transferase 
activity with L-Ara4N decoration, E. coli, Shigella flexneri, and S. enterica favour lipid A 1-
phosphate as the dominant and usually sole pEtN-modification site107,114.  
1.9.2 Structure  
Phosphoethanolamine transferases are integrated within the inner membrane, allowing them to 
draw upon a readily accessible pool of phosphatidylethanolamine from which the pEtN moiety is 
extracted152. Despite a protein sequence identity of ~40% between LptA, EptC, and MCR-1, 
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strong conservation at the active sites does permit some structural extrapolation150. The catalytic 
domain of MCR-1 and the full crystal structure of LptA in Neisseria spp. can therefore be used 
to infer key class features of the pEtN-transferases.  
Topologically, EptA can be divided into two domains; a transmembrane anchor that spans the 
inner membrane and a soluble region that extends into the periplasm. Five TMH studded with 
hydrophobic amino acids constitute the N-terminal of the enzyme, a stretch of 176-amino acids 
in S. enterica EptA107. These helices carry charged patches that provide an interface with 
phospholipid head-groups on target lipid A substrates. From the transmembrane domain, a 
bridging helix extends into the periplasm linking to the 370-amino acid C-terminal34. This soluble 
domain contains a conserved threonine residue that is phosphorylated when reactive; THR-280 










The catalytic THR-280 residue is represented as red sticks embedded within the centre of Neisseria 
meningitidis EptA152. As of yet, there is no full structural model of MCR-1, MCR-2, or other EptA enzymes.  
 
Theoretical pathways of how EptA conducts the modification of lipid A start with the collection 
of phosphatidylethanolamine via two small periplasmic helices, harbouring a GLU-114 that 
hydrogen bonds pEtN amine groups152. Phosphothreonine launches a nucleophilic attack on the 
Figure 1.11 Structural Model of N. meningitidis EptA with THR-280 Highlighted. 
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donor phosphate of phosphatidylethanolamine, briefly holding the pEtN residue to form an pEtN-
enzyme intermediate150. Binding of lipid A elsewhere on EptA, allows pEtN to subsequently be 
donated to either the 1- or 4’-phosphate head group. Conserved residues of the active site 
implicated in catalysis are GLU-246, ASP-465, and HIS-466 and it is suggested that these amino 
acids coordinate a Zn2+ ion necessary for site stability150. 
1.10 Targeting L-Ara4N and pEtN for the Development of Anti-virulence Strategies 
The shift toward anti-virulence drug targeting stems from a desire to make compounds that are 
“evolution-proof”; unburdened by the rising tide of resistance that accompanies treatment with 
bactericidal antibiotics154. In any given population of enteric bacteria, ~10-7 to 10-6 mutations are 
inflicted per cell, per generation, with the ability to theoretically bestow a CAMP resistant 
phenotype51. Infective populations in bacterial meningitis (109 cells/mL), urinary tract infections 
(106-1010 cells/mL in bladder), and pulmonary tuberculosis (105-106 cells/mL) easily eclipse the 
size necessary to reasonably expect the presence of CAMP resistant cells at the onset of any 
antibiotic treatment 38.  
Abrogating the induction of resistance via anti-virulence compounds could prevent these CAMP 
resistant variants from establishing a foot-hold in vulnerable patients. Targeting the individual 
enzymes conducting pEtN and L-Ara4N synthesis, and their associated regulatory architecture 
has been pursued on several fronts. Successful obstruction of ArnT and ArnB has previously been 
demonstrated by N-formylated substrate analogues, and cycloserine L-/D-isomers, 
respectively89,155. Further targets within the arnBCADTEF operon include ArnC, which may be 
vulnerable to tunicamycin derivatives based on prior successful inhibition of Bordetella pertussis 
ArnC homolog, LgmA156. However, neither terminal lipid A transferase has been selectively 
inhibited to the extent of diminishing clinically relevant PMR via removal of L-Ara4N or pEtN.  
1.11 Hypothesis of Project 
This project aims to access the potential of ArnT and EptA as antimicrobial drug targets. By 
investigating the activity of each in vitro, and the impact of selective arnT and eptA single deletion 
mutants; I will determine the relative influence that both pathways exert on the PMR phenotype 
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and features associated with pathogenesis. Based on the prominence of EptA modification in the 
acid response of E. coli O157:H7, and Shigella flexneri; I hypothesise that E. coli JW5730-2 
(∆eptA::kan), unable to modify its lipid A with pEtN, will be more vulnerable toward a variety of 
bactericidal stimuli.  
1.12 Project Aims 
1.12.1 Expression and characterisation of ArnT 
E. coli K-12 strain, BW25113 will be used as the template for creating recombinant ArnT. 
Amplification of arnT via PCR will be used to form a suitable insert for further manipulation. 
The insert will be cloned into the expression vector pET15-b, which will be transformed into 
specialised expression strains of E. coli: BL21(DE3) pLysS, BL21(DE3) Rosetta-2 Gami, and the 
overexpression strains C41 and C43. Small scale expression will be performed utilising protocols 
designed to enhance recovery of membrane proteins. Expression will be assessed using Western 
immunoblot. If successful, collection of protein will be shifted to a large-scale expression method. 
ArnT will then be analysed by researchers at the UWA School of Molecular Sciences to assess 
its structural features, and if time permits its enzymatic activity.  
1.12.2 Expression and characterisation of EptA  
E. coli K-12, strain BW25113 will again be used as the template for creation of recombinant 
EptA. PCR amplification to yield an eptA insert will be performed as per 1.12.1, however eptA 
will instead be cloned into expression vector pET28a(+) to ensure appropriate placement of the 
HisX6-Tag. Expression strain BL21(DE3)pLysS will be used to generate EptA via small-scale 
expression, protein confirmation will occur via Western immunoblot before transfer to large-scale 
expression. Collected protein will be sent to the School of Molecular Sciences for Analysis.  
1.12.3 Investigate the phenotype of mutant E. coli: BW25113∆arnT, and BW25113∆eptA  
Both strains will be subjected to a series of tests relevant to their pathogenic potential in a clinical 
setting. To ensure that any deleterious effects can be attributed to ∆arnT or ∆eptA, growth curves 
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will be conducted for each strain in rich media. Differences in generation time, or lack thereof, 
will be accounted for in subsequent assays.  
For eliciting strain specific phenotype, a panel of abiotic challenges that provoke lipid A 
modification have been selected from the literature. Extreme or moderate acidity and magnesium 
limitation form the basis of this test battery. Further to this aim, bacteria will be exposed to 
Polymyxin B to highlight any clinically relevant vulnerabilities in mutant strains. Minimum 
inhibitory concentrations (MIC) of PxB collected from each strain provide a base-line measure of 
susceptibility from which predicted additive effects conferred by pre-exposure to pH and Mg2+-
limitation can be investigated.   
Within a diverse array of hosts, both ArnT and EptA have been observed to support functions 
critical to pathogenicity. One such ability is persistence inside the macrophage phagolysosome. 
While relatively few E. coli pathotypes can establish phagolysosomal residency, a macrophage 
survival assay could indicate whether E. coli unable to fully decorate lipid A present a defective 
host-defence phenotype. In this study, murine monocyte/macrophage cell line J774A.1 has been 
selected as the in vitro host proxy for challenge with wild-type E. coli, BW25113∆arnT, and 
BW25113∆eptA.  
1.13 Significance of the project  
High degrees of structural and functional conservation in EptA and ArnT attracts the possibility 
that both could form the basis of a Gram-negative wide drug targeting regime. By focusing on E. 
coli this project can provide valuable first-principles insight into the validity of pursuing ArnT 










2.1 Escherichia coli strains and Plasmids  
All E. coli strains investigated in this study obtained from the Yale CGSC Keio Collection are 
summarized in Table 2.1. Strains used as expression hosts, plasmid sources, or recombinant hosts 
are outlined in Table 2.2, Table 2.3 and Table 2.4 respectively. Plasmids created or used in this 
study are summarized in Table 2.5., along with their necessary genetic information.  
2.2 Oligonucleotide Primers 
All oligonucleotide primers created during this study are listed in Table 2.6. 
Table 2.1 Keio Collection E. coli Strains. 
Database ID Strain Genotype Source 
ExEC747 BW25113  F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-
1, Δ(rhaD-rhaB)568, hsdR514 
CGSC 
ExEC748 JW5730-2 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-
1, Δ(rhaD-rhaB)568, ΔeptA740::kan, hsdR514 
CGSC 
ExEC749 JW2251-1 F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, 




F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-




F-, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, 
















Table 2.2 E. coli Expression Strains 
Strain Genotype Source 
OverExpressTM 
C41(DE3) 
Derivative of BL21(DE3), resistant to OCGP 
















Δ(ara-leu)7697 ΔlacX74 ΔphoA PvuII phoR araD1n 39 
ahpC galE galK rpsL (DE3) F′[lac+ lacIq pro] 
gor522::Tn10 trxB pLysSRARE2 (CamR, StrR, TetR 
Supplies AGA, AGG, AUA, CUA, GGA, CCC, and CGG 
via CmR plasmid. 
Novagen, Merck 
Millipore (USA) 
Lemo21(DE3) fhuA2 [lon] ompT gal (λ DE3) [dcm] ΔhsdS/ 
pLemo(CamR)λ DE3 = λ sBamHIo ΔEcoRI-B 




Light Source (UK 
 
 
Table 2.3 E. coli Strains Harbouring Plasmid 
Database ID Strain Genotype Source 
EXEC79 DH5α F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rk-, mk+) phoA 
supE44 λ-thi-1 gyrA96 relA1 
A/Prof. C. Kahler 
ExEC99 JM109  
(pET-15b) 
endA1, recA1, gyrA96, thi, hsdR17 (rk
–, 
mk
+), relA1, supE44, Δ( lac-proAB), [F´ 
traD36, proAB, laqIqZΔM15]. 
Dr. C. Bond 
ExEC744 DH5α 
(pCP20) 
As above, plus plasmid pCP20 A/Prof. C. Kahler 
CKEC961 DH5α 
(pET28a(+)) 









Table 2.4 E. coli Strains Transformed During This Study 
Database ID Strain Genotype  Source 
N/A One Shot® TOP10 
Chemically Competent 
F–, mcrA, Δ(mrr-hsdRMS-mcrBC), 
φ80lacZ ΔM15, ΔlacX 74, deoR, recA1, 
araD139, Δ(ara , leu )7697, galU, galK, 





CKEC1136 TOP10 with TOPO_arnT N/A This study 
CKEC1137 TOP10 with TOPO_eptA N/A This study 
CKEC1138 TOP10 with pET-
15b_arnT 
N/A This study 
CKEC1139 DH5α with TOPO_arnT N/A This study 
CKEC1140 DH5α with pET-15b_arnT N/A This study 
CKEC1141 DH5α with TOPO_eptA N/A This study 
CKEC1142 DH5α with 
pET28a(+)_eptA 
N/A This study 
CKEC1143 BL21(DE3) pLysS with 
pET-15b_arnT 
N/A This study 
CKEC1144 Rosetta-Gami 2 with pET-
15b_arnT 
N/A This study 
CKEC1145 C41 OverExpress with 
pET-15b_arnT 
N/A This study 
CKEC1146 C43 OverExpress with 
pET-15b_arnT 
N/A This study 
CKEC1147 BL21(DE3) pLysS with 
pET28a(+)_eptA 
N/A This study 
CKEC1148 Rosetta-Gami-2 pLysS 
with pET28a(+)_eptA 
N/A This study 
CKEC1149 C41 OverExpress with 
pET28a(+)_eptA 
N/A This study 
CKEC1150 C43 OverExpress with 
pET28a(+)_eptA 
N/A This study 
CKEC1151 Lemo21(DE3) with pET-
15b_arnT 
N/A This study 
CKEC1152 Lemo21(DE3) with pET-
15b_arnT 





Table 2.5 Plasmids Used During This Study 
Database ID Plasmid Features Source 
NA pET-15b High copy N-terminal HisX6 tag 
expression vector, harbouring 
Ampicillin resistance. Multiple cloning 





High copy cloning vector harbouring 
Kanamycin/Zeocin resistance. Supplied 




NA pET28a+ Expression vector with N-terminal His-
Tag and optional C-terminal His-Tag. 
Controlled by T7 promoter. Contains 




NA pCP20 pSC101-based low copy number vector 




pCMK1136 TOPO_arnT TOPO containing E. coli BW25113 
arnT following PCR amplification 
This study 
pCMK1137 TOPO_eptA TOPO containing E. coli BW25113 
eptA following PCR amplification 
This study 
pCMK1138 pET-15b_arnT pET-15b containing E. coli BW25113 
arnT cloned into the NdeI/BamHI site 
This study 
pCMK1142 pET28(+)_eptA pET28a+ containing E. coli BW25113 




Table 2.6 Oligonucleotide Primers Used in This Study 




CCC CAT ATG AAA TCG GTA CGT 





CCC GGA TCC TCA TTT GGG ACG 





CCC CTC GAG TTC ACT CAC TCT 





CCC CCA TGG ATG TTG AAG CGC 




EptA_del_screen_Top External to 
eptA 
CTT TGT TCC GCC ATC CGC G This study 
EptA_del_screen_Bot External to 
eptA 
TCC AGC CAT AAA AGC CAA CC This study 
arnT_del_screen_Top External to 
arnT 
CGG ACG TGA AGG CTG GCT GG This study 
arnT_del_screen_Bot External to 
arnT 
GCC GGG CAG TTG TGT CAG AAA 
C 
This study 
M13 Forward (-20) Sequencing in 
TOPO 
GTAAAACGACGGCCAG Invitrogen, Life 
Technologies 
(USA) 
M13 Reverse Sequencing in 
TOPO 




2.3 Bacterial Growth media  
All media outlined in this study was subject to sterilization by autoclaving at 121°C for 
15 minutes. Formulations requiring further supplements and/or antibiotics were cooled to ~55°C 
to assist preservation of temperature sensitive reagents. Agars intended to support growth on solid 
media were aliquoted into petri dishes while molten, set at room temperature, and dried under 
sterile conditions and stored in sealed bags at 4°C. Liquid growth media was stored at room 
temperature.  
2.3.1 Lysogeny Broth (LB) 
Consisted of (0.5% (w/v) Yeast extract, 1.0% (w/v) NaCl, 1.0% Tryptone). LB was created in 
400 mL quantities, consisting of; 2.0 g Yeast Extract, 4.0 g NaCl, and 4.0 g Tryptone dissolved 
in ddH2O.  
2.3.2 Lysogeny Agar (LBA) 
Consisted of (0.5% (w/v) Yeast extract, 1.0% (w/v) NaCl, 1.0% Tryptone, 1.0% Bacteriological 
Agar). LA was created as per the ingredients of LB, with the addition of 4.0 g Bacteriological 





2.3.3 N-Minimal Media  
N-minimal media was made as previously described135. In 1 L ddH2O, the following reagents 
were dissolved: 0.1M Bis-Tris, 5 mM KCl, 7.5 mM (NH4)2SO4, 0.5 mM K2SO4, 1 mM KH2PO4, 
0.10% casein hydrolase, 0.20% glucose, 0.0002% thiamine, 15 µM FeSO4, and 10 µM 
MgSO4.7H2O.  
2.3.4 Long Term Storage of Bacterial Cells  
Lysogeny-glycerol broth was used to store Escherichia coli at – 80°C. Aliquots consisted of 250 
µL 80% (v/v) glycerol, and 750 µL LB containing suspended bacterial cells.  
2.3.5 Tissue Culture Media  
Tissue culture media was used to maintain J774.A1 macrophage cell lines. Supplements were 
added or excluded according to individual experimental needs as specified in the results. 
Table 2.7 Tissue Culture Media 
Base Media Supplementation Source 
Leibovitz’s L-15 Medium GlutaMAXTM 
Foetal Calf Serum (10% v/v) 
Gibco, Life 
Technologies (USA) 
RPMI 1640 Medium Foetal Calf Serum (10% v/v) 
Pen-Strep antibiotic (10 000 U/mL 




2.4 Media Supplements 
2.4.1 Isopropyl β-D-1-thiogalactopyranoside (IPTG)  
IPTG stock was made to a concentration of 1 M by dissolving 2 g IPTG in 8 mL ddH2O (Progen 
Industries Ltd. (USA). IPTG solutions were filter sterilized (0.2 µm filter (Millipore)) and stored 
as 1 mL aliquots at – 20°C.  
2.4.2 Antibiotics  
All antibiotics were sourced from Sigma Chemical Company (USA), listed in Table 2.10. Prior 




2.5 Reagents, Buffers, and Chemicals  
All reagents and buffers used in this study are summarized in Table 2.8. Chemicals used in the 
supplementation of media, or specific experimental methods are listed in Table 2.9.  
 
Table 2.8 Reagents and Buffers 





0.1% (v/v) conjugated monoclonal 




Blocking Buffer 2% (w/v) Bovine Serum Albumin 
(BSA) was dissolved in PBS to a final 






Proprietary non-ionic detergent, 20 mM 
Tris HCl, pH 7.5. Lysozyme (50 
mg/mL) and DNase I (2500 U/mL) were 






11.1 g CaCl2 (110.98 g/mol) was 
dissolved in dH2O to a final volume of 
1 L. Solution was autoclaved and stored 




(85 mM), 15% 
glycerol v/v 
1.72 g CaCl2 was dissolved in dH2O to a 
final volume of 85 ml. Solution was 
autoclaved prior to addition of 15 ml 
100% glycerol and storage at 4°C.  
  
3.6 
Coomassie Stain Coomassie stain was created in 400 mL 
quantities, consisting of 1 g Coomassie 
Brilliant Blue, 180 mL methanol, 180 




Coomassie De-Stain 50 mL methanol and 75 mL acetic acid, 





Two solutions mixed immediately 
before use; 30 mg of 4-chloro-1-naphtol 
dissolved in 10 mL methanol, and 40 














4 mL 1.5 M Tris-Cl (pH 6.8), 10 mL 
glycerol, 2 g SDS, 5 mL β-
mercaptoethanol, and 1 mL 1% (w/v) 
bromophenol blue. Stored at -20°C, in 
1.5 mL aliquots 
 3.8.8 
Magnesium 
Chloride (100 mM) 
20.3 g MgCl2 (203.30 g/mol) dissolved 
in dH2O to a final volume of 1 L. 
Solution was autoclaved and stored at 
4°C.  
 3.6 
MES SDS Running 
Buffer (20X) 
1 M MES, 1 M Tris Base, 2% SDS, 20 








100 mM Magnesium acetate, 0.5 M 
Potassium acetate, 200 mM Tris acetate 













Dissolve 1 x PBS Tablet in 500 mL 
ddH2O. 
Sigma-Aldrich 




(TAE) buffer (1X) 
20 mL of 50 x TAE buffer diluted to 1 L 





50 mL NuPAGE® Transfer Buffer 





Table 2.9 Chemicals and Enzymes 
Chemical/Enzyme Source 
10X Taq Reaction Buffer New England Biolabs (USA) 
4-Chloro-1-napthol Sigma-Aldrich PTY LTD (Australia) 
6x-His Tag Monoclonal Antibody (HIS.H8), HRP Sigma-Aldrich PTY LTD (Australia) 
Agarose (Molecular Biology Grade) VWR Chemicals (USA) 
Ammonium Chloride (NH4Cl) Univar (USA) 
Ammonium sulfate (NH4)2SO4) Univar (USA) 
Bacteriological Agar Oxoid (Australia)  
Bis-Tris Sigma-Aldrich PTY LTD (Australia) 
Blue Prestained Protein Standard, Broad Range (11-
190 kDa) 
New England Biolabs, (USA) 
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Bovine Serum Albumin (BSA) Sigma-Aldrich PTY LTD (Australia) 
dNTP mix Invitrogen, Life Technologies (USA) 
D-Glucose  Scharlau (Spain) 
Ethanol BDH Chemicals (Australia) 
Glycerol Univar (Australia) 
Hydrochloric Acid (32 % (w/w)) BDH Chemicals (Australia) 
Isopropylthio-β-D-galactosidase (IPTG) Progen Industries Ltd. (USA) 
Iron sulfate (FeSO4) Bio-Strategy Laboratory Products (Australia) 
Magnesium sulphate heptahydrate  
(MgSO4∙7H2O) 
Invitrogen, Life Technologies (USA) 
Methanol Merck Millipore (Germany)  
PBS Gibco, Life Technologies (USA) 
Phusion HF 5X Buffer New England Biolabs, (USA) 
Phusion High-Fidelity DNA Polymerase New England Biolabs, (USA) 
Potassium phosphate monobasic (KH2PO4) ThermoFisher Scientific (USA) 
Potassium Chloride (KCl) Bio-Strategy Laboratory Products (Australia) 
Potassium sulfate (K2SO4) Bio-Strategy Laboratory Products (Australia) 
S.O.C Medium Invitrogen, Life Technologies (USA) 
Sodium Chloride  Univar (Australia) 
Sodium phosphate dibasic (Na2HPO4) Bio-Strategy Laboratory Products (Australia) 
SYBR® Safe DNA Gel Stain Life Technologies (USA)  
T4 DNA ligase Invitrogen, Life Technologies (USA) 
T4 DNA ligase buffer (5 x) Invitrogen, Life Technologies (USA) 
Taq DNA polymerase  New England Biolabs (USA)  
Thiamine Bio-Strategy Laboratory Products (Australia) 
Tryptone Peptone Oxoid (Australia) 









Table 2.10 Antibiotics Used in This Study 








300 mg of chloramphenicol dissolved in 10 











50 mg tetracycline hydrochloride salts 
dissolved in 2.5 mL ddH2O, made up to 10 





2.048 mg polymyxin B sulfate salt, dissolved 































3 Methods  
3.1 Growth Conditions  
E. coli strains were grown either on lysogeny agar (LBA), or in lysogeny broth (LB) under aerobic 
conditions at 37oC for appropriate periods of time. During certain experiments, cells were also 
grown in N-minimal media under the same conditions as described.  
3.2 Culture Storage 
For short-term storage, E. coli cultures on LA and in LBA were stored at 20°C and 4°C 
respectively. For long-term storage, LB glycerol stocks for E. coli strains were made of cultures 
from overnight growth on solid media and stored at -80°C.  
3.3 Growth Curve 
Growth curves were performed in either LB, or N-minimal media as per individual experiments. 
Broth cultures were incubated at 37°C, 220 RPM (Ratek Orbital Mixer Incubator), from which 1 
mL samples were withdrawn at appropriate intervals. Broth aliquots were read at OD600 using the 
UVmini-1240 UV-Vis Spectrophotometer (Shimadzu). During individual experiments, broth 
aliquots were serial diluted 10-fold to a final concentration of 10-8, after which 50µL of each 
dilution step was used to inoculate LBA. Samples were taken for 24-hours. Plates were incubated 
overnight at 37°C and enumerated the following day.  
3.4 DNA Manipulation Techniques  
3.4.1 Extraction of E. coli genomic DNA  
Single colonies were inoculated into 10 mL LB, and incubated overnight at 37°C, 220 RPM 
(Ratek Orbital Mixer Incubator). Genomic DNA was extracted from 500 µL aliquots of 
overnight culture using the Gentra Puregene Yeast/Bact. Kit B (Qiagen), as per the manufacturer’s 
instructions.  
3.4.2 Plasmid Extraction  
Single bacterial colonies were inoculated into 10 mL LB with appropriate antibiotics and 
incubated overnight at 37°C, 220 RPM (Ratek Orbital Mixer Incubator). Cells were harvested 
via centrifugation at 14 100 x g. Plasmids were extracted using QIAprep Spin Miniprep Kit 
(Qiagen), as per the manufacturer’s instructions. Extraction of low copy plasmids was enhanced 
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by performing cell harvest in triplicate, and pooling samples following addition of neutralisation 
buffer.  
3.4.3 Polymerase chain reaction (PCR)  
Initial amplification of target genes from gDNA templates was performed using Phusion® High-
Fidelity DNA Polymerase with 5 X Phusion® HF Buffer. All other routine PCR amplifications 
were performed using Taq DNA Polymerase with 10X Taq Reaction Buffer. Standard reaction 
mixtures contained 50 – 250 ng template DNA, 200 µM dNTPs, 0.5 µM Forward Primer, 0.5 µM 
Reverse Primer, reaction buffer, DNA Polymerase, and ddH2O up to 50 µL. Composition of 
reaction mix varied per experimental protocol, as stated in Results.  
For initial amplification of target genes, thermocycler conditions were set at 1 cycle of 98°C for 
30 s, 35 cycles of [98°C for 10 s, 69°C for 20 s, 72°C for 60 s], 1 cycle of 72°C for 10 minutes, 
before being held at 20°C. With both Phusion and Taq DNA Polymerase, cycling conditions were 
altered to suit template according to manufacturer’s guidelines.  
3.4.4 Agarose gel electrophoresis  
Unless otherwise stated, all agarose gels were prepared through addition of 0.4 g agarose to TAE 
(1X) buffer, to a final volume of 50 mL (0.8% (w/v)). Gel solutions were mixed and heated until 
agarose entirely dissolved, before being cooled to approximately 50°C. A 3 µL aliquot of SYBR® 
Safe DNA Gel Stain (Life Technologies) was added to the solution, which was then immediately 
transferred to a gel tray and set.  
DNA samples were mixed with 10X loading buffer (Life Technologies) to a final concentration 
of 1X, prior to loading. Agarose gels were electrophoresed at 100 V for 45 minutes and visualized 
by LAS-3000 imager (Fujifilm) 
3.4.5 Purification of DNA from Gel  
Excision and purification of DNA bands was performed using the QIAquick Gel Extraction Kit 
(Qiagen), as per the manufacturer’s instructions.  
3.4.6 Restriction Digest  
DNA digests were performed as follows, using optimized incubation temperatures and time 
periods specified by the manufacturer (New England Biolabs). Reactions comprised of 2 µg 
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plasmid DNA, estimated via NanoDrop 2000 UV-VIS spectrophotometer (Thermo Scientific), 
10 U restriction endonuclease, 1 x NEB CutSmart Buffer, and sterilised ddH2O to a final volume 
of 20 µL. Digests were verified via agarose gel electrophoresis, and visualized using a LAS-3000 
imager (Fujifilm) prior to continuation (Method 3.4.4).  
3.4.7 DNA Ligation 
Ligation reactions were performed in 30µL volumes, consisting of > 5 ng digested plasmid, > 15 
ng digested DNA insert, 1 U T4 DNA ligase, 1X T4 DNA ligase buffer (Invitrogen, Life 
Technologies) and 10 µL ddH2O. Reactions were subjected to overnight incubation on ice prior 
to transformation into E. coli.  
3.4.8 TOPO Cloning  
PCR products were cloned into pCR®-Blunt II-TOPO® (Invitrogen) as per manufacturer’s 
instructions. 
3.5 E. coli Transformation 
3.5.1 DH5α and BL21(DE3) 
Ligation reaction (Method 3.4.7) was transferred onto 50 µL aliquots of thawed calcium 
competent E. coli, in 2 µL aliquots. Suspensions were incubated on ice for 30 min, prior to heat-
shocking at 42°C for 45 s. Cells were then returned to ice for 2 min. For recovery, cells were 
supplemented with 250 µL S.O.C media and incubated at 37°C for 2 hrs, 220 RPM (Ratek 
Orbital Mixer Incubator). Recovered cells were plated onto LBA supplemented with selective 
antibiotics. Transformants were verified by phenotype, plasmid extraction (Method 3.4.2), and 
restriction digest where necessary (Method 3.4.6).   
3.5.2 TOP10  
OneShot® Top 10 chemically competent E. coli (Invitrogen, Life Technologies) were transformed 
according to manufacturer’s instructions.  
3.5.3 One Shot BL21(DE3)pLysS Chemically Competent E. coli 
Transformation into OneShot BL21(DE3)pLysS chemically competent E. coli (Invitrogen, Life 




3.5.4 Rosetta-gamiTM 2(DE3)pLysS Competent Cells   
Transformation of Rosetta-Gami 2 was performed according to the manufacturer’s instructions 
(Invitrogen, Life Technologies).  
3.5.5 OverExpress C41(DE3) and C43(DE3) Competent Cells 
OverExpress strains were transformed according to the manufacturer’s instructions (Lucigen). 
3.5.6 Lemo21(DE3) E. coli  
Lemo21(DE3) was transformed as per the manufacturer’s instructions (Membrane Protein 
Laboratory, Diamond Light Source)   
3.5.7 Transformation of Keio Collection Strains JW2251-1, JW5730-2 E. coli with pCP20 
Transformation into chemically competent (Method 3.6.1) JW2251-1 and JW5730-2 was 
performed as per section 3.5.1. with the following modifications. Cells were recovered with 1 mL 
S.O.C media before incubation at 30°C with agitation for 2 hrs. Suspensions were plated onto 
LBA containing selective antibiotics and incubated overnight at 30°C.  
3.6 Preparation of chemically competent cells  
3.6.1 Keio Strains E. coli JW2251-1, JW5730-2 and E. coli Lemo21(DE3) 
Single colonies of each strain were inoculated into 10 mL LB, and incubated at 37°C, 
overnight at 220 RPM (Ratek Orbital Mixer Incubator). A 1 mL aliquot of overnight culture 
transferred to 99 mL LB, which was then incubated at 37°C, 220 RPM (Ratek Orbital Mixer 
Incubator), until OD600 value ≥0.4 was attained. Broth cultures were chilled on ice for 30 min 
before transfer in 25 mL aliquots to pre-chilled, sterile 30 mL tubes (Sarstedt). Cells were then 
harvested by centrifugation at 3000 x g, 4°C, 15 min. Supernatant was discarded and cell pellets 
were resuspended in 10 mL ice cold MgCl2, before transfer to a single centrifuge bottle.  
Pooled cells were harvested by centrifugation at 2000 x g, 4°C, 15 min. Supernatant was 
discarded, and pellets were resuspended in 20 mL ice cold CaCl2. Suspensions were incubated on 
ice for 20 min, prior to harvesting via centrifugation at 4°C and 2000 x g, 15 min. Supernatant 
was then discarded and before resuspension of pellets in 5 mL ice cold CaCl2, with 15% glycerol. 
Cells were harvested via centrifugation at 1000 x g, 4°C, 15 min. Supernatant was discarded, with 
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competent cell pellets resuspended in 1 mL ice cold CaCl2, 15% glycerol. Competent cells were 
divided into 50 µL aliquots and snap-frozen in LN2, prior to storage at -80°C until required.  
3.7 Curing of E. coli Strains JW5730-2, JW2251-1.  
Excision was performed as per prior established guidelines157. Keio collection strains were 
rendered calcium competent, as per section 3.6.1. before being transformed with plasmid pCP20 
as per section 3.5.7. After incubation at 30°C for 24 hrs, single colonies were inoculated in 5 mL 
LB and shaken overnight at 45°C to induce expression of FLP-recombinase, and temperature 
dependent ejection of pCP20. Overnight cultures were spread onto LBA plates and incubated at 
30°C for a further 24 hrs. Thirty colonies from each strain were patch plated in triplicate onto 
LBA, LBA containing 100 µg/mL ampicillin, and LBA containing 50 µg/mL kanamycin. Plates 
were incubated overnight at 37°C, after which isolates sensitive to all antibiotics were selected 
and stored at -80°C.   
3.8 Expression of Recombinant Protein: ArnT::HisX6 and EptA::HisX6 
3.8.1 Chemical Transformation of Expression Strains 
Expression strains were selected on the basis of favourable characteristics, i.e. reduction of basal 
recombinant protein expression or provision of rare codons. Commercial expression strains were 
transformed with each plasmid construct, according to the manufacturer’s instructions. 
Transformants were plated for single colonies on selective LBA and incubated at 37°C overnight.  
3.8.2 Induction of Protein Expression 
Following overnight growth, single colonies of transformant were inoculated into 10 mL aliquots 
of antibiotic-selective LB. Broth culture was incubated overnight with agitation at 37°C, 220 
RPM. For small scale expression studies, 500 µL of overnight broth culture was transferred to 50 
mL antibiotic-selective LB. Expression cultures were incubated at 37°C, 220 RPM (Ratek Orbital 
Mixer Incubator). During the course of optimization, cultures were grown until OD600 readings of 
0.4 – 0.6, or 1.0 – 1.2 were attained via UVmini-1240 UV-Vis Spectrophotometer (Shimadzu). 
IPTG was added to a final concentration ranging from 0.4 mM – 1 mM, in accordance with 




3.8.3 Induction of Protein Expression, Lemo21(DE3) 
Induction of protein expression from Lemo21(DE3) E. coli was performed as outlined above with 
the following modifications. Antibiotic-selective LB was supplemented with 750 µM L-
Rhamnose, and expression proceeded at room temperature for 16 hrs prior to initial sample 
collection. Samples were collected at 16 hrs and 24 hrs only.  
3.8.4 Sample Collection  
Bacterial cultures were incubated at 37°C, 220 RPM (Ratek Orbital Mixer Incubator) following 
the addition of IPTG. Post-induction, 5 mL aliquots of culture was withdrawn at 0, 2, 4, and 24 
hours. Aliquots were subjected to centrifugation at 4 000 x g, 20°C, for 10 min. Supernatant was 
discarded. In accordance with experimental design, cell pellets were either resuspended in 100 
µL PBS (Gibco, Life Technologies), frozen via LN2 immersion, or immediately transferred to 
refrigeration at -20°C. 
3.8.5 Preparation of Cell Lysate by Sonication 
Pelleted cells were disrupted via Ultrasonic Processer XL-2020 (Misonix) for three 15 s intervals, 
interspersed with submersion in ice for 30 s. Cell lysate was immediately transferred to 
centrifugation at 14 100 x g for 15 min. Supernatants were carefully decanted into separate 1.5 
mL microfuge tubes, pellets were retained and suspended in 20 µL PBS.  
3.8.6 Preparation of Cell Lysate by In-House Lysis Buffer  
Pelleted cells were resuspended with 4 mL In-House Lysis Buffer, per gram cell pellet. The 
suspension was supplemented with 1 mg/mL Lysozyme solution, and incubated at room 
temperature for one hour. Cell suspensions were then snap-frozen in LN2, and thawed at 25°C. 
The freeze/thaw cycle was repeated twice more. Each sample was subsequently treated with 
DNase I (80 U) and incubated on ice for 30 min. Following incubation, lysate was transferred to 
1.5 mL centrifuge tubes for centrifugation at 14 100 x g for 10 min. Supernatants and insoluble 





3.8.7 Preparation of Cell Lysate via B-PER® Bacterial Protein Extraction Reagent  
Pelleted cells were prepared as outlined in the manufacturer’s instructions (Thermo Scientific). 
Briefly, samples were resuspended in 4 mL B-PER® Reagent, per gram of cell pellet. Suspensions 
were treated with 2 µL Lysozyme, and 2 µL DNase I, per mL B-PER® Reagent. Where PierceTM 
Protease Inhibitor Mini Tablets were used, complete B-PER® Lysis Buffer was assembled in 10 
mL aliquots to accommodate manufacturer specifications, i.e. one tablet per 10 mL buffer. 
Samples were incubated at room temperature for 15 min, lysate was then centrifuged and 
separated into supernatant and insoluble fractions as described above (Methods 3.8.5, 3.8.6).  
3.8.8 SDS-PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) 
A 16 µL aliquot of fractionated lysate (Methods 3.8.5 - 3.8.7) was mixed with 4 µL Laemmli 
sample buffer. For 24-hour time point samples, the insoluble cell pellet was diluted 1:4 in ddH2O 
prior to addition of sample buffer. From each sample, 8 µL aliquots were loaded into a Bolt® 4% 
- 12%, Bis-Tris Plus Gel (Novex, Life Technologies). To determine relative size of recovered 
recombinant protein, 5 µL Blue Prestained Protein Standard, Broad Range (11-190 kDa) (New 
England Biolabs) was loaded into each gel. An in-house positive control (~ 25kDa) was included, 
5 µL aliquots were mixed with 4 µL Laemmli buffer; from which 5 µL was loaded alongside 
experimental samples. Gels were electrophoresed at 200 V constant for 25 minutes within an 
XCell SureLock™ Mini-Cell Electrophoresis System (Novex, Life Technologies) containing 1X 
NuPAGE MES SDS Running Buffer.  
3.8.9 Visualisation of polyacrylamide gels 
Following SDS-PAGE (Method 3.8.8) Bis-Tris Plus Gels were strained with Coomassie blue R-
250 (Bio-Rad) for 2 hrs at room temperature, on a shaking platform set to 20 RPM (Stuart 
Scientific Platform Shaker STR6). Coomassie stain was collected and gels were incubated in 







3.8.10 Western Immunoblot  
Gels collected from SDS-PAGE (Method 3.8.8) were transferred to an InvitrolonTM PVDF 
Membrane (Novex, Life Technologies) via western immunoblot using an XCEll IITM Blot Module 
(Novex, Life Technologies). Blotting was performed as per manufacturer’s instructions.  
3.8.11 Development of Western Immunoblot  
Following transfer, PVDF membranes were immersed in blocking buffer at room temperature for 
1 hour, with rocking. Blocking buffer was discarded and membranes were washed with PBS, 4 
times for 5 min. Membranes were incubated in anti-HisX6 HRP conjugated antibody solution 
overnight at room temperature with rocking. Membranes were washed with PBS for 5 min, 4 
times. Development solution was then applied and discarded upon appearance of banding.   
3.9 Phenotypic Investigation 
3.9.1 Resistance to Polymyxin B  
3.9.1.1 MIC via Broth Microdilution 
Overnight LB cultures of E. coli BW25113, BW25113∆arnT, and BW25113∆eptA were diluted 
in LB to a concentration of ~ 5 x 106 CFU/mL. Polymyxin B stock solution (2048µg/mL) was 
diluted in LB to 128 µg/mL and transferred in 200 µL aliquots to the second column of a 96 well 
plate. Remaining wells were filled with 100 µL LB. Two-fold serial dilutions were performed 
along the plate, from Column 2 – 12. Standardized E. coli suspensions were transferred in 100µL 
aliquots to either designated test wells or Column 1, which constituted the positive growth control. 
Rows A and H contained blank LB only. Plates were incubated overnight at 37°C. Overnight 
OD600 values were assessed via xMark™ Microplate Absorbance Spectrophotometer (Bio-Rad). 
For pre-adaptive assays, broth cultures were subjected to adaptation in either pH 4.5, or N-
minimal media (10 µM, 200 µM Mg2+) overnight prior to dilution and polymyxin exposure.  
3.9.2 Resistance to Acidity 
All pH values were determined using the  HI2211-01 Benchtop pH/mV Meter (Hanna 





3.9.2.1 MIC via Broth Microdilution: Hydrochloric Acid 
A modified MIC to determine the presence of an acid responsive phenotype was performed as per 
section 3.9.1.1. Antibiotic solutions were replaced by acidified LB (256 µg/mL HCl from 10 M 
stock). 
3.9.3 Adaptive Acid Survival at Lethal pH Boundary (pH 2.5).  
Single colonies of E. coli BW25113, BW25113∆arnT and BW25113∆eptA were inoculated into 
LB for overnight growth at 37°C, with agitation. Broth cultures were subsequently diluted to 
OD600 0.1 in 5 mL fresh LB and incubated for 1 hour at 37°C, until OD600 ~ 0.3. Bacterial 
suspensions were collected by centrifugation at 4000 x g, 25°C, for 10 min. Pelleted cells were 
subjected to two treatments; immediate resuspension in 10 mL LB, adjusted to pH 4.5 (Set A) or 
resuspension in PBS (Set B). Aliquots were taken from both sets and diluted 10-fold in PBS 
before plating onto LBA for CFU/mL calculation. Moderately acidified broth cultures (Set A) 
were incubated for 1 hour at 37°C, with agitation.  
PBS re-suspensions (Set B) were transferred in 500 µL aliquots to 5 mL pH 2.5, after which 
acidified broths were either immediately returned to non-lethal pH by the addition of 5 mL LB 
(pH ~7.5) or incubated at 37°C with agitation for 15 – 30 min. Aliquots for CFU/mL calculations 
were taken from both LB rescued cultures and T15, T30 treatments. Set A was subsequently 
retrieved from incubation, and aliquots were taken determine CFU/mL. This was used to 
determine the generation time of BW25113, BW2113∆arnT, and BW25113∆eptA at pH 4.5. Set 
A broth cultures were then re-adjusted to OD600 0.3 in 5 mL fresh LB (pH 4.5). Cell pellets were 
collected via centrifugation, resuspended in PBS, and subjected to the same pH 2.5 challenge as 
Set B. LBA plates used for CFU/mL cell counts were incubated overnight at 37°C, colonies were 
counted after 24 hrs. Percentage survival at was derived from the CFU/mL of LB rescued culture, 
and CFU/mL recovered after 15 – 30 min exposure. Values were adjusted to account for dilution.  
3.10 Macrophage Invasion Assay  
3.10.1 Cell count via Haemocytometer  
Neubauer improved counting chambers were used to enumerate overnight growth of J774.A1 
cells prior to subculture. Cells collected from tissue culture flasks were resuspended in 1 mL 
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antibiotic-free DMEM (Gibco), and loaded into the channels of the haemocytometer in 10 µL 
aliquots. Inverse light microscopy was used to count cells, allowing calculation of cells/mL. 
Following cell count, aliquots were used to propagate continuous culture flasks or seed new 24 
well plates. 
3.10.2 Cell culture 
J774.A1 cells were cultured in DMEM (Gibco), supplemented with Pen-Strep (Gibco) and 10% 
FCS (Gibco), within Corning® T-75 75 cm2 flasks. Subculturing occurred every 2 – 3 days. Spent 
culture media was removed, and monolayers were washed with 5 mL 1X PBS. Cell monolayers 
were treated with 5 mL Tryple (Gibco) and incubated at 37°C, 5% CO2, for 15 min to disrupt cell 
adherence. Monolayers were scraped from the flask base until completely detached. The resultant 
cell suspension was transferred to 15 mL FalconTM conical centrifuge tubes containing 10 mL 
10% DMEM to halt trypsinization. Cells were centrifuged at 400 x g for 5 min, room temperature. 
Pelleted cells were resuspended in 1 mL culture media to separate cell aggregates. Cell counts 
were performed per section 3.10.1, prior to re-seeding of original T-75 culture flasks with known 
cell concentrations in 10 mL fresh DMEM (10% FCS) 
3.10.3 Seeding 24-well plates for Invasion Assay  
J774.A1 cells collected during subculture were enumerated via haemocytometer as per 3.10.1., 
and resuspended in DMEM (10% FCS) without antibiotics to a final concentration of 4 x 104 
cells/mL. Cell suspension was added in 1 mL aliquots to the six centre wells of labelled 24-well 
plates. To prevent desiccation, remaining wells were filled with 1 mL 1X PBS. Plates were 
incubated at 37°C, 5% CO2 for 16 hrs prior to use.  
3.10.4 Preparation of BW25113, JW5730-2, and JW2251-1 bacterial stock 
Four 24-well plates were seeded as per 3.10.3, the assay commenced the following day. 
Monolayers were assessed for confluency by inverted light microscopy. Overnight LB broth 
cultures of BW25113, BW25113∆arnT, and BW25113∆eptA were diluted 10-fold in L-15 (10% 
FCS) without antibiotics and briefly vortexed. Dilute cultures were assessed for turbidity at 
OD590, and further adjusted to OD590 ~ 0.3. From these standardized bacterial stocks, two 10-
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fold serial dilutions were performed in 10 mL L-15 (10% FCS), forming concentrations of ~ 1 x 
108 CFU/mL, and ~ 1 x 107 CFU/mL. Ten-fold serial dilutions were performed in L-15 (10% 
FCS) to 10-5, 10-6, 10-8, and 10-9; these dilutions were plated onto LBA as previously described to 
provide assay-specific overnight CFU/mL counts.   
3.10.5 Infection Step  
All test plates were retrieved from the cell culture incubator. Spent media was discarded from 
each plate. Wells were infected with 1 mL aliquots from ~ 1 x 107 CFU/mL bacteria in antibiotic 
free L-15 (10% FCS), to achieve a final MOI of approximately 10 E. coli per macrophage. Plates 
were returned to the incubator for 2 hrs, 37°C.  
3.10.6 Kill Step  
Following 2-hour incubation, plates were removed from the incubator. Infection media was 
discarded from wells. Monolayers were washed with 1 mL 1X PBS three times. Wells were 
treated with 1 mL L-15 (10% FCS) containing 200µg/mL Gentamicin. Plates were then returned 
to the incubator for 1 hour, 37°C.  
3.10.7 Collection  
The conclusion of the 1 hour Kill step was considered time zero (T0) for the purposes of this 
assay. After incubation time had elapsed, the T0 plate was retrieved. Aliquots of kill step media 
from each well were transferred to LBA plates for assessment of killing efficacy, the remainder 
was then discarded. To lyse J774.A1 cells, 1 mL ddH2O was added to each well and the monolayer 
was then vigorously scraped. Cell lysates were serially diluted ten-fold, to 10-5 (100 µL in 900 µL 
1X PBS). Dilute lysate from each strain was plated in three 50 µL drops onto LBA. Droplets were 
dried, then transferred to overnight incubation at 37°C.  
At T0, the remaining unprocessed 24-well plates were replenished with 1 mL maintenance media, 
consisting of L-15 (10% FCS) and 20µg/mL Gentamicin.  The T0 collection step was repeated at 
each time point, with both supernatant and cell lysate aliquots transferred to LBA for growth. All 




3.11 Macrophage Adherence Assay 
Preparation of 24-well plate monolayers and bacterial stock performed as outlined in 3.10.3 – 
3.10.4. Prior to infection (Method 3.10.5.), cells were treated with 1 µg/mL Cytochalasin D and 
incubated at 37°C for 30 mins. Media was discarded and cells were inoculated as per 3.10.5., with 
the addition of 1 µg/mL CD to each bacterial suspension. Plates were subsequently incubated for 
2 hours at 37°C. Following infection, cell monolayers were either treated with 200 µg/mL 
Gentamicin and subjected to further incubation as per 3.10.7., or immediately lysed using 1 mL 
ddH2O. Collection, plating, and enumeration of cell lysate contents was performed as outlined in 
3.10.7. 
3.12 Bioinformatics Tools  
 Websites and programmes used to characterize E. coli ArnT and EptA were:  
1. Jalview Version 2158  
2. Clustal Omega: http://www.ebi.ac.uk/Tools/msa/clustalo/.159 
3. Jmol: http://www.jmol.org/.160 
4. Phyre2: http://www.sbg.bio.ic.ac.uk/~phyre2/html/page.cgi?id=index.161 















4 Exploration of E. coli ArnT and EptA Homologues across the GNB, Construction of 
BW25113∆arnT and BW25113∆eptA mutants.  
4.1 The Complementary Role of ArnT and EptA 
Integral membrane proteins ArnT and EptA mediate the decoration of lipid A with twin cationic 
moieties, L-Ara4N and pEtN. Modification begets considerable polymyxin resistance in select 
bacteria, such as the Intrinsically Colistin/Polymyxin-Resistant Enterobacteriaceae (IRCE), and 
pathogenic Neisseria species162,163. Access to either ArnT or EptA supplies pathogenic GNB with 
the means to avert the bactericidal effects of endogenous CAMPs, and the polymyxin antibiotics 
colistin and polymyxin B, frequently reserved for the most severe cases of MDR GNB infection35. 
Escherichia coli, Klebsiella pneumoniae, Shigella flexneri, and Salmonella enterica serovar 
Typhimurium harbour both ArnT and EptA homologues, but are generally unable to attain 
therapeutically dangerous PMR outside of that acquired secondary to polymyxin exposure48,164. 
Whether ArnT and EptA are truly redundant in function remains to be discerned. There may 
instead be a “false dichotomy” being presented by two entirely separate enzymatic pathways and 
cationic moieties, converging at PMR but supplying vastly different phenotypic benefits under 
certain environmental conditions. Parallel assessment of each enzyme in isolation could uncover 
the full breadth of their function in E. coli, and similar GNB pathogens.  
To further investigate the duality of ArnT and EptA, E. coli single mutant strains JW2251-
1(arnT::kan), JW5730-2(eptA::kan), and the isogenic wild-type BW25113 were procured from 
the Yale Coli Genetic Stock Centre (CGSC). The construction of isogenic strains BW25113∆arnT 
and BW25113∆eptA from these isolates formed the first aim of this study. Complementary to this 
aim, a brief exploratory study into ArnT and EptA homologues across select pathogens liable to 
attain MDR status was conducted. This was performed within the purview that such lipid A 






4.2 Conservation of ArnT and EptA in Gram-Negative Bacteria.  
Protein homology across bacterial pathogens dictates the potential usefulness of prospective 
broad-spectrum targets. Without sufficient homology in residues critical to function, the efficacy 
of any therapeutic targeted to either ArnT or EptA is immediately constrained. Bioinformatics 
studies were conducted to determine the extent to which non-pathogenic E. coli ArnT and EptA 
were representative of their homologous counterparts within select clinically important GNB.  
Escherichia coli K-12, sub-strain MG1655 was selected as the protein reference. The NCBI 
Protein Database (https://www.ncbi.nlm.nih.gov/protein/) was subsequently queried with ArnT 
and EptA amino acid sequences obtained from this strain. Homologues were identified using 
NCBI Protein BLAST (blastp) directed toward pathogenic GNB of interest including the 
ESKAPE pathogens K. pneumoniae, A. baumannii, and P. aeruginosa, where appropriate. 
Proteins identified by this process are collected in Table 4.1 and Table 4.2. Additionally, an isolate 
of MCR-1 initially identified in 2016 from pathogenic PMR E. coli was incorporated for 
comparison with endogenous EptA (GenBank: ANH55937.1)165. 
Multiple sequence alignments (MSA) were initially conducted using the Clustal Omega MSA 
Web Service to identify regions of high homology or identity between the collected sequences159. 
Percentage Identity Matrices were created for both ArnT and EptA proteins (Table 4.1, 4.2). 
Alignments were subsequently visualized using desktop Jalview 2 software (Method 3.12)158. 
Import into Jalview 2 allowed further investigation via Java linked web services (JABAWS), 








Table 4.1 Exploration of EptA across the GNB. E. coli MG1655 EptA (NP_418538.2) was used to 
interrogate taxa of interest via NCBI Protein BLAST. 
 Strain Identifier  Identities Positives Expect 









































































MCR-1 plasmid E. coli  ANH55937.1 185/537(34%) 293/537(54%) 1e-106 
 
Table 4.2 Exploration of ArnT across the GNB. E. coli MG1655 ArnT (AAC75317.1) was used to 
interrogate taxa of interest via NCBI Protein BLAST. 























Yersinia pestis CO92 
 




YP_005229298.1 351/551 (64%) 421/551 (76%) 0.0 
Salmonella enterica 
subsp. enterica serovar 
Typhimurium 







4.3 ArnT retains features that are highly conserved in Multiple Sequence Alignments.  
Alignment of ArnT homologues in GNB shows that two primary motifs were apparent; 42RYA44, 
and 66YFEKP70 (Figure 4.1). These residues were previously predicted to reside within the first 
periplasmic loop of B. cenocepacia ArnT, and their arrangement pertains to L-Ara4N transferase 








Sequences included in analysis were: B. cenocepacia (WP_006482861.1), P. aeruginosa (NP_252246.1), 
E. coli (AAC75317.1), K. pneumoniae (YP_005229298.1), S. Typhimurium (AAL34393.1), and Y. pestis 
(YP_002347381.1). Conservation Histogram included in gold states the level of identity in each residue. 
Asterix (*) reflects complete conservation, plus signs (+) indicate physiochemical conservation despite 
changes in residue identity. Placement of the DEX motif outlined in red. 
 
 
Histogram commences at E. coli ARG-25. The 31DExRYAE37 and 58YFEKP62 motifs are separated by 20 
residues, residing on the first periplasmic loop of ArnT. Visualized in JalView.  
 
The predominance of each motif has been fundamental in recognition of a broader “canonical 
consensus sequence” considered the type signature of ArnT proteins; 
DExRYAx(5)Mx(3)GxWx(9)YFEKPx(4)W147 (Figure 4.2). Occupying the start of this shared 
signature is the DEx motif, a modified marker of the broader Glycosyltransferase-C Family which 
encompasses all ArnT proteins147. Indicative of their importance, these residues are entirely 
conserved in the six bacteria assessed by MSA (Figure 4.1). In E. coli, the DEx motif consists of 
Aspartic acid-31, Glutamic acid-32, and Threonine-33, substituted by a Glycine in the ArnT of 
Figure 4.2 ArnT “Signature Sequence” is apparent in Consensus Histogram. 
Figure 4.1 Clustal Omega Alignment of ArnT across the GNB, visualized in JalView. 
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B. cepacia complex. Beyond the DEX motif, individual residents of the first periplasmic loop; 
tyrosine-43 (TYR-35 in E. coli), lysine-69 (LYS-61), and the polarised residues arginine-254 and 
glutamic acid-493 (ARG-245, GLU-480) are all implicated in the expression of functional B. 
cenocepacia ArnT and concomitant lipid A modification142 (Figure 4.3). Due to their critical role 







Coordinating residues GLU-493 and ARG-254 highlighted in green and red respectively. 
Table 4.3 Percentage Identity Matrix of ArnT.  
 B. c P. a Y. p K. p MG1655 S. T 
B. cepacia 100.00 26.05 23.06 24.71 24.57 23.14 
P. aeruginosa 26.05 100.00 39.74 43.09 40.04 41.00 
Y. pestis 23.06 39.74 100.00 54.00 53.37 52.93 
K. pneumoniae 24.71 43.09 54.00 100.00 63.82 63.25 
E. coli MG1655 24.57 40.04 53.37 63.82 100.00 71.48 
S. Typhimurium 23.14 41.00 52.93 63.25 71.48 100.00 
Values calculated from Clustal Omega Multiple Sequence Alignment. Bolded values indicate percentage 
identity derived from E. coli MG1655 ArnT amino acid sequence (AAC75317.1). 
 
4.4 EptA exhibits low amino acid identity between members, however key individual 
residues are preserved across disparate bacteria.  
For analysis of EptA, nine phosphoethanolamine transferases were selected as outlined in Table 
1.4. Overall percentage identity was low, with the highest identities recorded between S. flexneri 
and E. coli MG1655 at 99.45%, the two Neisseria species at 98.53%, and both E. coli strains 
(100%) (Table 4.4). 
Figure 4.3 Residues Beyond the ArnT periplasmic loop are still Highly Conserved.  
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Table 4.4 Percentage Identity Matrix of EptA.  
 H. p MCR-1 A. b N. g N. m K. p O157 MG S. f 
H. pylori 100.00 24.54 26.01 26.51 26.51 27.91 28.32 28.11 27.91 
MCR-1 24.54 100.00 32.32 35.50 35.31 33.65 33.90 34.03 33.84 
A. baumannii 26.01 32.32 100.00 35.69 35.87 40.22 40.99 41.14 41.14 
N. gonorrhoeae 26.51 35.50 35.69 100.00 99.26 41.59 43.81 43.81 43.62 
N. meningitidis  26.51 35.31 35.87 99.26 100.00 41.77 43.81 43.81 43.62 
K. pneumoniae  27.91 33.65 40.22 41.59 41.77 100.00 71.61 71.61 71.25 
O157:H7 28.31 33.90 40.99 43.81 43.81 71.61 100.00 100.00 99.45 
MG1655 28.11 34.03 41.14 43.81 43.81 71.61 100.00 100.00 99.45 
S. flexneri 27.91 33.84 41.14 43.62 43.62 71.25 99.45 99.45 100.00 
Values generated from Clustal Omega Multiple Sequence Alignment of nine EptA protein sequences, 
outlined in Table 1.1. Bolded values indicate the percentage identity derived from E. coli MG1655 EptA 
amino acid sequence (NP_418538.2). 
 
Structural and physiological investigation of the phosphoethanolamine transferases has 
predominately been pursued in mcr-1, -2, and Neisseria meningitidis; these studies were used to 
guide analysis of the MSA (Figure 4.5) 151,152,167,168. Catalytic sites isolated from MCR-1 and 
MCR-2 begin at residue THR-219, corresponding to the end of the transmembrane domain. While 
this residue is poorly conserved in our alignment, homology gradually increases within its 
immediate surroundings.  
Within this broad area of increased homology lies the arbiter of pEtN transfer, catalytic 
nucleophile Threonine-285. In the MCR-1 and MCR-2 enzymes, several residues necessary for 
transferase activity form a catalytic pocket that coalesces around THR-285, including Histidine -
395, -478, and -466, Glutamic acid-246 and -405, and Aspartic acid-465 (Figure 4.4)53,167. These 
residues are arranged in a tetrahedral geometry to bind two zinc ions; Zn1 is held by GLU-246, 
THR-285, ASP-465 and HIS-466, whereas the secondary zinc ion Zn2 is bound by a single water 
molecule, in concert with HIS-478, GLU-405, and HIS-395168.  
Superimposition of EptANm and MCR-2 suggests strict conformational conservation, and our 
MSA indicates similarly strict conservation of these seven residues168. In E. coli, the identities of 
GLU-244, THR-282, ASP-455, HIS-456, HIS-468, HIS-385 are conserved, however GLU-405 
is replaced by Proline-395 (Figure 4.5). The PRO-395 substitution is also present in K. 












Catalytic Domain; EptA (PDB 5FGN). Architecture of catalytic site shown with accessory residues, and 
Threonine 280. Structural models of MCR-1 that were subsequently derived by mapping to Neisseria 
meningitidis EptA, harbour the following concordant residues: GLU-246(240), THR-285(280), HIS-
395(383), ASP-465(452), HIS-466(453), and HIS-478(465). For MCR-2, residue numbering shifts 2 
places downwards from that of MCR-1, i.e. THR-283. All residues depicted above are critical for PMR in 
E. coli MG1655 hosting MCR-1 or MCR-2, as confirmed by Alanine substitution11. Model visualized in 







A) Catalytic residue THR-285 indicated by red marker. Residues coloured blue are 100 percent 
conserved.  
B) PRO-395 of E. coli, and Enterobacteriaceae bordered with red. Replaced with GLU- in A. baumannii, 
N. gonorrhoeae, N. meningitidis, and MCR-1. The EptA of H. pylori substitutes PRO and GLU with 




A.          B. 
Figure 4.5 Excerpt of EptA MSA Demonstrates Critical Residue Conservation 




4.5 Preparation of Marker-less Mutants BW25113∆arnT and BW25113∆eptA. 
Keio Collection E. coli strains JW2251-1 (∆arnT::kan), JW5730-2 (∆eptA::kan), and the isogenic 
wild-type E. coli BW25113 were obtained from the Yale Coli Genetic Stock Centre (CGSC) and 
resurrected from soaked filter paper discs according to CGSC instructions. The Keio Collection 
consists of 3985 single gene deletions, entirely supplanted by a modified kanamycin (kan) 
cassette. Cassettes are flanked by homologous regions targeted to specific loci, and harbour two 
34-bp flippase-recognition sites (FRT-sites) to facilitate the generation of unmarked mutants via 
Saccharomyces cerevisiae flippase (FLP-recombinase)169. Homologous regions permit 
chromosomal integration via λ Red Recombination, and preserve the terminal 21-bp of the 










The λ Red Recombination System was used to integrate kan cassettes into the E. coli BW25113 genome. 
Resultant single deletion mutant strains are designated by a “JW-” code, i.e. JW2251-1 and JW5730-2. 
Marker-less deletion mutants are generated by transforming these JW-strains with plasmids harbouring 
FLP-recombinases, targeting FRT-sites inside each cassette.  
 
Strains received by this study were screened for the presence of kan cassettes, and cured of their 
selectable resistance marker prior to phenotype assessment. Kanamycin resistance exerted by the 
kan cassette is conferred by Tn5 neomycin phosphotransferase, originally derived from plasmid 













kanamycin, after which both JW2251-1(arnT::kan) and JW5730-2(eptA::kan) achieved confluent 
growth in comparison to the BW25113 wild-type, which was completely extinguished.  
4.5.1 The Kanamycin Resistance Marker was Removed via FLP-Recombination, 
Secondary to Transformation with pCP20. 
Removal of the kan cassette via FLP-recombinase activity mars the extraction site with a 
characteristic 102-bp ‘scar’, consisting of FRT sites and the 18-bp C-terminal fragment of the 
target gene. (Figure 4.7). Excision necessitated transformation of each strain with plasmid pCP20. 
The pCP20 construct facilitates FLP-recombination via expression of the Saccharomyces 
cerevisiae FLP-recombinase. Strains are selected for pCP20 by ampicillin resistance, and are 
subsequently cured by growth at 37°C post-excision due to the sensitivity of pCP20 to 
temperature elevation.   
JW5730-2 (eptA::kan), and JW2251-1(arnT::kan) were rendered chemically competent prior to 
transformation with pCP20. Growth at selective temperatures was conducted to excise the 
cassette, and eject pCP20 from each strain (Method 3.7). Patch plating of thirty colonies on 
100µg/mL Ampicillin, 50µg/mL Kanamycin and non-selective LBA plates provided a tentative 
phenotypic confirmation of excision. Strains that were unable to grow under both antibiotic 
conditions were renamed “BW25113∆arnT”, “BW25113∆eptA” and preserved in glycerol stock 
(Method 3.2).  
4.5.2 Confirmation of BW25113∆arnT and BW25113∆eptA strain construction by Whole 
Genome Sequencing.  
Final confirmation was provided by subjecting the cured strains to whole-genome sequencing, 
performed by Dr. Stanley Pang at Murdoch University. Briefly, characteristic matrix-assisted 
laser desorption/ionization time-of-flight (MALDI-TOF) signatures were used to verify the 
identity of each colony as E. coli, excluding the presence of contaminant organisms. DNA 
libraries were prepared from each strain prior to quantitation and validation by LabChip® GX 
(PerkinElmer, USA). Sequencing of normalized libraries was conducted using the Illumina 
Miseq® System. Sequences were analysed using the Nullarbor software pipeline. Raw FASTA 
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reads were compiled using SPAdes within this program (Seemann T, Goncalves da Silva A, 
Bulach DM, Schultz MB, Kwong JC, Howden BP. Nullarbor Github 
https://github.com/tseemann/nullarbor). The assembled contigs were imported into Geneious and 
mapped against the closed reference genome of the parent E. coli strain BW25113 to confirm the 
single deletion mutants and the correctly excised kan cassette (Figure 4.7). The presence of the 
‘scar’ sequence within the normal site of arnT and eptA provided confirmation that FLP-










A) All mutant strains within the Keio Collection cohort demonstrate the following ‘scar’ sequence at their 
respective target loci, following FLP-recombination. Both the start codon and the terminal 18-bp of the 
original targeted gene are preserved170. Whole genome sequences were interrogated with the 32-bp FRT 
site, and the entirety of the post-FLP scar sequence. Both BW25113∆arnT and BW25113∆eptA 
demonstrated complete preservation of the post-FLP ‘scar’ sequence, with their individuated C-terminal 
18-bp fragment.  
B) The ∆arnT sequence was situated between arnD and arnE. Image adapted from mapped contigs 
imported into Geneious.  
C) The ∆eptA sequence was situated between a featureless upstream region, and basR. Image adapted 












5 Determining the Phenotypic Differences between E. coli BW25113 wild-type and 
Single Deletion Mutants BW25113∆eptA, BW25113∆arnT.  
5.1 Background 
In the L-Ara4N, and pEtN lipid A modification pathways ArnT and EptA fulfil the role of 
“capstone” enzymes, performing the final transfer of the respective substrates to the phosphoryl 
head-group106,144. Insertional inactivation of ArnT renders the entire arnBCADTEF-ugd cellular 
architecture redundant, dedicated to the de novo synthesis and preparation of unusable UndP-α-
L-Ara4N donors106,139,171. By comparison, EptA utilises the membrane lipid 
phosphatidylethanolamine and is the sole executor of pEtN modification within lipid A106,108. 
Frustrated synthesis of upstream constituents can still be induced provided that the regulatory 
systems governing each pathway remain intact and open to stimulation139. However, the expected 
changes in phenotype normally invoked by such stimuli cannot occur as demonstrated in Figure 
5.1)139. This provides a means of delineating which moiety in E. coli BW25113, if any, can mimic 
the expected phenotypic profile of the isogenic wild-type when challenged with a series of 











Embedded in the inner membrane, sensor kinase PhoQ detects LPS derangement via Mg2+ chelation and 
CAMPs. PhoQ also detects lowered cytoplasmic pH. Each stimulus results in activation of cognate 
response-regulator PhoP, which exerts control over the PhoPQ and BasRS regulons. A) BW25113 wild-
type E. coli expressing both arnT and eptA. B) BW25113∆arnT expressing eptA only. C) BW25113∆eptA 
expressing arnT only. With the deletion of either arnT or eptA, this response may be compromised to the 
extent that phenotypic changes are observable in BW25113∆arnT, or BW25113∆eptA.   




The paired Enterobacteriaceae two-component regulatory systems (TCRS); BasRS and PhoPQ 
(Figure 5.2), exert regulatory control over both ArnT and EptA. As such, the repertoire of known 
stimuli detected by each TCRS within E. coli and other GNB became the basis of the phenotypic 
assays constructed for this study (Figure 5.2). In addition to investigating inorganic challenges 
encountered during infection, the ability of each strain to adhere to, and persist within a 
macrophage was assessed (Table 5.1).  
Studies of this nature have not as of yet been performed on E. coli BW25113, BW25113∆arnT, 
or BW25113∆eptA. As such, the operability of PhoPQ and BasRS in BW25113 was also assessed 














Both sensors are triggered by a specific set of inorganic metal cations, in addition to a common pool of 
stimuli. The PmrD coupling protein allows cross-talk between the two enzymes and their separate 
downstream cohorts, allowing pmrB (basS) regulated programs to be induced by Mg2+ or Ca2+ starvation 











Table 5.1 Phenotypic Battery Selected to Highlight Differences in E. coli Knockout Mutants. 
Test Methods Targets* 
Growth curve in LB 
 
Method 3.3 Differences in metabolic burden 








Method 3.9.1.1 PhoPQ/BasRS 
Growth in Polymyxin B 
Following Mg2+-starvation 
 
Method 3.9.1.1 PhoPQ/BasRS 
Growth in Polymyxin B 
Following low pH-stress 
 
Method 3.9.1.1 PhoPQ/BasRS 
Growth in dilute Hydrochloric 
acid 
Method 3.9.2.1 PhoPQ/BasRS 
Growth in LB adjusted to pH 
4.5 
 
Method 3.9.3 PhoPQ/BasRS 
Survival at Lethal Acidity 
Given Prior Growth at pH 4.5 
Method 3.9.3 PhoPQ/BasRS 
Survival Following Exposure to 
Foetal Calf Serum 
 
Concurrent with 3.10 N/A 
Adherence to J774.A1 
Macrophages 
 
Method 3.11 Differences in Lipid A 
morphology 
Survival Within J774.A1 
Macrophages 
 
Methods 3.10.1– 3.10.7 Differences in survival due to 
altered Lipid A morphology 
 
*Specification of “Targets” indicates either the specific upstream regulatory systems, or downstream 
phenotypes intended to be discriminated by the test. 
 
 
5.2 Single Deletion Mutants BW25113∆arnT, and BW25113∆eptA Retain Wild-type 
Growth Kinetics in Rich Media.  
Interrogation of phenotypic difference began with determining the growth kinetics of each strain 
in a rich broth media (Method 3.3). A growth deficit due to the removal of ArnT or EptA was 
unlikely to eventuate, as neither participates in the normal metabolic processes of E. coli. The 
growth rate of E. coli BW25113, BW25113∆arnT, and BW25113∆eptA was determined in LB 
media. Overnight broth cultures were diluted 100-fold in 10 mL LB, which was then used to 
inoculate 40 mL LB media, for a final test volume of 50 mL. Growth was monitored via OD600 
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values over 24 hrs. The deletion of neither arnT nor eptA had any discernible effect on growth 
kinetics, as shown in Figure 5.3. Generation time was calculated using OD600 values recorded at 











Generation times were calculated as 21.34, 19.52, and 22.27 min respectively. Growth was monitored 
over 24 hrs, (1440 min) at OD600 nm. Values are from experiments performed as biological triplicates. 
 
5.2.1 Under Mg2+ Limitation, No Differences in Growth Kinetics were Evident between 
Wild-type E. coli and BW25113∆arnT, BW25113∆eptA  
The growth rate of E. coli under nutrient limitation was investigated using N-Minimal 
Media, with and without physiologically sufficient magnesium (Material 2.3.3). Growth of 20 mL 
broth cultures at 37°C was monitored over 27 hrs, with OD600 readings collected intermittently 
(Method 3.3). Two sets of cultures, containing 10 µM and 200 µM Mg2+ were assessed over this 
period. Growth kinetics during lag phase (0 – 120 min) appear concordant between Mg2+ 
treatments, however constraints placed upon cells undergoing Mg2+-starvation were apparent 
following entry into late logarithmic (~300 - 360 min), and stationary phase (520 min onwards). 
Final OD600 values attained by the 10 µM restricted group were 3.58-fold smaller than those of 
their Mg2+-replete counterparts (Figure 5.4A).  
 
 






















Panel A) N-minimal media supplemented with 200 µM Mg2+ returned generation times with a range of 
36.74 – 44.33 min. Mean values are from a single biological replicate, consisting of three technical 
repeats.  
Panel B) Generation times increased where Mg2+ was restricted to 10 µM, with a range of 47.30 – 51.61 
min. Growth was monitored over 27 hrs, (1600 min) at OD600 nm. Values are from a single biological 



















                               





5.3 Survival During Challenge by Physiologically Relevant Abiotic Stressors  
5.3.1 The Relationship Between Polymyxin Survival and Adaptive Exposure.  
Modification of lipid A does not occur unless a sufficiently motivational stressor is 
received by TCRS and relayed to the necessary operons128,172. Under non-inducing conditions, 
protective lipid A species form the minority of the resting cell envelope. Therefore, to expose any 
underlying frailties within E. coli BW25113∆arnT and BW25113∆eptA, were subjected to mildly 
preparatory stimuli prior to encountering strongly bactericidal Polymyxin B. This ensures that the 
lipid A species harboured within the outer envelope upon PxB challenge are representative of the 
full suite of cationic modifications available within each strain. Two abiotic stressors were 
selected in order to promote preparatory modification; low pH and low Mg2+. Adaptive exposure 
was conducted prior to performing PxB MIC via broth microdilution, any difference in survival 
was predicted to be discernible by shifting MIC values (Figure 5.5).  
 
5.3.2 Wild-type E. coli Record Higher PxB MIC Values than BW25113∆arnT, 
BW25113∆eptA.  
Polymyxin B challenge was leveraged across 20 – 0.02µg/mL. Prior to each test, overnight broth 
cultures were titrated to ~5.0 x 106 CFU/mL using predictive OD600 values (Method 3.9.1.1). 
Wild-type BW25113 obtained an MIC value of 1.25µg/mL, whereas both single deletion mutants 
obtained MIC of 0.625µg/mL (Figure 5.5, Panel A). At subinhibitory concentrations, 
BW25113∆arnT and BW25113∆eptA demonstrated highly similar survival curves. Although 
percentage turbidity of the mutant strains exceeded that of the wild-type across 0.16 – 0.02µg/mL 


























A) Polymyxin Survival is Decreased in E. coli Lacking Either L-Ara4N, or pEtN. Strains were 
subjected to overnight growth at 37°C, in 20 – 0.0195 µg/mL PxB. MIC values obtained from this 
experiment were 1.25µg/mL (BW25113 wild-type), and 0.625µg/mL (BW25113∆arnT, ∆eptA). 
B) Pre-Adaptation by Moderate Acidity represses the induction of ArnT and EptA in Wild-type 
BW25113. Strains were exposed to acidified LB broth (pH 4.5) for 24-hours prior to PxB treatment. MIC 
values were 0.625µg/mL, 1.25µg/mL, and 2.50µg/mL for BW25113 wild-type, BW25113∆eptA, and 
BW25113∆arnT respectively.  
C) Induction of PhoPQ Mediated Lipid A Modification by Mg2+ Limitation (10µM). Strains were 
grown in N-minimal media, supplemented with 10µM Mg2+, prior to PxB MIC. MIC values were 
2.50µg/mL, 0.625µg/mL, and 0.625µg/mL for the BW25113 wild-type, and both BW25113∆arnT and 
BW25113∆eptA respectively.  
D) Suppression of PhoPQ Mediated Lipid A Modification by Mg2+ (200µM). Growth in N-minimal 
media supplemented with 200µM Mg2+ suppressed the PxB MIC of BW25113 wild-type. MIC values were 
0.625µg/mL for both BW25113 wild-type, and BW25113∆arnT, whereas BW25113∆eptA recorded an 
MIC of 1.25µg/mL.  
Mean and SEM of three biological replicates shown. No statistical significance (Mann-Whitney U, non-




Figure 5.5 Polymyxin B MIC of Wild-type BW25113, BW25113∆arnT, and BW25113∆eptA 
A.                                                                     B.  
C.                                                                     D.  
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5.3.3 Limitation of Divalent Cations Evokes Protective PhoPQ Response in BW25113 
Wild-type.  
A generalist growth media such as Lysogeny broth is unsuitable for disentangling 
differences in phenotype that arise from nutrient limitation. Estimates as to the Mg2+ concentration 
for such a heterogenous media are understandably broad, and ranges vary from between 30 – 
40µM, up to 100 – 200µM173,174. Along this extreme Mg2+ gradient, E. coli can be potentially 
starved or satiated by the same broth. To prevent confounding results, N-minimal media provides 
a suitable replacement for LB when performing Mg2+-limitation studies135. Two Mg2+ 
concentrations, 10µM and 200µM, were selected to supply cells with broadly PhoPQ expressive 
or suppressive stimuli respectively (Figure 5.5, C & D).  
Polymyxin survival of each E. coli strain was assessed following overnight growth at both Mg2+-
conditions (Figure 5.5). Under PhoPQ suppressive conditions, MIC values attained by BW25113, 
∆arnT, and ∆eptA were 0.625, 0.625, and 1.25µg/mL respectively (Method 3.9.1.1). For 
conditions representative of Mg2+-limitation and prospective PhoPQ induction, BW25113 
attained an MIC of 2.50 µg/mL, while both single deletion mutants recorded MIC two-fold below 
that of the wild-type (0.625 µg/mL).  
5.3.4 Wild-type BW25113 E. coli was Non-Responsive to Moderate Acidity (pH 4.5)  
Magnesium starvation is not typically encountered in the host environments populated by 
E. coli. A protective response to steep pH gradients is more pertinent for the Enterobacteriaceae; 
linking a host-restricted cue to programmes of outer leaflet alteration that can simultaneously 
protect against endogenous CAMPs, lethal acidity, and resident immune responses. With PxB 
functioning as a model defensin, the ability of BW25113∆arnT, and BW25113∆eptA to mount 
an adaptive response was assessed following overnight stimulation at pH 4.5 (Figure 5.5). The 
predicted increase in BW25113 wild-type MIC was not evident in this experiment (Method 
3.9.1.1). Notably, buffered survival in comparison to unacidified bacteria was observed in 
BW25113∆arnT with MIC increasing from 0.625 to 2.50 µg/mL. All three strains were 
concordant in their survival curves, as opposed to the highly variable growth percentages recorded 
in the unadapted PxB MIC.  
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5.3.5 Summary of PxB MIC Experiments; Divergent PhoPQ Responses Implicated in 
BW25113 wild-type Survival. 
Adaptive stimuli were selected for their ability to influence the Enterobacteriaceae TCRS PhoPQ, 
with the objective being downstream alteration of arnBCADTEF-ugd and eptA transcriptional 
responses. Constraining E. coli BW25113 to a single cationic modification had a detrimental 
effect on PxB survival, reducing MIC two-fold for both BW25113∆arnT and BW25113∆eptA. 
The BW25113 wild-type was responsive to Mg2+ gradients; presenting a two-fold increase in MIC 
under inductive conditions (10µM Mg2+). However, this strain did not demonstrate MIC increase 
post-acidification.  
Table 5.2 Polymyxin B MIC* Values With and Without Prior Adaptive Exposure. 
*All values presented are in mg/l, performed in LB broth. Clinical MIC values for PxB are typically drawn 
from Cation-adjusted Mueller-Hinton Broth as per ISO-20776 standard broth microdilution method175. 
 
 
5.4 Assessment of BW25113 wild-type, BW25113∆arnT, BW25113∆eptA Performance in 
Tests Relevant To Pathogenesis.  
The abiotic stressors assessed in this study are analogous to the obstacles encountered by GNB 
during infection and colonization. However, they are by necessity displaced from their biological 
context. In the host, Mg2+ limitation inflicted upon the GNB outer membrane only infrequently 
arises as a by-product of starvation, but can instead occur via chelation driven by negatively 
charged macromolecules (i.e. DNA) in the immediate microenvironment119,176. Moderate acidity 
within the host also rarely occurs in isolation. Immersion in a low pH compartment bears not only 
a risk to cellular physiology, but may also signal the presence of bactericidal enzymes potentiated 
 Polymyxin B MIC (mg/L) 
Adaptive Conditioning 







1.25 0.625 0.625 
pH 4.5 
 
0.625 2.50 1.25 
N-Minimal 
(10µM Mg2+) 
2.50 0.625 0.625 
N-Minimal 
(200µM Mg2+) 
0.625 0.625 1.25 
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by acidity104,177. Re-contextualizing these abiotic stressors within a host model, may highlight 
survival deficits in BW25113∆arnT, and BW25113∆eptA, relative to the BW25113 wild-type.  
The phagolysosome presents bacteria with a synthesis of these disparate abiotic stressors, 
therefore survival within a macrophage model was selected as our key test of phenotypic 
difference117. Phagocytosis delivers bacteria into a relatively neutral host compartment which 
becomes increasingly hostile as the phagosome proceeds through a set maturation programme178. 
As the phagolysosome forms and the luminal contents fall to a pH < 5, the generation of reactive 
oxygen species and lysosomal hydrolases is promoted178,179. Facultatively intracellular bacteria 
are able to avoid destruction as they carry the means to disrupt the maturation process, exit the 
active compartment, or simply persist in spite of the lytic microenvironment117,179-181. 
 
5.5 E. coli BW25113 Wild-type, and BW25113∆arnT, BW25113∆eptA Demonstrate 
Identical Survival in J774.A1 Murine Macrophage Model.  
Laboratory E. coli are not considered capable of withstanding phagocytosis after 24 hrs. 
Consequently, the diminishing survival of each strain is compared at various increments during 
the phagocytotic process182. Prior investigations into E. coli survival within various macrophage 
models typically incorporate a 2-hour infection step, and a 1-hour “kill” step in which high 
concentrations of antibiotic are used to deplete any external bacteria182-186. These steps are not 
included in the collection period therefore at time zero, bacteria recovered from monolayers have 
been internalized by macrophages for at least three hours.  
The survival of BW25113, BW25113∆arnT, and BW25113∆eptA over 24-hours is depicted in 
Figure 5.6 (Method 3.10). All strains possess a shared survival curve, with minimal growth 
gradually subsumed by cell death and eventual population collapse. Wild-type bacteria attained 
lower CFU/mL counts at each time point, yet this discrepancy was narrowed at 6 hrs and 
indistinguishable at 24 hrs. No statistically significant differences (Mann-Whitney U, non-
parametric test) in percentage survival could be discerned at any time point, suggesting that a lack 
of diversity in lipid A modification phenotype may not exert an appreciable effect on 















Bacteria were recovered from macrophage lysate. Supernatant was periodically sampled and plated onto 
non-selective agar to ensure only phagocytosed E. coli were being retrieved. A small growth effect is 
present from T0 – T60; this equates to a generation time of 65.55, 45.06, and 46.80 minutes for 
BW25113, ∆arnT, and ∆eptA respectively. Values at T0, T60, T120, and T360 represent three biological 
repeats, with each experiment containing two technical repeats. Vales at T24 and T30 represent one 
biological repeat, with each experiment consisting of  two technical repeats; SEM shown. 
 
5.6 Absence of ArnT or EptA Has No Significant Effect on Macrophage Adherence 
The outer membrane is the primary interface through which GNB contact surfaces in their 
immediate surroundings. Disruption of the lipid A species available to each knockout strain raises 
the possibility that BW25113∆eptA, and BW25113∆arnT could exhibit altered profiles upon 
encountering cellular surfaces. To investigate this possibility, the BW25113 wild-type and the 
BW25113∆arnT, BW25113∆eptA knockout strains were assessed for differences in macrophage 
adherence (Method 3.11). Actin filament antagonist Cytochalasin D (CD) was used to prevent 
internalization, theoretically isolating all bacteria upon the macrophage surface187-190. 
Externalized bacteria were readily killed by gentamicin (200µg/mL), which functioned as the 
negative control to preclude the possibility that E. coli had escaped into the phagosome. Bacteria 
recovered from CD-treated J774.A1 monolayers were enumerated and are displayed in Figure 
Figure 5.6 The J774.A1 Macrophage Exerts an Identical Killing Effect on BW25113 wild-type, 




5.7. No significant deficit in adherence was apparent, slight trends of increased adherence were 
however demonstrated by BW25113∆arnT although this was not significant. It follows that no E. 
coli strain used in this study was found to be invasive as all were only capable of entering the cell 











As demonstrated by the figure, almost the entirety of bacterial inoculum delivered onto the cell 
monolayers was recovered following 2-hours incubation. Neither mutant exhibits adherence deficits. All 
strains returned CFU/mL of zero following 1-hour treatment of cell monolayers with 200µg/mL 
gentamicin. Mean CFU/mL representative of three biological repeats.  
5.6.1 Growth of BW25113∆arnT, BW25113∆eptA is maintained in Media Containing 
Foetal Calf Serum  
Before the development of a successful macrophage survival protocol, the survival of each strain 
was tested in a series of tissue culture media; RPMI-1640, DMEM (10% FBS), and Leibovitz’s 
L-15 (Gibco). The primary goal of this was to assess whether foetal bovine serum used to 
supplement each media was suppressing E. coli growth. FBS is routinely heat-inactivated prior 
to use, reducing the active titre of potentially bactericidal complement proteins191. All media were 
found to have no detectable detrimental effects on growth of all E. coli strains (data not shown).  
5.7 The Acid Phenotype of BW25113 wild-type, BW25113∆arnT, and BW25113∆eptA 
Mild acidity exists at the junction of BasRS and PhoPQ, able to provoke phenotypic responses in 
bacteria lacking either system. The expression of eptA homologue pmrC is directly influenced by 
exposure to pH 5.5 in Citrobacter rodentium, and Acinetobacter baumannii. Enterobacteriaceae 
Figure 5.7 Adherence to J774.A1 Macrophages is not significantly affected by lack of L-Ara4N or 
pEtN.    
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S. Typhimurium and Shigella flexneri also demonstrate pH-responsive pEtN modification. 
Further to this, acid tolerant strains of EHEC O157:H7 esterify lipid A with pEtN under non-
inducing laboratory conditions. In this study, the acid phenotype of E. coli BW25113 was 
explored to discern whether BW25113∆eptA, unable to generated pEtN-lipid A, was particularly 
disadvantaged under mild acidity.  
5.7.1 BW25113 wild-type, BW25113∆arnT, BW25113∆eptA Demonstrate Identical 
Survival During Growth in Acidified LB.  
Broth microdilution was initially employed to determine whether a titratable difference in acid 
resistance could be drawn from each strain (Figure 5.8B). Hydrochloric acid (10 M) was added 
to LB at a concentration of 128 µg/mL, pH values were not collected for this test (Method 3.9.2.1). 
All strains demonstrated similar percentage growth, with growth suppression occurring at ≥128 
µg/mL, before recovery of BW25113∆arnT, and BW25113∆eptA to unexposed quantities at 32 
µg/mL HCl. Wild-type E. coli did not attain unexposed levels of growth until concentration fell 
between 0.25 – 0.125 µg/mL.  
5.7.2 Viability at pH 4.5 Unaffected by Absence of L-Ara4N or pEtN in Single Deletion 
Mutants.  
Persistent, uninterrupted growth at moderate pH stress is a key feature of GIT-adapted 
Enterobacteriaceae. Bacteria unable to activate protective acid-stress pathways during prolonged 
exposure will lose viability, represented by decreased CFU/mL counts. As evidenced by Figure 
5.8, no defect in viability is apparent between strains over 1-hour exposure to pH 4.5 (Figure 
5.8A), (Method 3.9.3). Minimal growth is also observed. Mild acidity is therefore unlikely to 
deter BW25113∆arnT or BW25113 ∆eptA from persisting within acidified host niches such as 
the phagolysosome, to an extent that is comparable with the wild-type. 
5.7.3 Adaptive Survival at Lethal Acidity, Given Prior Adaptive Exposure at pH 4.5 
No growth restriction was evident at pH 4.5, however pH limited growth was evident at higher 
concentrations of H+ in acidified LB (Figure 5.8B). To further explore the acid resistance 
phenotype survival was assessed at pH 2.5, considered the lethal boundary for E. coli and far 
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below the established growth range for laboratory strains (pH ≤ 4.4). In the Enterobacteriaceae, 
enhanced survival in extremely low pH environments is readily conferred by cross-protective 
challenges with mild acidity. This buffered survival effect is demonstrated in (Figure 5.9) 
whereby the wild-type and knockout strains are preserved following 15-minutes exposure to pH 
2.5 (Method 3.9.3).  
Given prior adaptation, mean percentage survival values at T15 ranged from 61.0% (BW25113), 
to 38.7% and 44.5% for the BW25113∆arnT, BW25113∆eptA strains. However, the intra-strain 
variation was extensive, suggesting that this mean has been unduly influenced by a single 
biological replicate (Figure 5.9). In the absence of this adaptive period, pH 2.5 is effectively 
capable of extinguishing all E. coli survival within 15 minutes (Figure 5.9). Mean percentage 
survival of unadapted cells fell to 0.78% (BW25113), 0.95% (BW25113∆arnT), and 0.13% 
(BW25113∆eptA).  
The survival buffer provided by adaptive exposure is narrowed during prolonged lethal challenge. 
At 30-minutes of exposure, survival for all strains fell below 1%, regardless of prior adaptive 
growth (data not shown).  
The BW25113 wild-type, and single deletion mutants BW25113∆arnT, BW25113∆eptA are 
equally competent at presenting a buffered phenotype (Figure 5.9). This suggests that lipid A 
modification contributes a minor amount to acid survival, or that the diversity of decorations 





























A) Unimpeded Growth of BW25113 wild-type, BW25113∆arnT, BW25113∆eptA at pH 4.5. Over the 
60-min period, generation times were calculated as 10.32, 14.36, 7.136 for BW25113 wild-type, 
BW25113∆arnT, and BW25113∆eptA respectively. Mean CFU/mL is representative of three biological 
repeats.  
B) Acidified LB Exerts Bactericidal Effects at High [H+]. Hydrochloric acid (10 M) was added to LB 
(final concentration: 256 µg/mL) and diluted two-fold across a 96-well plate. Across all three strains, only 



















Adaptive stimulation (A) was provided by 1-hour incubation within LB adjusted to pH 4.5, at 37°C with 
agitation. Bacteria that did not experience adaptation (U) were grown for the same period in un-acidified 
LB, prior to OD-adjustment and inoculation. Pelleted cells were washed, adjusted to a standard OD600 
(nm) of 0.3 in PBS and used to inoculate LB adjusted to pH 2.5. Bacterial growth was enumerated by 
CFU/mL counts taken immediately at inoculation and 15- and 30 min post-exposure (30 min data not 
shown). Values are representative of three biological repeats; SEM shown. 
Figure 5.9 Adaptive Acid-Resistance is Present in BW25113 E. coli. 
A.                                                                     B.  
Figure 5.8 No Individual Acid Phenotypes were Evident Between BW25113 wild-type, 
BW25113∆eptA, or BW25113∆arnT.  
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6 Expression of Recombinant EptA::HisX6 and ArnT::HisX6 from E. coli BW25113  
6.1 Recombinant Protein in Antivirulence Drug Design  
Reliable, high-yield, recombinant protein expression permits deeper investigation into anti-
virulence targets. Generating structural information is critical for the development of inhibitors, 
and mandates the use of X-ray crystallography, among other protein-intensive procedures192. 
Enzymatic activity may also be assessed within substrate-specific assays if a sufficient quantity 
of recombinant protein can be supplied for repeat tests193. Adding to the pool of successfully 
expressed and characterized ArnT or EptA is essential to refine current understandings of 
enzymatic activity.  
At present, there is no structural information for E. coli EptA or ArnT. The successful expression 
and characterization of full-length homologues; N. meningitidis EptA and C. metallidurans ArnT, 
provides precedent as to how expression parameters should be optimized for each enzyme. For 
ArnT (PDB 5EZM), the C. metallidurans construct consisted of an N-terminal His-tag within the 
pNYCOMPS-LIC-FH10T+ vector141,194. Expression was achieved in the BL21(DE3)pLysS host 
at lower temperatures (22°C), under moderate IPTG-induction146. To partially replicate these 
parameters, this study opted to place arnT of BW25113 E. coli within an N-terminal hexa-
histidine (HisX6) tagged expression plasmid using the pET-15b backbone. Recombinant N. 
meningitidis EptA (PDB 5FGN) was expressed as a C-terminal HisX6-tagged protein, using 
plasmid pTrc99A152. Expression of N. meningitidis EptA::HisX6 was achieved in the 
BL21(DE3)pLysS host, under moderate IPTG-induction, and mild temperatures (25°C)152. A C-
terminal HisX6 tag was pursued in this study, by placing E. coli BW25113 eptA within the 
pET28a(+) plasmid. From these two expression constructs, strategies to achieve appreciable 
recombinant protein yields were pursued with the objective of obtaining pure protein for future 
characterization.  
6.2 Cloning Strategy 
The Keio Collection parent strain E. coli BW25113 provided both the arnT and eptA template 
sequences for generation of ArnT::HisX6, EptA::HisX6. Target genes were subject to the same 
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basic cloning strategy, with key differences in expression vector and HisX6-tag placement (Figure 
6.1, Figure 6.2). Verification at each step was provided by restriction enzyme (RE) digest to 
generate restriction maps of predicted band sizes.  
6.3 Amplification of arnT and eptA genes from E. coli strain BW25113  
For each target, primer design was conducted with the eventual vector recipient in mind. The 
plasmids pET15-b and pET28-a (+) were selected for ArnT and EptA respectively, due to their 
maintenance of high copy numbers, IPTG-inducible expression, and favourable placement of the 
HisX6-tag sequence according to prior expression success. Consequently, primers 
“ArnT_pET15b_For” and “ArnT_pET15b_Rev” were constructed to include the restriction sites 
NdeI and BamHI at the 5’- and 3’-ends of arnT, allowing N-terminal Hisx6-tagging to occur upon 
integration within the pET-15b multiple cloning site (Figure 6.1)  
Primers “EptA_Expression_Forward” and “EptA_Expression Reverse” were constructed to 
include the restriction sites NcoI and XhoI at the 5’- and 3’-end of eptA, facilitating expression of 
a C-terminally HisX6-tagged product from pET28a(+) (Figure 6.2). Genomic DNA extracted from 
E. coli BW25113 was used as a template in a PCR reaction for each primer pair to yield fragments 
of 1665-bp and 1655-bp (gene size plus two hexanucleotide RE-sites) for arnT and eptA 





































Expression Strategy for ArnT. A) arnT insert amplified from BW25113 gDNA is cloned into high copy 
number vector pCR®-Blunt II-TOPO®. Insertion is verified by digest with EcoRI. B) Tandem digest of 
pET-15b and arnT with NdeI/BamHI followed by T4 DNA Ligase reaction. C) Complete expression 






















A) eptA insert amplified from BW25113 gDNA is cloned into high copy number vector pCR®-Blunt II-
TOPO®. Insertion is verified by digest with EcoRV. B) Tandem digest of pET28a(+) and eptA with 
NcoI/XhoI followed by T4 DNA Ligase reaction. C) Complete expression constructs transformed into E. 









A) Amplification via EptA_Expression_Forward/Reverse primer pair, yielding eptA PCR-fragment of 
1655-bp 1) 1-kb ladder, 2) BW25113, 3) BW25113∆arnT 4) BW25113∆eptA (eptA absent). B) 
Amplification via ArnT_pET-15b_For/Rev primer pair, yielding arnT PCR-fragment of 1665-bp. 1) 1-kb 
ladder, 2) BW25113, 3) BW25113∆arnT (arnT absent) 4) BW25113∆eptA. 
Figure 6.3 Amplification of eptA and arnT using Expression Primers.  
A.                                                        B.  
1650 
1650 
1         2       3        4                                1      2       3      4 
Figure 6.2 Expression Strategy for EptA::HisX6. 
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6.4 Construction of the shuttle plasmid TOPO_arnT 
The amplified arnT insert was subsequently inserted into the pCR®-Blunt II-TOPO® (TOPO) 
vector system, forming the shuttle vector TOPO_arnT (Figure 6.1). To confirm insertion had 
occurred correctly, TOPO_arnT was subjected to EcoRI RE-digest yielding a band of 1650-bp 
(Figure 6.4B) (Method 3.4.6). Sanger sequencing of the TOPO_arnT construct was performed as 
per the manufacturer’s instructions and sequence was verified (Invitrogen, Life Technologies 
(USA)) by the Australian Genome Research Facility (AGRF). 
6.5 Construction of the expression Vector: pET-15b_arnT 
TOPO_arnT was treated with NdeI/BamHI, in tandem with the selected expression vector pET15-
b. Digested fragments of insert and vector were visualized by gel electrophoresis prior to excision, 
and extraction from the agarose gel.   
Overnight ligation with T4 DNA ligase was subsequently performed (Method 3.4.7) and the 
resultant ligation mixture was immediately transformed into DH5α E. coli for growth on selective 
antibiotic agar (Method 3.5.1). Plasmids were extracted after overnight growth and screened for 









A) Lane identities as follows; 1) 1-kb ladder, Lanes 2 – 4) TOPO_arnT RE-digest with EcoRI mixture, 
clones 1 – 3. Restriction fragment profiles correspond to the expected size of arnT replicon which is 
1665-bp. B) 1) 1-kb ladder, 2) Empty vector pET-15b linearized by NdeI/BamHI, 3) pET-15b_arnT 
digest mixture, the presence of a 1665-bp insert beneath linearized pET-15b indicates that the arnT insert 
has been successfully ligated into pET-15b. 
 




      A.            B.  
1      2      3      4                    1            2                       3 
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6.6 Construction of Shuttle plasmid TOPO_eptA 
As outlined above in Section 6.4, amplified eptA was also cloned into the pCR®-Blunt II-TOPO® 
(TOPO) vector system. The shuttle vector was verified by EcoRV RE-digest targeted toward a 
unique eptA internal EcoRV site, and an external EcoRV site on the TOPO vector. The presence 
of two bands (727-bp and 4433-bp) within the gel is conditional on eptA being present within 
TOPO; in its absence, only vector linearization can occur (Figure 6.5). Sanger sequencing of 
TOPO_eptA was performed as outlined above, confirming the presence of eptA and the NcoI/XhoI 
5’ and 3’-end modifications. 
6.6.1 Construction of Expression Vector  
To collect the verified insert, TOPO_eptA was subjected to restriction enzyme digest by 
NcoI/XhoI, as per Figure 6.2. Due to the presence of multiple XhoI and NcoI RE-sites within 
pCR®-Blunt II-TOPO, recoverable bands were predicted to contain a heterogenous mix of both 
eptA and TOPO fragments (Figure 6.6). Upon visualization by gel electrophoresis, the 1647-bp 
eptA insert was entangled with two bands; 1614-bp NcoI/XhoI and a 1421-bp NcoI/NcoI (Figure 
6.6). A segment of gel corresponding to the expected size of eptA was collected in lieu (Figure 
6.6). Fragments were indiscriminately transformed into pET28a(+) following NcoI/XhoI RE-







1) 1-kb ladder, 2) TOPO_eptA EcoRV RE-digest mixture, restriction fragment of ~950 bp indicates that 
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A) TOPO vector map illustrating the presence of NcoI RE-sites at 3439 and 3878, and XhoI RE-site at 
2018. In combination with the NcoI/XhoI RE-sites flanking eptA, RE-digest was predicted to yield 
fragments of 1647-bp, 1614-bp, 1421-bp, 439-bp, and 39-bp. The 1647-bp fragment corresponds to eptA 
only.  
B) Gel Image of NcoI/XhoI RE-digest. 1) 1-kb ladder, 2) uncut TOPO vector, 3) TOPO-eptA digest 
mixture. Note the indistinct boundaries of the collected band. Dotted red box indicates expected location 
of eptA amplicon 
 
6.6.2 RE-digest with EcoRV Confirmed Successful pET28a(+)_eptA Constructs Prior to 
Expression. 
Multiple constructs consisting of pET28a(+) and the mixed NcoI/XhoI fragments were screened 
via secondary RE-digest with EcoRV. Screening was performed in parallel with an NcoI/XhoI 
RE-digest, to confirm insert size and orientation within the pET28a(+) site. In total, six successful 
transformants were assessed (Figure 6.7). Upon digest with EcoRV, pET28a(+) harbouring TOPO 
linearizes to a single >5000-bp fragment. However, in correctly assembled constructs the presence 
of an eptA-carried RE-site ensures two fragments are recovered instead (2211-bp and 4667-bp). 
This is apparent in Figure 6.7. Three constructs demonstrated the expected pET28a(+)_eptA 
restriction patterns for each RE-digest, these clones were preserved in glycerol stock for later 
expression studies.  
 
 
Figure 6.6 NcoI/XhoI RE-digest yields Heterogenous TOPO, eptA Fragments in Restriction Map 
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Six plasmids were subjected to RE-digest by EcoRV (even numbered lanes), and NcoI/XhoI (odd 
numbered lanes). Clones A, B, and F are predicted to contain eptA only on the basis of their banding 
patterns. Plasmids C, D, and E, demonstrate the banding patterns predicted for pET28a(+) harbouring 
TOPO-fragments and were discarded. Lanes 1, 14) 1-kb ladder. 
 
6.7 Preliminary Protein Expression Trial: ArnT::X6  
Since ArnT is an inner membrane protein with eight transmembrane domains, a variety of 
conditions including expression strain, induction turbidity, IPTG concentration, and induction 
temperature were tested to promote the expression of this membrane protein. Successive small-
scale expression trials are summarised in Table 6.1. Preliminary attempts at expression within the 
BL21(DE3)pLysS and Rosetta-Gami 2 host were unable to yield any ArnT::HisX6. No Hisx6-
tagged protein banding was apparent in western immunoblots, except for the positive control 
indicating that expression had not occurred (Method 3.8.11).  
6.7.1 Successful Expression of ArnT::Hisx6 within E. coli OverExpress Strains C41 and 
C43.  
Expression with OverExpress strains C41 and C43 which are specifically engineered to overcome 
toxicity and plasmid instability associated with heterologous protein overexpression were 
trialed195. Induction proceeded as per Method 3.8.2., with aliquots collected prior to the addition 
of IPTG and at 2, 4, and 24-hours following induction. To ascertain the effect of lysate preparation 
on protein integrity, whole cell lysates of C41 and C43 strains were prepared by both sonication 
Figure 6.7 Restriction Map Confirming Identity of pET28a(+)_eptA.   
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and enzymatic lysis (Methods 3.8.5, 3.8.7). After fractionation into soluble and insoluble 
fractions, samples were separated via SDS-PAGE and transferred to PVDF membrane for 
visualization (Figure 6.8) (Methods 3.8.8, 3.8.9).  
Recombinant ArnT::Hisx6 is expected to attain a molecular weight (MW) of ~61 kDa given 
conditions of complete denaturation. Western immunoblots did not consistently detect a 61 kDa 
protein which may have been the result of sample preparation (Figure 6.8).  
Table 6.1 Summary of ArnT Expression Methodology Trialled Throughout Study. 
Strains OD600 °C IPTG 
(mM) 






































































*Note: The presence of “Protein” does not indicate that a protein correspondent to either arnT or eptA was 
expressed, only the presence of banding in western blots.  
 
Alternatively, incomplete denaturation could account for this effect. Resuspension in 
Laemmli buffer provided two sources of reductant for denaturation; β-mercaptoethanol (BME), 
and the detergent sodium dodecyl sulfate (SDS)196. Disulfide bonds interspersed throughout the 
protein and between subunits are reduced by BME, whereas SDS provides reconstructive 
denaturation of the entire tertiary and quaternary structure197. Subject to complete denaturation, 
peptides should migrate according to molecular weight. Any retention of disulfide bonds allows 
peptides to assume a more compacted form, migrating further through the gel their predicted MW 
boundaries197. Standard protocols mandate boiling of sample buffers to assist denaturation. No 
protein preparations were boiled during this study, as integral membrane proteins are liable to 
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form thermal aggregates or degrade at heat thresholds necessary for denaturation198. Therefore 
the suboptimal ArnT::HisX6 MW was ascribed to the conservative, membrane-protein optimized 
denaturation protocol pursued in this study.  
This effect reoccurred throughout the four repeat ArnT expression studies and was ascribed to 
incomplete denaturation each time. Furthermore, sonication appeared to decrease the yield of 
protein regardless of time-point compared to cell lysis.  
C41 and C43 strains were revisited to express ArnT::HisX6, with alterations in induction 
temperature, IPTG concentration, and preparation of lysate (Table 6.1). Consistency of protein 








Panel A) Expression studies in C41, lysed by In-House Lysis Buffer. Lane 1) 25 kDa positive control, 2) 
Blue Prestained Protein Standard, Broad Range (11-190 kDa), 3) Pre-induction insoluble fraction, 4) 2-
hour insoluble fraction, 5) 4-hour insoluble fraction, 6) 24-hour insoluble fraction, 7) Pre-induction 
soluble fraction, 8) 2-hour soluble fraction, 9) 4-hour soluble fraction, 10) 24-hour soluble fraction.  
Panel B) C43 containing expression construct, lysed by sonication. Lane identities are in the same order 








A.                                                                   B.         











Panel A) C41 containing pET15-b_arnT expression construct, lysed by B-PER®. Lane 1) Blue Prestained 
Protein Standard, Broad Range (11-190 kDa), 2) 25 kDa positive control, 3) Pre-induction insoluble 
fraction, 4) 2-hour insoluble fraction, 5) 4-hour insoluble fraction, 6) 24-hour insoluble fraction, 7) Pre-
induction soluble fraction, 8) 2-hour soluble fraction, 9) 4-hour soluble fraction, 10) 24-hour soluble 
fraction. 
Panel B) C43 containing pET15-b_arnT expression construct. Lysed by B-PER®.  Lane identities are in 
the same order as Panel A, with the exception of Lanes 1 and 2, which were reversed for ease of 










C43 containing pET15-b_arnT expression construct. Lysed by B-PER®. Lane 1) 25 kDa positive control, 
2) Blue Prestained Protein Standard, Broad Range (11-190 kDa), 3) Pre-induction insoluble fraction, 4) 2-
hour insoluble fraction, 5) 4-hour insoluble fraction, 6) 24-hour insoluble fraction, 7) Pre-induction 
soluble fraction, 8) 2-hour soluble fraction, 9) 4-hour soluble fraction, 10) 24-hour soluble fraction. 
 
 
Figure 6.9 Expression of ArnT::HisX6 At Lowered Induction Temperature Reduces Yield, and Non-
specific Background Expression within C41 and C43.  
Figure 6.10 Increased pET15-b_arnT Expression within C43, Attributed to Moderate Induction 
Temperature (22°C) and Raised OD600 Values (1.0).   
A.                                                                   B.         
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6.7.2 Summary of Positive ArnT::HisX6 Expression Trials 
ArnT::HisX6 was obtained primarily from the insoluble fraction in our expression trials.  Small, 
dissipated bands in the soluble fraction were ascribed to nonspecific anti-HisX6 antibody 
background reactivity. Ultimately, recombinant protein contained within the soluble fraction is 
better suited to immediate downstream investigation. Solubilized protein has a greater likelihood 
of being in the correct conformation, and as a consequence; biologically active. Conversely, 
recombinant products collected from the insoluble fraction are more likely to be agglomerates of 
poorly folded, inactive protein. However, the appreciable yield of ArnT::HisX6 expressed in these 
studies provides a solid foundation from which further optimization can proceed.  
6.8 Preliminary Protein Expression Trial: EptA::HisX6 
Guided by prior success in expression of the N. meningitidis EptA homologue, expression 
construct pET28a(+)_eptA was first trialled within strains RG-2 and BL21152. This initial trial was 
unsuccessful as with the exception of the positive control, no HisX6-tagged product was 
recoverable. Attempts to optimise BL21 expression by elevating induction turbidity, lowering 
temperature, and lowering IPTG concentration were also unable to yield recombinant protein. 
Expression within the BL21 strain was therefore discontinued for the remainder of this study. All 
expression trials conducted with pET28a(+)_eptA are summarized in Table 6.2.  
Table 6.2 Summary of EptA Expression Methodology Trialed Throughout Study. 


































*Note: The presence of “Protein” does not indicate that a protein correspondent to either arnT or eptA was 




6.8.1 First Recoverable HisX6-tagged Product from pET28a(+)_eptA Expression 
The successful expression of ArnT::HisX6 via the C43/C41 OverExpress Strains encouraged 
transformation of C43 OverExpress with pET28a(+)_eptA. Concurrent transformation of RG-2 
was also repeated at this stage. Expression turbidity was lowered to an OD600 of 0.4, prior to 
induction with 0.4mM IPTG (Table 6.2). Recoverable HisX6-tagged products collected by 
Western immunoblot are shown in Figure 6.11.  
Despite similarities in pellet preparation and induction, the development of each banding pattern 
was highly divergent between the RG-2 and C43 OverExpress Strains. Few distinct bands are 
present in the C43 OverExpress blot, whereas the RG-2 blot displays multiple clearly demarcated 
bands of variable size (Figure 6.11, Panel A, B). Across both blots, overall yields were greatest 
within the insoluble fraction. However similar degrees of protein degradation are evident across 
all lanes in RG-2 (Figure 6.11). In its native, fully denatured form E. coli EptA is expected to 
attain a MW of 61.6 kDa. Potentially, a ~ 58kDa band situated within the 24-hour insoluble 
fraction of RG-2 may represent successful EptA expression. Notwithstanding, the repetitive non-
specific banding displayed by both PVDF membranes suggests that EptA expression has either 
not been induced, or has been distorted by proteolysis prior to recovery. 
6.8.2 Recovery of Non-specific Anti-HisX6 Antibody Reactive Product Following Lemo21 
E. coli Strain Expression of pET28a(+)_eptA 
To mitigate the deleterious effects that can accompany membrane protein overexpression, 
pET28a(+)_eptA was transformed into the tuneable host Lemo21(DE3) E. coli. The 
Lemo21(DE3) strain permits titratable expression from the T7-RNA promoter (T7-RNAP) via 
introduction of plasmid pLemo; harbouring T7 lysozyme (T7-lys) under the strict control of 
rhamnose-promoter rhaBAD199. Coordinating expression of T7-RNAP with its natural inhibitor 
T7-lys tempers the deleterious effects of membrane overexpression. Achieving beneficial levels 
of T7-RNAP is entirely protein specific, and dependent upon provision of appropriate rhamnose 
concentrations into the induction system. For this study, induction broth cultures were 
supplemented with 750 µM L-Rhamnose (Table 6.2). Turbidity at induction was raised to OD600 
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of 1.0, while induction temperature and IPTG concentrations remained low (22°C, 0.4 mM). The 
western blot recovered from this trial retained several non-specific <25 kDa bands originally 
developed in prior RG-2 expression (Figure 6.11). In addition, new bands at ~32 kDa appeared 
across all lanes (Figure 6.12). Unfortunately, the putative >58 kDa “EptA” band previously 








Panel A) C43 containing pET28a(+)_eptA expression construct. 1)  2) Blue Prestained Protein Standard, 
Broad Range (11-190 kDa), 3) Pre-induction insoluble fraction, 4) 2-hour insoluble fraction, 5) 4-hour 
insoluble fraction, 6) 24-hour insoluble fraction, 7) Pre-induction soluble fraction, 8) 2-hour soluble 
fraction, 9) 4-hour soluble fraction, 10) 24-hour soluble fraction. 
Panel B) RG-2 containing pET28a(+)_eptA expression construct. Lane identities are in the same order as 
Panel A, with the exception of Lanes 1 and 2.  
 
6.8.3 Summary of EptA::HisX6 Expression Trials; More Optimization is Necessary To 
Achieve Successful Expression.  
Despite attempts to optimize culture parameters, EptA::HisX6 was not able to be expressed in this 
study. Due to time constraints, the titratable Lemo21(DE3) host was not fully explored, which 
raises the possibility than the optimal L-rhamnose concentration for T7-RNAP induction may be 
obtained in future studies.  
 
 
Figure 6.11 Potential Expression of pET28a(+)_eptA within C43 and RG-2 E. coli (22°C, OD600 0.4).  













Lemo21(DE3) containing pET28a(+)_eptA expression construct. Lane identities as follows: 1) Blue 
Prestained Protein Standard, Broad Range (11-190 kDa), 2) 25 kDa Positive control 3) Pre-induction 
insoluble fraction, 4) 2-hour insoluble fraction, 5) 4-hour insoluble fraction, 6) 24-hour insoluble fraction, 
7) Pre-induction soluble fraction, 8) 2-hour soluble fraction, 9) 4-hour soluble fraction, 10) 24-hour 
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7.1 Conserved Features in E. coli BW25113 ArnT and EptA Suggest that Both Proteins 
Could be Broad-Spectrum Druggable Targets. 
Reducing the critical protein effectors of MDR GNB down to a set of shared, potentially 
druggable targets begins with assessing whether basic inter-species homology can be found at the 
sequence level. A broad-spectrum antivirulence drug would be of most use to current therapeutic 
polymyxin regimens; able to target the primary infection (polymicrobial or otherwise) and re-
sensitize any latent pathogenic colonists in possession of inherent PMR162. For any prospective 
inhibitor to exert a broad-spectrum protective effect, a certain degree of target homology is 
necessary.  
The DsbA disulphide oxidoreductases provide an exemplar illustrating the constraints sequence 
homology can impose upon antivirulence drug (AVD) design. Amino acid identity demarcates 
DsbA subclasses200. Proteins derived from the Enterobacteriaceae typically share >80% of 
residues with E. coli DsbA, and rescue all facets of virulence upon cross-species 
transformation201. Highly dissimilar sequences (23 – 40% aa ID) bestow only partial phenotypic 
rescue to GNB outside their respective subclasses201,202. As sequence identity depreciates, so too 
does the likelihood that inhibitors targeted against the sole reference protein will exert a 
comparable effect on the cross-species target200. Complementary facets of each targeted enzyme 
may relax this constraint, as structure, regulatory control, and active site identity mediate overall 
protein functionality.   
With respect to two AVD candidate criteria; diverse pathogenic species and sequence homology, 
this study commenced by interrogating the NCBI protein database for relevant MDR GNB 
harbouring ArnT, EptA or both47,203,204.  
7.2 High Percentage Identity between Enterobacteriaceae ArnT is Supportive of 
Prospective Antivirulence Targeting. 
Direct comparisons of overall residue identity indicated that E. coli ArnT shared a considerable 
degree of identity with both K. pneumoniae (63.82%) and S. Typhimuirum, (71.48%). This 
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Enterobacteriaceae grouping did not however extend to ArnT in Y. pestis (YP_002347381.1), as 
identity decreases to 53.37%. The most divergent enzyme investigated was that of the multi-
species Burkholderia cepacia complex (WP_006482861.1) which had less than 25% identity 
toward any interspecies ArnT, with the exception of P. aeruginosa (26.05%). Physiologically, the 
Burkholderia spp. are utterly reliant on L-Ara4N for lipid A transport to the outer membrane 
leaflet, therefore their relatively unique ArnT may facilitate this higher burden of demand that is 
absent in all other GNB121. 
7.3 Conservation of Residues Implicated in Catalysis Between Divergent ArnT Suggests 
Broader Spectrum of Inhibition Possible. 
Whether these discrepancies in percentage identity permit sub-classification, or independent 
AVD strategies is unclear. Although the enzymes are divergent at the overall amino acid 
sequence, preservation of certain critical residues enable divergent enzymes to be targeted by 
inhibitory compounds, irrespective of overall identity. For ArnT critical residues in the active site 
have previously been uncovered during successive cycles of site-specific mutagenesis116,142,144. 
Polymyxin sensitivity was recorded in B. cenocepacia ArnT following the replacement of TYR-
43, LYS-69, ARG-254, and GLU-493 with cysteine. Furthermore, alanine substitution of TYR-
43 and LYS-69 abolished all ArnT enzymatic activity suggesting that all inherent 
physicochemical properties of these amino acids are functionally important at the active site, as 
opposed to charge alone142. This position is reversed for ARG-254 and GLU-493, as suitably 
charged residues at each site can preserve some degree of PMR post-substitution. The 
contribution of these amino acids to active site functionality appears to be preserved in Salmonella 
ArnT. Replacement of S. enterica TYR-36, LYS-62, and GLU-478 renders the entire ArnT 
enzyme non-functional, and unable to rescue low-level PMR in laboratory strain E. coli 
BL21(DE3)∆arnT142. 
The Multiple Sequence Alignment conducted within this study supports the possibility 
that ArnT escapes the constraints of sequence homology to some extent, in that E. coli MG1655 
ArnT (AAC75317.1) retains corresponding active site residues with both B. cenocepacia, and S. 
enterica ArnT despite the breadth of sequence diversity between these three enzymes. The array 
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of residues predicted to support ArnT function was further widened by recognition that as 
members of the GT-C superfamily, a conserved 39DEX41 motif was apparent in B. cenocepacia 
and S. enterica ArnT147. Any mutation in this motif confers total loss of PMR147. The concordant 
residues forming this motif in E. coli are ASP-31 and GLU-32, with the “X” residue represented 
by threonine in both S. Typhimurium and E. coli MG1655, and replaced with glycine in the B. 
cenocepacia Complex ArnT.  
Reliance on select residues as the basis for AVD design risks the development of tunnel vision. 
Residues cannot exert enzymatic activity beyond that which is permitted by the protein structure, 
i.e. the regions implicated in substrate collection, coordination, and anchorage. Exploratory 
analyses of residue homology therefore require contextual information provided by protein 
structural studies to discern whether putative active sites are in fact coherent given the 
architectural constraints.  
At present, the only successful crystal structure of ArnT is that of the non-pathogenic 
environmental bacterium Cupriavidus metallidurans CH34 (PDB 5EZM, 5F15). Co-
crystallography with Undecaprenyl-phosphate has divided previously highlighted residues into 
members of a catalytic focus (ASP-55, ASP-158) and their opposing anchor residues (ARG-58, 
and LYS-203) implicated in supporting the L-Ara4N transfer141,205 (Figure 7.1). A prospective E. 
coli MG1655 catalytic focus, seeking only to reflect the established distance between each amino 
acid, would consist of ASP-47, VAL-50, TRP-150, and TRP-194. It is immediately evident 
however, that these residues would not operate like those implicated in C. metallidurans. The role 
of secondary catalytic ASP-158 may instead be fulfilled by ASP-135, 100 percent conserved in 
our six species MSA but replaced by LEU-143 in C. metallidurans. 
Whether these residues do indeed participate in lipid A modification needs experimental 
validation. Diversity in ArnT proteins may instead reflect the need for enzymes to recruit species-
specific substrates, as evidenced by the blindness of E. coli ArnT to endogenous lipid A lacking 
a 3’-acyloxyacyl-linked myristate206. Therefore, ArnT expressed by C. metallidurans should 
possess a selectivity toward lipid A derived from its natural host membrane, and if so this 
association could reoccur throughout the bacteria harbouring ArnT homologues. This tailoring of 
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ArnT to its bacterial host is immediately apparent when considering the inability of C. 
metallidurans ArnT to restore PMR in an E. coli WD101∆arnT∆eptA double deletion mutant 
(supplementary materials, Petrou et. al, 2016)141. No such deficiencies are present where S. 
enterica ArnT was expressed in the same E. coli WD101∆arnT∆eptA strain or E. coli 
BL21(DE3)∆arnT suggesting that among the Enterobacteriaceae, some functional distances 










Catalytic residues depicted as sticks with three-letter amino acid codes. Red colouring of cartoon helices 
and loops indicates residency within the ArnT Signature sequence. Image constructed using PyMOL. 







LYS-69 ARG-254 GLU-493 ASP-39 GLU-40 
S. Typhimurium 
(548-aa) 
TYR-36 LYS-62 ARG-246 GLU-478 ASP-48 GLU-33 
E. coli MG1655 
(550-aa) 
TYR-35 LYS-61 ARG-245 GLU-480 ASP-31 GLU-32 
*ArnT of B. cenocepacia was used to inform construction of Table 7.1141,142. Concordant residues within 
S. Typhimurium and E. coli discovered via MSA. Residues shaded yellow indicate membership within 
the 39DEX41 motif, shared by GT-C family enzymes. Amino acids proven experimentally necessary for 
ArnT function via charge provision are shaded green, whereas those in possession of mult iple necessary 
physiochemical properties are shaded red. 








7.4 Interspecies EptA Conserve Residues that Affect pEtN-Transfer, Despite Low 
Residue Identity. 
At present, the bulk of structural information describing EptA is based upon a singular crystallised 
Lipooligosaccharide pEtN transferase originating from within N. meningitidis (PDB 5FGN)152. 
From this same enzyme, residues SER-210 to PRO-543 have been separately crystallized (PDB 
4KAY), and constitute the soluble catalytic domain163. No other speciated EptA has been 
investigated to this extent, as of yet. Catalytic domains presented without their transmembrane 
anchors have also been crystallised for MCR-1 (PDB 5GRR151, 5K4P150, 5GOV207) and MCR-2 
(PDB: 5MX9167). Contributing to the concern that surrounds MCR is the indiscriminate pEtN-
transferase activity it exerts toward the individuated lipid A of very diverse species; E. coli, K. 
pneumoniae, S. enterica, A. baumannii, P. aeruginosa, and Cronobacter sakazakii 14,208,209. 
Characteristics essential for enzymatic activity in MCR-1, MCR-2, and N. meningitidis EptA are 
therefore expected to be reasonably conserved throughout the EptA enzyme family. To transfer 
pEtN in N. meningitidis, preservation of catalytic nucleophile THR-280 is essential152,163. 
Substitution of concordant residue THR-285 in MCR-1 with alanine abolishes all PMR in an 
BL21(DE3) E. coli host reverting MIC from 6.0µg/mL to 0.032µg/mL150. The relative importance 
of this residue is reflected by its presence across all EptA homologues investigated by our MSA; 
and as THR-282 in E. coli MG1655 EptA. 





THR-280 HIS-453 ASP-452 GLU-240 HIS-383 HIS-465 LYS-328 
MCR-1 
(541-aa) 
THR-285 HIS-466 ASP-465 GLU-246 HIS-395 HIS-478 LYS-333 
E. coli MG1655 
 (547-aa) 
THR-282 HIS-456 ASP-455 GLU-244 HIS-385 HIS-468 LYS-330 
*Residues shaded green have been confirmed as both functionally significant (by inflicting PxB MIC 
decrease where substituted), and structurally significant by shared identity in N. meningitidis full-length 
EptA152,168. Residues shaded red have been found functionally significant in MCR-1 alone. Unshaded 




Beyond THR-280, critical residues in N. meningitidis (PDB 5FGN) can be classified into three 
main functional groups. Those belonging to the THR-280 Zn2+ coordination complex (HIS-453, 
ASP-452, and GLU-240), residues able to trap a second Zn2+ ion (HIS-383, HIS-465), and the 
occupants of loops hypothesized to direct substrate-selection (periplasmic helices PH2/PH2’ with 
GLU-114)152,163. Crystallography was necessary to identify these key residues, primarily due to 
their metal-ion proximity, and the activity of their counterparts across the Alkaline phosphatase 
metalloenzyme superfamily168. Actual functional deficit in MCR-1 lacking amino acids GLU-
246, THR-285, LYS-333, HIS-395, GLU-469, and HIS-478 was demonstrated by alanine 
substitution168. Residues found across all three enzymes, and highlighted by our MSA in E. coli 
MG1655 EptA are outlined in Table 7.2. At these seven select sites, 100 percent identity was 
observed across all nine EptA homologues that were assessed. Spatial arrangement of these 











Catalytic nucleophile THR-280 is depicted in magenta, Zn2+ coordination residues in light blue. 
Periplasmic border helices PH2 and PH2’ are shown as tan, with GLU-114 embedded within PH2’. The 
dashed red line spanning GLU-114/THR-280 indicates the site postulated to contain pEtN during 










Figure 7.2 Residues outlined as Active Site Residents in N. meningitidis EptA (PDB 5FGN). 
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7.5 Summary of Targeted ArnT, EptA MSA.  
ArnT and EptA have been identified as the interlocutors for two entirely separate PMR pathways 
that converge at the outer membrane. Scenarios in which polymyxin treatment is initiated also 
coincide with those where clinicians must contend with complex, polymicrobial infections210,211. 
The ability to decisively sensitize the diverse constituency prior to polymyxin treatment within a 
polymicrobial urinary tract infection, bacteraemia or CF pulmonary exacerbation, is certainly 
worth pursuing212-214. 
Both enzymes are prospective candidates for AVD development. The targeted MSA conducted 
in this study positions both enzymes as broad-spectrum targets, due to their preservation across 
distantly related pathogens on the MDR/XDR radar. Although the presence of functionally 
relevant cavities, and the more thoroughly resolved enzymatic pathways of ArnT perhaps provide 
more avenues for immediate exploration than EptA, prima facie 141,200. The contribution of EptA 
or ArnT inhibitors to pre-existing therapeutic regimens would be considerable, ultimately 
extending the “shelf-life” of polymyxins as a salvage therapy class215.   
7.6 Characterizing the Phenotype of E. coli BW25113, BW25113∆arnT, and 
BW25113∆eptA.  
Persistence in host compartments under the continual pressure of CAMP exposure can be obtained 
by esterifying anionic lipid A phosphates with the cationic moieties L-Ara4N and pEtN. 
Reductions in OM electronegative charge can repulse endogenous CAMPs and polymyxins alike, 
providing each bacterial species in possession of the means to synthesize protective moieties with 
a potential pathway to PMR. Select Enterobacteriaceae retain both the arnBCADTEF-ugd and 
eptA operons, expression of which can generate lipid A modification by L-Ara4N or pEtN 
respectively. In this study, E. coli BW25113 and the isogenic single deletion strains 
BW25113∆arnT, BW25113∆eptA were investigated to discern whether L-Ara4N or pEtN 





7.7 Wild-type E. coli BW25113 Able to Present a Modification Replete OM Exceed the 
Polymyxin B MIC Value of BW25113∆arnT and BW25113∆eptA.  
The arrival of PMR Enterobacteriaceae (MIC ≥2 µg/mL) indicated that a new high watermark of 
AMR had been established in tertiary care institutions216,217. Sporadic isolates of E. coli or K. 
pneumoniae bear PMR at the exclusion of all other resistance determinants, however a 
considerable subset accrue high-level resistance after sabotaging carbapenem based therapy via 
acquired carbapenemases46,218.  
Wild-type BW25113 E. coli obtained a PxB MIC of 1.25µg/mL, with BW25113∆arnT and 
BW25113∆eptA returning values of 0.625µg/mL. This result is in line with expectations; that a 
wild-type strain demonstrates greater survival under conditions known to induce absent genes. 
Nevertheless, the consistency of MIC across both BW25113∆arnT and BW25113∆eptA deviated 
from that observed in the literature.  
PMR is predominately ascribed to the presence of L-Ara4N in Enterobacteriaceae, despite 
the co-occurrence of both the arn-operon and eptA116. Clinical K. pneumoniae isolates that attain 
PMR express lipid A species decorated by singular L-Ara4N or pEtN moieties, typically absent 
in their sensitive predecessors219. Subjecting these strains to ∆arnC mutation nullifies all 
observable PMR, yet removal of pEtN-lipid A via ∆eptA only inflicts a moderate decline in 
polymyxin survival219. Entirely different patterns of predominance are suggested by observing 
PMR E. coli WD101, which harbours constitutively active BasR (BasRC)220. Excessive 
transcription of the BasRS-regulon enables WD101 to attain a PxB MIC 40-fold beyond that of 
its isogenic parent strain, E. coli W3110 (12.5 µg/mL, cf. 0.30 µg/mL)220. However, in the absence 
of eptA, and therefore pEtN, polymyxin sensitivity was greater than the WD101∆arnT strain (0.60 
µg/mL, cf. 1.50 µg/mL)220. This study was unable to distinguish phenotypic shifts in PMR of this 
magnitude within E. coli BW25113175. The BW25113 strain is highly derivatized from both the 
ancestral K-12, and early MG1655 strains221. As E. coli pathotypes demonstrate an extensive 
PMR range, despite retaining identical ArnT and EptA, standards for polymyxin sensitivity must 




7.8 Select Adaptive Stimuli Able to Provoke PMR in Pathogenic GNB Are Recognized 
by E. coli BW25113. 
Abiotic signals alert bacteria to the shift from host to non-host, and vice versa. Assembling 
sensory and regulatory pathways that leverage these non-lethal stimuli for the activation of wholly 
separate virulence-dedicated transcriptional programmes is a characteristic of S. Typhimurium, 
P. aeruginosa, A. baumannii, and Y. pestis among other prominent pathogens133,223,224. Diverse 
host compartments, such as lung tissue, the gastrointestinal tract, or the insect hemocoel possess 
indelible features that cue their individual antagonists225,226. Changing concentrations of hydrogen 
ions and the presence of cationic chelators instigate the transcription of ArnT and EptA in E. coli, 
shifting the outer membrane into a CAMP repellent state135. To assess whether any deficit 
associated with single-moiety modification could be discerned in these primed bacteria, E. coli 
BW25113, BW25113∆arnT, and BW25113∆eptA were grown overnight at pH 5.5, 10µM Mg2+, 








Low Mg2+ (green circles) promotes the dissociation of divalent cation inter-bridges at the inner membrane, 
prompting a shift in PhoQ to the active state227. A similar conformational change is provoked by pH, as H+ 
ions (blue crosses) easily breach the outer membrane and lower the pH of the periplasm228. Subsequent 
activation of the PhoPQ regulon drives expression of arnT and eptA, resulting in a primed membrane able 
to repel the abiotic antagonists. If these modifications are retained, marked increases in survival are 
observed during CAMP as positive charges deflect cationic peptides away from the cell. 
 
 
Figure 7.3 Adaptive Pre-treatment Primes Lipid A, is Protective During CAMP Challenge.  
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7.9 Growth at 10 µM Mg2+ is Sufficient To Provoke E. coli BW25113 PMR, 200 µM 
Mg2+ Suppresses This Phenotype. 
Deprivation of Mg2+ weakens LPS-packing in the outer membrane227. Where environmental 
conditions permit, Mg2+ will saturate the outer membrane at concentrations of 100 mM in E. coli 
and S. enterica, contributing to membrane morphology and acting as a crucial participant in 
enzyme activity173. Growth in micromolar Mg2+ or exposure to Mg2+-chelators such as 
extracellular DNA, is in effect magnesium starvation and is redressed by TCRS-linked 
transcriptional programmes that maintain Mg2+-dependent processes173. One such Mg2+-sensory 
pathway is mediated by TCRS PhoPQ, preserved across multiple GNB and arbiter of the 
arnBCADTEF-ugd and pmrCAB (basRS-eptA) regulons in Enterobacteriaceae135,229.  
Under sufficiently limiting Mg2+ concentrations, PhoQ phosphorylates its cognate response 
regulator PhoP (Figure 7.4)133,230. The downstream effect of this event varies according to 









Magnesium chelation or starvation are accompanied by inner membrane disturbances. PhoQ detects change 
in membrane morphology, phosphorylating the transcription factor PhoP. In E. coli, PhoP binds 17-bp PhoP 
box sequences to shift the transcriptional programme to a Mg2+-responsive state. Adding to the magnitude 
of the Mg2+-limitation response is the downstream transcription of pmrA, which transcribes members of the 
arnBCADTEF-ugd operon and eptA by recognition of the PmrA consensus sequence. Lipid A modification 
is a minor component of the PhoPQ Mg2+ transcriptome, broadly conserved in S. enterica, S. marcescens, 
P. aeruginosa, and Y. pseudotuberculosis54,172,174.   
Figure 7.4 The PhoPQ Regulon Implicated in Mg2+-responsive L-Ara4N and pEtN-modified Lipid 
A species.  
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In E. coli MG1655 and W3110, Mg2+-restrictive growth media (10 – 100 µM) induces a rapid 
transcriptional response, leveraging the entire PhoPQ regulon within minutes232. The resultant 
protective OM phenotype demonstrates the efficacy of the PhoPQ response, wherein 89 percent 
of lipid A species express either single-moiety alterations or the heterogenous L-Ara4N/pEtN 
doublet135 
Whether E. coli BW25113 can reproduce OM modifications to this extent under Mg2+-restriction 
is unknown. Conditions selected to strongly induce arnT, eptA transcription (10 µM Mg2+) 
resulted in a two-fold increase in MIC of the wild-type parent, compared to un-induced 
conditions. However, although the BW25113∆arnT and BW25113∆eptA still possessed either 
pEtN or L-Ara decorations respectively, alone these decorations were not enough to result in an 
increased MIC when PhoPQ was induced at 10 µM Mg2+. Given PhoPQ suppressive conditions 
(200 µM Mg2+), the MIC of the parent isolate reduced three-fold, however there was no further 
reduction in PMR for either single mutant.  This result implies that it is the mixture of both 
decorations on lipid A, that enhances resistance to polymyxin. While Mg2+ concentrations in the 
upper micromolar range (100 – 200 µM) remain inductive for S. marcescens, and S. 
Typhimurium, the upper limits of E. coli BW25113 PhoPQ have not yet been determined174,232.  
7.10 Moderate Acidity (pH 4.5) Was Not Sufficiently Stimulatory To Confer Protective 
Lipid A Modification in E. coli BW25113 wild-type. 
As an enteric species, E. coli must be responsive to pH gradients encountered in the oral cavity 
(pH 6.3 – 7.3), through to the stomach (pH 1.5 – 3.5) and distal GIT (pH 5 – 6)233. Extreme acidity 
exerts a strictly bactericidal effect, whereas moderate acidity functions as a host cue, largely 
incorporated into transcriptional programmes that heighten enteric GNB virulence91.  
Embedded within the full E. coli acid-responsive transcriptome, arnT and eptA appear to be 
extraneous by-products of PhoPQ induction. Pathogens that encounter pH gradients during 
infection often demonstrate connections between PMR and acidity, reliant on overexpression of 
either L-Ara4N or pEtN. Opportunistic pathogen P. aeruginosa favours overexpression of L-
Ara4N following growth in media acidified to pH 5.5234. Protonation of extracellular DNA inside 
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debris-laden biofilms can reduce pH to a similar extent, providing a pathological connection to 
an abnormal stimulus within the lung234. Alternatively, Shigella flexneri 2a present lipid A solely 
decorated with pEtN at pH 5.5, despite retaining a functional arn-operon235. Further 
overproduction of S. flexneri EptA via high-copy plasmid enables transformants withstand pH 
levels that emulate gastric acidity235. In the absence of L-Ara4N synthetic pathways, pEtN 
dominates the OM of acid-adapted V. cholerae and A. baumannii, appreciably enhancing 
PMR236,237.  
In the pre-adaptive PxB assays, overnight immersion in pH 4.5 is meant to induce lipid A 
esterification with the full complement of cationic moieties available to each strain (Method 
5.3.4). A two-fold decrease in the wild-type MIC could indicate that only a mild, or non-existent, 
triggering of the response was achieved under these conditions. A milder two-fold improvement 
in PMR was observed with BW25113∆eptA, which can only decorate with L-Ara4N. However, 
acid induced PMR within BW25113∆arnT was evident, with PxB MIC increasing three-fold. 
This raises the possibility that pEtN possesses unique properties that are magnified in the absence 
of L-Ara4N. Prior studies indicate that within the E. coli W3110 background, single deletion 
mutants W3110∆arnT and W3110∆eptA demonstrate differential induction of homogenous pEtN 
and L-Ara4N doublets, with 1-pEtN/4’-pEtN lipid A recovered at greater quantities104,220. The 
effect this tendency toward increased esterification had on PMR was not investigated. 
Alternatively, the pre-adaptive acid exposure conditions may have been too mild to elicit a 
stronger, definitive, phenotype from the bacterial cells.  
7.11 Components of E. coli Acid-Resistance Phenotype Present in BW25113 Wild-type 
were Unaffected by ArnT, EptA Removal. 
Tests designed to assess different aspects of the E. coli BW25113 acid phenotype were developed 
from prior studies performed on S. Typhimurium, S. flexneri, and E. coli MC4100238. Adaptive 
growth at pH 4.5 for 1-hour interval conferred statistically significant improvements in percentage 
survival for the BW25113 wild-type alone, between each strain, improvements in survival 
conferred by adaptation were statistically insignificant. Intra-strain differences in acid survival 
are evident throughout E. coli. EHEC O157:H7 is renowned for its acid resistance phenotype, 
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rendering it a persistent hazard in fermented meat products (pH 4.5 – 4.8)239. Individual EHEC 
pathotypes (clinical or bovine-biased) can further predispose a population to acid resistance, as 
those derived from a bovine reservoir demonstrate significantly bolstered survival in model 
stomachs240. The fine-point discrimination in acid persistence displayed by EHEC may carry 
through to laboratory compromised strains such as BW25113 and K12241. Expected moderate 
acidity phenotypes are also inconsistent among strains. Wild-type BW25113, BW25113∆arnT, 
and BW25113∆eptA preserve their unacidified generation times at pH 4.5, whereas previous 
studies reported that parental E. coli strain K12 and E. coli MC4100 were constrained below 0.5 
generations per hour at this level, with growth abolished entirely at pH <4.4238. 
7.12 ArnT and EptA in BW25113 E. coli are Extraneous to Growth, Indicating 
Suitability for Anti-Virulence Drug Development. 
Growth kinetics of both BW25113∆arnT and BW25113∆eptA were identical to that of the 
isogenic wild-type, regardless of media composition. Unrestrained growth is indicative of the 
specialized position ArnT and EptA occupy as virulence factors within GNB. The effect ∆eptA 
and ∆arnT exert upon growth in rich media is uniformly negligible, regardless of co-occurrence; 
as evidenced by prior studies in N. gonorrhoeae FA1090, and S. Typhimurium242,148. Conversely, 
biological costs associated with PMR are evident in A. baumannii, and UPEC E. coli EC958 as 
both otherwise competent pathogens are out-competed by their respective wild-type strain. Both 
ArnT and EptA are candidates for Antivirulence drug (AVD) design, partially due to their 
inability to exert selective pressure. By restricting activity to pathogenesis in vivo, AVD targeted 
at virulence factors aim to avoid crossing the selective threshold for AMR. Mixed 1:1 inoculum 
in growth media or a suitable host has previously clarified the role that growth rate plays in 
subsequent virulence defects, as evidenced by S. Typhimurium ∆arnC and ∆arnF; able to 





7.13 E. coli BW25113, BW25113∆arnT, and BW25113∆eptA Are Unable To Persist in 
J774.A1 Macrophages, Regardless of Lipid A Modification. 
Internalization into a macrophage phagosome forces E. coli to contend with an onslaught of 
abiotic stressors known to exert bactericidal effects in vitro, complemented by other factors as yet 
uncharacterized (Figure 7.5). For Enterobacteriaceae, PhoPQ is the intermediary of phagosome 
protective responses with its predominant role in detection of both low pH and CAMPs already 
established227,244. As a corollary, arnBCADTEF-ugd and eptA appear to be welcome participants 










After ingestion, the nascent phagosome proceeds through a defined developmental process, culminating in 
the acquisition of bactericidal effectors. The early phagosome is unacidified (pH 6.0 – 7.0), reflecting the 
extracellular milieu245. Acidity arises after ~10 min due to the function of vacuolar ATP-ase (vATP-ase), 
the resident proton pump of late phagosomes (pH 5.0 – 6.0), and phagolysosomes (pH 4.0 – 5.5)246-248. This 
pH level is insufficient for bacterial killing alone, acting instead as an accessory to microbial killing via 
activation of hydrolytic enzymes such as cathepsin D178,249. Comparatively, vacuolar CAMPs are critical 
bactericidal participants, with both human LL-37 and its murine counterpart CRAMP inflicting OM 
derangement250,251. In the presence of both CAMPs and low pH, E. coli is predicted to express all protective 
lipid A species encompassed by the PhoPQ regulon, as observed in S. Typhimurium recovered from 
RAW264.7 macrophages104,249.  
 
Accrual of L-Ara4N directly supports pathogenic macrophage residency in Y. pestis, whereby 
disruption of arnT, phoPQ, arnA, ugd, or the upstream galU loci affects survival during both 




J774.A1 and Bone Marrow Macrophage phagocytotic programmes252,181. Defective survival of 
Salmonella enterica serovar Enteritidis bearing ∆ugd, or ∆arnC in the HD-11 chicken 
macrophage cell line also reiterates the primacy of L-Ara4N demonstrated by pathogenic 
Yersiniae species253.  
However, there are no uniform benefits conferred by lipid A modification in the macrophage. 
Subjected to prolonged RAW264.7 exposures, wild-type S. Typhimurium lipid A present both 
pEtN and L-Ara4N esterification104. No survival defects were observable in S. Typhimurium 
restricted to singular or double-pEtN modification alone, given the removal of L-Ara4N 
(∆ugd)104. As the alternate phosphate head-group mutation was not pursued (∆eptA), pEtN cannot 
be definitively stated to rescue wild-type S. Typhimurium survival; both L-Ara4N and pEtN may 
instead be extraneous to the phagolysosomal phenotype. 
This study did not observe any survival benefit conferred by the presumably L-Ara4N, 
pEtN replete OM of wild-type E. coli BW25113, within J774.A1 macrophages. Construction of 
a double mutant strain (BW25113∆arnT∆eptA) is necessary to ascribe survival to either moiety, 
as neither BW25113∆arnT, nor BW25113∆eptA were perturbed. There has been no investigation 
into intracellular arnT, eptA expression within phagocytosed pathogenic E. coli that is comparable 
to that of the Yersiniae spp. If arnT and eptA are indeed expressed during phagocytosis, the weight 
each modification exerts within the overall network of E. coli specific phagosome-induced 
effectors is potentially minimal182.  
Encounters between E. coli and macrophages are typically underpinned by pre-existing 
dysbiosis or pathogenic elements operating within the host. Chronic inflammatory bowel 
diseases, including Crohn’s disease (CD) present GIT mucosae that are unusually permissive to 
E. coli invasion182,186. Macrophage laden cellular infiltrates provide a key point-of-contact 
between two antagonists restricted by compartment in the healthy host. Isolates recovered from 
CD mucosae exhibit extraordinary survival and replication within the J774.A1 macrophage186. 
Macrophage survival as a function of pathogenicity is also evident in E. coli K1, causative agent 
of newborn meningitis254. Converting macrophages and neutrophils into replicative vehicles 
enables E. coli K1 to breach the blood-brain barrier254. Pursuing ∆arnT or ∆eptA single mutant 
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deletions in CD isolate LF82, or K1 E. coli may establish a role for L-Ara4N and pEtN in 
phagosome persistence, that would be otherwise irrelevant in non-pathogenic E. coli.   
7.13.1 Considering Experimental Design  
Gentamicin (GM) has been postulated to breach the cellular membrane via pinocytosis, before 
trafficking directly to the phagosomes to assist bactericidal processes255. Exposure to 5µg/mL GM 
is sufficient to alter the overall capacities of resident mouse peritoneal macrophages to eliminate 
E. coli K-12256,257. Concentrations in excess of 80µg/mL force vacuolated Salmonella spp. into 
growth arrest and premature cell death,  although suppression is not evident at 20µg/mL256Of 
particular importance to this study, prior investigations into E. coli survival within J774.A1 
macrophages found that viability was unperturbed during 6 hrs prolonged incubation with 18 
µg/mL gentamicin media183. Significant survival deficits instead arose after 24 hrs, effectively 
halving the viability of the bacteria recovered183. Gentamicin therefore represents a source of 
confounding bacterial death, leading to the risk that survival of any GM-susceptible pathogens 
may be underestimated in this assay. While the overall conclusions of this experiment were 
unlikely to be drastically changed by elevated intracellular GM, reducing the concentration of 
GM in the kill-step media to 20 µg/mL, or shortening exposure time, is certainly advisable for 
future experiments. 
7.14 Within E. coli, ArnT and EptA have No Effect on Macrophage Adherence. 
Members of the adherent invasive and enterohemorrhagic E. coli pathotypes (AIEC, EHEC) 
direct coordinated derangement of host cell membranes that promote tight epithelial and 
macrophage adherence182,186,189. No adherence defect was observed between the BW25113∆arnT, 
BW25113∆eptA strains and the BW25113 wild-type. This indicates that the absence of neither 
pEtN, nor L-Ara4N, can perturb the ability of J774.A1 macrophages to collect E. coli upon their 
cytoplasmic membrane. The contribution that phosphate head-group modification makes to 
adherence has been explored only within N. meningitidis; a species entirely restricted to the pEtN-
modification. Meningococci lacking the 4’-pEtN conferred by Neisserial EptA present a clear 
adherence defect during in vitro infection of the HUVEC, HBMEC, A549, and HEp-2 cell lines258. 
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In comparison to E. coli, Neisseria spp. lacking EptA are placed into a zero-sum situation. In its 
absence, N. meningitidis cannot place any cationic moiety onto either phosphate head-group, 
whereas BW25113∆eptA can theoretically present a twin-L-Ara4N structure163,259.  
7.14.1 Complementary Experiments 
The experimental panel used in this study was unable to resolve distinct phenotypes for either 
mutant strain. To posit that the lack of L-Ara4N or pEtN is inconsequential in an otherwise 
modified OM would disregard the potential for other analyses to uncover as yet unidentified 
functions. Of particular importance are the differences in LPS-packing and outer membrane 
integrity that have been described in Citrobacter rodentium (∆eptA), and between paired 
polymyxin-resistant/susceptible GNB24,260,261. At rest, C. rodentium unable to augment lipid A 
with pEtN exudes enzymes typically withheld within the periplasm; provision of labelled 
substrate reveals these deficiencies261. Alternatively, failure to maintain OM integrity under PxB 
treatment has been similarly quantified in sensitive E. coli by the activity of intracellular β-
galactosidase on O-nitrophenol-β-D-galactopyranoside262.  
Membrane impermeable antibiotics or noxious compounds deliver widely differing MIC values 
in accordance with PMR, secondary to PxB treatment24. These compounds may have utility in 
distinguishing sensitive (BW25113) and theoretically super-sensitive (BW25113∆arnT, 
BW25113∆eptA) E. coli. By exposing cells to subinhibitory PxB concentrations, subpar 
protective responses can be exposed with greater clarity by a less lethal challenge. Supplementing 
the MIC values collected in this study with that of a different membrane active cohort, i.e. 
erythromycin, could further delineate whether LPS packing has been sufficiently disturbed to alter 
known primary sensitivities261.  
7.15 Recombinant Expression of E. coli BW25113 ArnT::HisX6 and EptA::HisX6. 
Discerning the optimal conditions to achieve overexpression of target protein is the necessary 
antecedent to all assays directed toward enzymatic characterization. With the perspective that 
ArnT and EptA constitute underexplored AVD targets, expressed protein provides a gateway to 
understanding ligand binding and consequent inhibitor studies263. Therefore, systematically 
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adjusting the parameters to generate workable quantities of ArnT::HisX6 and EptA::HisX6 from 
pET15-b_arnT and pET28a(+)_eptA respectively, constituted the second aim of this study.  
Expression of both ArnT and EptA from other bacterial species is found throughout the literature, 
with the end goal typically being phenotypic assessment. Once a putative arnT or eptA has been 
identified from target organisms, and mobilized on a suitable plasmid, the non-native recombinant 
host expresses each enzyme for an observable PMR-effect, or change in lipid A spectra53,208,264. 
This is distinct from the targeted over-expression necessary to fuel downstream protein 
characterization152. Few studies are solely focused on overexpression of these two targets, and 
their technique and resultant enzyme products are outlined in Table 7.3, and Table 7.4; in addition 
to conditions where expression was achieved in this study (Table 7.5). 
7.16 E. coli BW25113 ArnT was Successfully Expressed Within OverExpress E. coli Host 
Strains 
In this study, the BL21(DE3)pLysS host strain was unable to achieve ArnT::HisX6 expression; 
contrary to successful generation of C. metallidurans ArnT::HisX10 within this same host, in 
sufficient quantities for downstream characterization141 (Table 7.3). This discrepancy was 
partially attributed to sonication, but may also originate from the selectivity with which E. coli 
hosts express α-helical integral membrane proteins (αIMPs)265. The underrepresentation of the 
transmembrane protein cohort at the structural level, forming less than 2% of all Protein Data 
Bank entries, is a clear indication that their overexpression is rarely straightforward194,266.  
Homologue expression may be terminated in a given host, due to appreciably minor differences 
in amino acid sequence or chain length such as those evident between C. metallidurans and E. 
coli BW25113 ArnT267,268. The OverExpress strains C41 and C43. in combination with pET15-
b_arnT are permissive to overexpression of BW25113 ArnT::HisX6, yet there is every likelihood 





Table 7.3 Features of Successful ArnT Expression in Prior Studies 
ArnT 
 








E. coli NovaBlue 
1.0 mM IPTG 
37°C 
24-hour collection 
~59 kDa band 
(SDS-PAGE) 














0.2 mM IPTG 
22°C 
24-hour collection 






*pNYCOMPS refers to the pNYCOMPS-LIC-FH10T+ (N term) vector utilized by the New York 
Consortium on Membrane Protein Structure194. Full information on this clone can be found via DNASU 
online Plasmid Repository entry:  http://dnasu.org/DNASU/GetCloneDetail.do?cloneid=454795. 
Phenotype indicates that PMR within the range expected to be conferred by expression, was present in the 
recombinant host. Where stated, stereospecific modification to either 4’-, and/or 1-PO4 of lipid A is 
included. 
Table 7.4 Features of Successful pEtN-Transferase Expression (EptA, MCR-) in Prior Studies. 
EptA 










0.4 mM IPTG 
25°C 
24-hour collection 











0.5 mM IPTG 
16°C 
24-hour collection 





*Phenotype indicates that PMR within the range expected to be conferred by expression, was present in a 
recombinant host. Where stated, stereospecific modification to either 4’-, or 1-PO4 of lipid A is included.  
 
Table 7.5 Features of Successful Protein Expression in This Study 
ArnT/EptA     









E. coli C43 OverExpress 
E. coli C41 OverExpress 
0.4 mM IPTG 
37°C/22°C 
0, 2, 4, 24-hour collection 
≥46 kDa band  
(SDS-PAGE) 










Rosetta-Gami 2  
22°C 
0.5 mM IPTG 
0, 2, 4, 24-hour collection  
~58 kDa band  
(SDS-PAGE) 




7.17 Variable Expression of EptA, Toxicity and HisX6-Tag Placement Implicated 
Unlike ArnT::HisX6 which was isolated as a band multiple times across two expression hosts, 
EptA::HisX6 was less amenable to expression. A band corresponding to ~58 kDa was recovered 
once, from the insoluble fraction corresponding to 24 hrs of expression in the RG-2 host, contrary 
to expression of EptA homologues in BL21(DE3)pLysS, and BL21(DE3) (Results 6.8.1)53. As 
discussed above, minor deviation between highly similar amino acid sequences can render protein 
overexpression untenable in certain host/plasmid/insert combinations. Furthermore, as no protein 
was recovered during several trials, EptA::HisX6 may be a toxic αIMP195. Driving expression in 
excess of physiological levels using T7-RNA polymerase places most E. coli hosts under extreme 
duress. Bottlenecks arise where nascent peptides cannot access the already saturated protein 
folding machinery, forming large insoluble agglomerates or inclusion bodies269. If a protein is 
sufficiently toxic, the host population will escape selective pressure by promoting transcription 
programmes or mutations that effectively eradicate all observable protein expression270,271. To 
mitigate potential toxicity of EptA::HisX6, the repressive threshold should be located by adjusting 
cultivation parameters including temperature, IPTG, and OD600 values.  
Alternatively, despite the successful expression of both EptA and MCR-1 as C-terminally tagged 
recombinant protein, this strategy may not be appropriate for E. coli EptA. Individual MCR-1 
soluble domains modified by N-terminal tags are amenable to expression, possibly indicating a 
new avenue for recombinant E. coli EptA should be pursued150.  Abandoning the HisX6 fusion 
strategy entirely for a dedicated solubility enhancer tag, e.g. Fh8, or amending it by cooperative 
addition of alternate fusion partners is also well within the scope of expression strategies that may 
be leveraged to express E. coli EptA in future studies272.  
7.18 Future Amendments To Expression Protocols 
With the purview that these two proteins should be progressed further along the characterization 
pipeline, a number of common issues can first be addressed. Exploratory trials of protein 
expression are typically conducted in smaller volumes, at incredibly high OD600 values (10.0 – 
20.0), with multiple candidate clones being assessed in parallel194,273,274. This study was not 
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conducive to this intensive high-throughput style, however permitting cultures to attain higher 
OD600 levels prior to induction could be implemented by growth media alteration274. Elevating 
cell density can facilitate increased protein yield, although careful optimization will be needed to 
navigate expression at higher OD600 values due to the risk of entering the non-productive 
stationary-phase.  
An objective that arose during this study was to improve protein solubility for the pET15-b_arnT 
clone. The insoluble fractions of each expression construct bore the vast majority of ArnT::X6 
product, a common feature of αIMP bearing long hydrophobic helices194. Solubility is desirable 
as it facilitates downstream biochemical characterization, and the recalcitrance of the αIMPs is 
reflected in their underrepresentation among known protein structures265. Treating membrane 
fractions with detergents and other chaotropic reagents allows proteins to attain temporary 
solubility, at the cost of enzymatic activity268. Whether such a strategy is appropriate for pET15-
b_arnT has not yet been determined, although C. metallidurans ArnT was solubilized in this 














8 Project Conclusion  
This study has revealed the fine-point discrimination with which E. coli leverages two parallel 
mechanisms of polymyxin resistance. The results of this study indicate that in the absence of ArnT 
or EptA, E. coli can withstand environmental insults encountered during pathogenesis, such as 
acidity, and phagocytosis. However, exposure to stringently bactericidal Polymyxin B was 
sufficient to reduce the survival of BW25113∆arnT, and BW25113∆eptA, below that of the 
isogenic wild-type strain. As such, diversity in lipid A modification may provide a protective 
effect under these circumstances. Alternatively, the BW25113 strain may be unresponsive to the 
stimuli selected in this study to provoke lipid A modification as the elevated Polymyxin B MIC 
of wild-type was not repeated in subsequent pre-adaptive assays.   
Whether the concordant phenotypes demonstrated reflect the capacity for L-Ara4N or pEtN 
to entirely compensate for the absence of their opposite is unknown. A double mutant strain 
lacking both ArnT and EptA (BW25113∆arnT∆eptA) should be constructed, in order to observe 
if E. coli BW25113 derives any benefit from its lipid A moieties. Potential exploration of paired 
single and double ArnT, EptA mutants in a pathogenic E. coli strain may also resolve this 
question.  
What is evident, is that ArnT, EptA and their respective cationic moieties are not directly 
equivalent across the Gram-Negative Bacteria. Observable Polymyxin Resistance can only be 
understood in the unique context of each pathogen, with the regulatory systems and biochemical 
properties that underpin each enzymes activity. Understanding each of these factors will facilitate 
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